Cardiovascular magnetic resonance of the arterial wall by Keenan, Niall Gerald James & Keenan, Niall Gerald James
  
 
CARDIOVASCULAR MAGNETIC 
RESONANCE OF THE ARTERIAL WALL 
 
MD(RES) THESIS 
 
 
NIALL GERALD JAMES KEENAN 
 
 
IMPERIAL COLLEGE, LONDON 
NATIONAL HEART AND LUNG INSTITUTE
 Page 2  
   
 
 
 
 
 
 
 
 
 
 
AMDG 
 
For my parents.
 Page 3  
   
ABSTRACT 
 
BACKGROUND  
Atherosclerosis is the single greatest cause of mortality and morbidity in the developed world. 
Cardiovascular magnetic resonance (CMR) is a non-invasive imaging technique which can 
interrogate the arterial wall and identify atherosclerotic disease. CMR can provide quantitative 
volumetric data of atherosclerosis burden which have begun to be used in clinical trials, however 
comparatively few studies have been performed. We aimed to validate this approach ex vivo, to use 
it to characterise a normal population in vivo, to further develop the methodology, and to apply the 
technique to novel ‘at risk’ populations. 
 
METHODS AND RESULTS 
We validated quantitative CMR arterial wall volume in post mortem carotid arteries against both a 
CMR comparator, and against histological data. For all correlations, R2 was greater than 0.95: 
(CMR v histology: lumen volume 354 vs 308mm3, p<0.01; arterial wall volume 388 vs 351 mm3, 
p<0.01; total volume 750 vs 665 mm3; p<0.01). We studied 100 normal subjects from age 20 to 69 
to determine normal ranges and the effect of normal ageing. Wall volume and total vessel volume 
increased significantly with age in both sexes (p < 0.006), and this was more marked in males. The 
W/OW ratio also increased significantly with age (p < 0.001). We showed that a 3-dimensional 
CMR sequence performs 63% faster than a conventional 2-dimensional sequence, with twice the 
signal-to-noise ratio (SNR), and highly correlated results (vessel volume: difference = 1.7%, R2 = 
0.93, p < 0.001; lumen volume: difference = 4.9%, R2 = 0.92, p < 0.001, wall volume: difference = 
4.7%, R2 = 0.77, p < 0.001, W/OW ratio: difference = 5.8%, R2 = 0.30, p < 0.001). Finally, we 
characterised atherosclerotic burden and arterial health in two populations with Takayasu’s arteritis 
and systemic lupus erythematosus by CMR. Carotid arterial wall volume was elevated in both 
populations: TA = 1045mm3, SLE = 761mm3, normals = 640mm3, p < 0.001, and myocardial late 
gadolinium enhancement was found 27% of TA patients, and in 60% of those with SLE. 
 
CONCLUSIONS 
Cardiovascular magnetic resonance of the arterial wall is an accurate way of measuring carotid 
atherosclerosis burden. This thesis validates this approach, and provides valuable normal data. It 
compares new techniques with old, aiding technical development. Finally, it demonstrates how the 
technique can be used in practice in populations with accelerated atherosclerosis. These data 
indicate that arterial wall CMR is ready to be applied in larger clinical trials. 
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SAP  Serum amyloid P component 
 
SAR  Specific absorption rate 
 
SBP  Systolic blood pressure 
 
SCMR  Society of Cardiovascular Magnetic Resonance  
 
SD  Standard deviation 
 
SELENA  Safety of Estrogens in Lupus Erythematosus- National 
Assessment  
 
SLE  Systemic lupus erythematosus 
 
SLEDAI  Systemic Lupus Erythematosus Disease Activity Index 
 
SLICC  Systemic Lupus International Collaborating Clinics 
 
SNR  Signal-to-noise ratio 
 
SPACE  Sampling Perfection with Application of Optimized 
Contrasts using different flip angle Evolutions 
 
SPECT   Single photon emission computed tomography 
 
SSFP  Steady state free precession 
 
STIR  Short T1 inversion recovery 
 
   
T    
 
T  Tesla 
 
TARA  Trial of Atorvastatin in Rheumatoid Arthritis 
 
T1W  T1-weighted 
 
T2W  T2-weighted 
 
TA  Takayasu’s arteritis 
 
TE  Echo time 
 
TexCaPS  Texas Coronary Atherosclerosis Prevention Study 
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TGF-β  Transforming growth factor-beta 
 
Th  T helper 
 
TI  Inversion time 
 
TIA  Transient ischaemic attack 
 
TNF-α  Tumour necrosis factor-alpha 
 
TOF  Time-of-flight 
 
TR  Repeat time 
 
   
U    
 
UK  United Kingdom 
 
US  United States (or ultrasound) 
 
USA  United States of America 
 
USPIO  Ultra-small superparamagnetic iron oxide 
 
UTE  Ultrashort Echo Time 
 
   
V    
 
VCAM  Vascular cell adhesion molecule 
 
VEGF  Vascular endothelial growth factor 
 
VLA  Vertical long axis or very late antigen 
 
   
W    
 
WHO  World Health Organisation 
 
WOSCOPS  West of Scotland Coronary Prevention Study 
 
W/OW  Wall/outer wall ratio 
 
   
X    
Y    
Z    
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CHAPTER 1 
SUMMARY AND OBJECTIVES 
  
Atherosclerosis is the major cause of morbidity and mortality in the developed world, 
and is predicted to be the predominant cause of death worldwide by 2020 [World 
Health Organisation 2002]. The diagnosis of atherosclerosis has conventionally been 
made with invasive angiography. However, as well as the small risk and radiation 
exposure associated with the procedure, angiography is a purely lumenographic 
technique, and provides no information about the atherosclerotic disease process in 
the arterial wall. Earlier diagnosis is important so that secondary prevention can be 
initiated in a timely manner. 
 
Cardiovascular magnetic resonance (CMR) can image the arterial wall, and so 
identify the presence of atherosclerosis in a non-invasive manner, without the use of 
ionising radiation or intravenous contrast [Keenan 2008b]. In addition, CMR can 
assess arterial distensibility and endothelial function. The majority of previous CMR 
arterial wall imaging research has attempted to characterise atherosclerotic plaque, 
mainly using the carotid artery. This work has been validated against histology by 
imaging patients before carotid endarterectomy, and comparing images with 
histological analysis of operative specimens [Yuan 2001]. As well as plaque 
characterisation, quantitative work has been performed by our group and by others 
using CMR to measure carotid artery wall and lumen volumes as a sensitive measure 
of arterial wall thickening [Varghese 2005a, Varghese 2005b]. These measurements 
have been used as the primary end-point in clinical trials [Corti 2001]. However this 
approach has never undergone basic validation against histology using post mortem 
arteries. We performed this validation on twenty carotid arteries, and this is described 
in chapter 7. 
 
Previous quantitative studies of vessel wall imaging have been small, and no 
population data have been acquired. No normal ranges for measured variables are 
available, and in particular the effect of normal ageing has not been studied. Chapter 8 
describes an observational study performed on 100 healthy volunteers, both male and 
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female, who had no modifiable risk factors for atherosclerosis, and who were evenly 
spread from the third to the seventh decade. 
 
There is no consensus on what imaging sequence should be used to image the carotid 
arterial wall. Conventionally a 2-dimensional (2D) fast spin echo (FSE) sequence has 
been used, however a 3-dimensional (3D) FSE sequence has been described [Crowe 
2003].  Chapter 9 provides a validation of the 3D sequence against the 2D sequence in 
100 subjects. 
 
Little work has been performed to assess the clinical utility of CMR volumetric 
arterial wall imaging in at risk groups. We used this approach to image patients with 
the inflammatory arthritides, including Takayasu’s Arteritis (TA) and systemic lupus 
erythematosus (SLE). In both diseases there is a significant excess of cardiovascular 
morbidity and mortality. Patients often have inflammatory arterial thickening 
secondary to vasculitis, but they are also are at a substantially increased risk of 
atherosclerosis. CMR of the carotid artery was used to perform a volumetric arterial 
wall assessment, and also to identify the presence of plaque. In addition, endothelial 
function was assessed as a marker of vascular damage, and a myocardial study with 
gadolinium was performed. Chapter 10 describes the study performed in Takayasu’s 
Arteritis, and chapter 11 describes the study performed in SLE. 
 
These studies provide basic validation for the quantitative CMR approach to arterial 
wall imaging and show application of this approach in clinical studies of at risk 
patient groups. These data advance the field for use of CMR in further clinical 
research and practice.  
 
. 
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CHAPTER 2 
ATHEROSCLEROSIS 
 
2.1 PATHOPHYSIOLOGY OF ATHEROSCLEROSIS 
 
2.1.1 Introduction 
Atherosclerosis is a disease of the arterial wall. Atherosclerotic plaque formation 
leads to thickening of the arterial wall. Initially, the artery remodels outwards, but 
ultimately the plaque may narrow and obstruct the arterial lumen. Any subsequent 
clinical syndrome depends on the arterial bed involved: stenosis of an epicardial 
coronary artery causes myocardial ischaemia, and hence angina, while stenosis of a 
lower limb artery may cause limb ischaemia, and hence intermittent claudication. 
  
Stable and Unstable Plaques 
Atherosclerotic arterial plaques can be classified as stable or unstable. Stable plaques 
may reduce the flow capacity of the lumen, but unstable plaques have the potential to 
rupture, disrupting the endothelium of the artery, and exposing circulating blood to 
thrombogenic plaque contents. The consequent activation of the clotting cascade leads 
to thrombus formation on the plaque surface. This may enlarge, occluding the arterial 
lumen, stopping blood flow, and rendering tissue distal to the blockage ischaemic. If 
flow is not restored then tissue death may occur. Occlusion of a coronary artery may 
cause the clinical syndrome of myocardial infarction (MI), while occlusion of a 
carotid artery may cause a cerebral infarction. As well as focal plaque formation, 
vessel stenosis and occlusion, atherosclerosis can lead to more diffuse arterial 
thickening (sclerosis), or arterial thinning and aneurysm formation. The aspect that 
dominates varies between individuals and between arterial beds [Libby 2005]. 
 
Onset in Childhood 
Atherosclerosis starts early in life. 77% of American soldiers killed in the Korean war, 
and 45% in the Vietnam war, had atherosclerosis on gross inspection at autopsy  
[Enos 1953, McNamara 1971]. The Pathobiological Determinants of Atherosclerosis 
in Youth (PDAY) study of several thousand Americans who died in adolescence or 
early adulthood of non-cardiac causes found intimal lesions in all the aortas and more 
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than half of the right coronary arteries of subjects between 15 and 19 years old 
[Strong 1999]. An intra-vascular ultrasound (IVUS) study performed on the coronary 
arteries of donor hearts pre-transplantation found atherosclerotic lesions in 17% of 
donors aged under 20 years [Tuzcu 2001], and a study of foetal aortas after 
miscarriage or neonatal death found areas of lipid accumulation in all 55 specimens 
studied. [Napoli 1997]. 
 
2.1.2 Clinico-Pathological Correlation 
The development of the symptoms of atherosclerosis is usually the culmination of a 
process that began decades before. Evidence from serial angiography and histology 
indicates that, during the asymptomatic period, plaque growth occurs at very variable 
rates, with quiet periods and periods of rapid expansion, often in response to plaque 
rupture [Yokoya 1999, Mann 1999]. 
 
The arterial bed in which atherosclerosis has been studied in most detailed is the 
coronary circulation. Most of the information that follows is therefore taken from the 
coronary literature and refers to coronary artery disease (CAD). This thesis is mainly 
concerned with the carotid arteries, which are important in the context of 
cerebrovascular disease, and are also used as a model for CAD as they are more 
accessible to cardiovascular magnetic resonance (CMR). CAD and carotid 
atherosclerosis have much in common, but it must be acknowledged that the carotid 
artery is an imperfect model, and where differences exist between the atherosclerotic 
process in the two arteries these will be highlighted. 
 
Glagov - Stable Angina 
Plaque in the arterial wall leads to outward remodelling of the vessel, so that at least 
initially plaque does not compromise flow down the arterial lumen. In a pathological 
study of left main coronary arteries, Glagov showed that outward remodelling occurs 
until approximately 40% of the cross-sectional area of the vessel is occupied by 
plaque. After this point, the plaque begins to encroach on the lumen [Glagov 1987]. 
When a stenosis of greater than 60% is present, the narrowed lumen cannot increase 
flow to meet demand, and symptoms may occur [Libby 2005].  
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Figure 2.1 Outward remodelling of left main coronary artery in response to the 
presence of plaque. The lumenal area only begins to decrease when the vessel is 
greater than 40% stenosed. Adapted from Glagov 1987. 
 
Unstable Angina / Myocardial Infarction 
The paradigm for vessel occlusion in the coronary arteries has changed from one of 
progressive stenosis of an epicardial vessel until occlusion, to one of plaque rupture, 
thrombus formation and propagation, and occlusion. Many patients presenting with a 
myocardial infarction (MI) have no preceding history of stable angina. Where plaque 
rupture has occurred, the culprit plaque may previously not have caused any lumenal 
narrowing at all. Pathologically, the plaque itself may often be large, but it is 
accommodated in an outwardly remodelled artery [Bezerra 2001]. 
 
In patients presenting with acute MI (AMI) who had had a previous angiogram, the 
mean degree of stenosis of the culprit lesion on the previous angiogram was only 34% 
in patients with Q wave MI, and 48% overall. Only 22% of culprit lesions had a 
stenosis of greater than 70% [Ambrose 1988]. Similarly, an angiographic study in 
acute MI assessing the effect of thrombolysis showed that, in half of AMI patients, the 
culprit lesion was less than 60% occlusive [Hackett 1988]. 
 
The Vulnerable Plaque 
The majority of acute myocardial infarctions are due to plaque rupture and thrombotic 
occlusion of a coronary artery, with a small minority attributed to plaque erosion, or 
embolism. The aetiology of plaque rupture is therefore of central importance in the 
pathogenesis of AMI. Plaques that are at high risk of rupture are referred to as 
vulnerable. Pathological and clinical studies have identified specific features of 
vulnerable plaques (table 2.1) [Falk 1983, Davies 1985, Bezerra 2001]. As noted 
below, carotid disease shares some but not all of these features. 
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Table 2.1 Features of a Vulnerable Plaque (from Naghavi 2003a) 
 
Major Criteria Minor Criteria 
Active inflammation (monocyte/macrophage  
and sometimes T cell infiltration) 
Superficial calcified nodule 
Thin cap with large lipid core Glistening yellow 
Endothelial denudation with superficial  
platelet aggregation 
Intraplaque haemorrhage 
Fissured plaque Endothelial dysfunction 
Stenosis >90% Outward (positive) remodelling 
 
Role of the Fibrous Cap 
The fibrous cap is the key component of plaque stability as it keeps the lipid core 
separate from the vascular lumen. When a plaque ruptures, contact between the highly 
thrombogenic lipid core and circulating blood causes thrombus formation. The thinner 
the fibrous cap, the more vulnerable the plaque. It should be noted that the fibrous cap 
is typically three times thicker in carotid disease than in coronary disease (mean 72µm 
v 23µm, in a study of plaques that had ruptured [Virmani 2007]). This reflects the 
considerably higher lumenal pressure in the carotid artery compared to the coronary 
artery, and indicates, as discussed below, that plaque rupture differs in mechanism and 
prevalence between carotid and coronary disease. 
 
Not all cap ruptures lead to vessel occlusion. Small subclinical fibrous cap ruptures 
(or erosions) are a strong stimulus for a process of repair that leads to plaque 
enlargement. This may occur as a repeated cycle. Multiple healed rupture sites are 
found in the hearts of over half of patients dying of MI [Burke 2001]. 
 
The Vulnerable Patient 
In patients with a clinical event related to a coronary plaque rupture, it is common to 
find more than one unstable plaque [Burke 1997]. This has led to the concept of the 
‘vulnerable patient’. In a study of 31 males who had died from acute myocardial 
infarction, 84 disrupted coronary plaques were found, an average of 2.7 per patient 
[Mann 1999]. This was confirmed in vivo by an IVUS study in patients with acute 
coronary syndrome (ACS) that found a mean of 2 plaque ruptures per patient. 79% of 
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patients had a second unstable plaque, of which 70% were in a different artery from 
the culprit lesion [Rioufol 2002]. A second IVUS study comparing AMI patients with 
patients with stable angina found more culprit lesion plaque ruptures, remote 
secondary plaque ruptures and multiple plaque ruptures in AMI patients [Hong 2004]. 
 
Inflammation 
Rupture of plaque remote from the culprit lesion suggests that a more generalised 
inflammatory process is taking place. Plaque rupture or erosion is always marked by 
an inflammatory process, and inflammation has a key role in destabilizing the fibrous 
cap [van der Wal 1994]. Markers of generalised inflammation have been identified in 
ACS patients. Blood samples from the great cardiac vein (which selectively drains the 
left coronary artery) showed evidence of neutrophil activation in ACS patients, 
whether the culprit stenosis was in the left or right coronary artery, indicating 
widespread coronary inflammation in unstable angina [Buffon 2002]. Current 
research is attempting to identify these patients by imaging or with biomarkers. 
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Figure 2.2 Different types of vulnerable plaque. A, Rupture-prone plaque with 
large lipid core and thin fibrous cap infiltrated by macrophages. B, Ruptured 
plaque with subocclusive thrombus and early organization. C, Erosion-prone 
plaque with proteoglycan matrix in a smooth muscle cell-rich plaque. D, Eroded 
plaque with subocclusive thrombus. E, Intraplaque haemorrhage secondary to 
leaking vasa vasorum. F, Calcific nodule protruding into the vessel lumen. G, 
Chronically stenotic plaque with severe calcification, old thrombus, and eccentric 
lumen. Reproduced from Naghavi 2003a.  
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2.1.3 Stages in the Progression of an Atherosclerotic Plaque 
The stages described here are applicable to atherosclerotic plaques anywhere in the 
arterial tree. Where are particular feature is more important in one arterial bed, this is 
indicated, and the specific differences between carotid and coronary plaque are 
discussed. 
  
A. Earliest stages 
The accumulation of lipoproteins in the arterial wall is a key early stage in 
atherogenesis. Small lipoproteins, such as low-density lipoprotein cholesterol (LDL) 
enter the arterial wall; if they enter more quickly than the artery can eliminate them 
then they accumulate [Williams 1998]. This process can be provoked in rabbits by a 
cholesterol-rich diet [Libby 2000]. 
 
Lipoproteins accumulated in the subendothelium are modified. Modifications both 
increase the likelihood of retention, and increase the pathogenicity of the lipoprotein. 
The biochemical processes involved include oxidation, glycation, immune complex 
formation, proteoglycan complex formation, aggregation and conversion to 
cholesterol-rich liposomes. For example, proteoglycan-binding increases retention: 
mice expressing LDL that is defective for proteoglycan-binding develop less 
atherosclerosis than wild-type [Skalen 2002]. 
 
LDL modification increases pathogenicity by increasing LDL uptake by macrophages 
and smooth muscle cells [Kruth 1997, Camejo 1998, Williams 1998, Tabas 1999].  
The most important LDL modification is oxidation, rendering LDL particularly 
atherogenic. It is performed by lipoxygenases, oxidases and myeloperoxidase 
produced by among others macrophages and leucocytes, and knock out (KO) mice 
experiments have confirmed the role of these enzymes [Steinberg 1997, Cyrus 1999, 
Cyrus 2001]. Oxidised lipoproteins may cause a chronic inflammatory process in the 
arterial wall, activating endothelial cells, leading to increased cholesterol 
accumulation and endothelial macromolecular permeability, and endothelial 
dysfunction, another important early step in atherogenesis [Rong 1998, Leitinger 
2003]. Oxidised lipoproteins have been found in high concentrations in unstable 
human plaques, particularly in macrophages [Sugiyama 2001]. Plasma oxidised LDL 
level is a strong predictor of coronary artery disease [Meisinger 2005]. 
Chapter 2 Page 34 Atherosclerosis 
 
Figure 2.3 Schematic of the evolution of the atherosclerotic plaque.  
1: Accumulation of lipoprotein particles in the intima. 2: Oxidative stress. 3: 
Leucocyte recruitment. 4: Activation of monocytes to become macrophages. 5: 
Lipid uptake by macrophages to become foam cells. 6 & 7: Smooth muscle cell 
migration and proliferation. 8: Apoptosis, fibrosis and calcification. From Libby 
2005. 
 
 
B. Leukocyte Recruitment 
The endothelial inflammation induced by, among other elements, oxidised 
lipoproteins, attracts leucocytes. These are attracted both by cell-surface signalling 
molecules and by chemokines. 
  
Adhesion and Diapedesis 
When leucocytes detect an activated endothelium, they marginate, attach to the 
endothelium, and penetrate the intima by diapedesis. This process is mediated by cell 
adhesion molecules such as selectins, integrins and immunoglobulins. Selectins are 
involved at the initial tethering and rolling stage [Eriksson 2001]. LDL induces P-
selectin expression and leucocyte adhesion in endothelial cells, and endothelial cells 
overlying atheroma express P–selectin [Vora 1997, Ley 2003]. P- and E-selectin KO 
mice develop less atherosclerosis than wild type [Dong 1998]. 
 
After initial tethering and rolling, immunoglobulin superfamily adhesion molecules, 
such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion 
molecule-1 (ICAM-1) facilitate firm adhesion of leukocytes to the endothelial surface 
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by binding to integrins. VCAM-1 is expressed on the endothelium overlying early 
lesions and at lesion prone sites. It is rapidly induced by an atherogenic diet 
[Nakashima 1998]. VCAM-1 binds to integrin very late antigen-4 (VLA-4) on 
monocytes and T-cells, recruiting them to the lesion [Ley 2001]. VCAM-1 KO mice 
have reduced atherosclerosis [Cybulsky 2001]. ICAM-1 is more promiscuous and 
constitutive than VCAM-1. It is present at lesion prone sites in response to altered 
blood flow and wall shear stress, but KO experiments have shown its role to be less 
important than VCAM-1 [Nakashima 1998, Cybulsky 2001]. 
 
Chemotaxis 
Chemokines are produced by endothelial and smooth muscle cells in response to 
inflammation. They induce leucocytes to penetrate the endothelium. Examples 
include: monocyte chemoattractant protein-1 (MCP-1), macrophage colony 
stimulating factor (M-CSF), Il-8 and oxidised LDL itself [Rajavashisth 1990, Qiao 
1997, Gu 1998, Boring 1998, Boisvert 2000]. 
 
C. Fatty Streak Formation - Foam Cells 
The formation of foam cells in the arterial wall leads to the development of the fatty 
streak. Foam cells are lipid-laden macrophages. Having entered the arterial wall, 
monocytes mature into macrophages in the subendothelial space in response to M-
CSF. Through scavenger receptors they internalise many particles, in particular 
modified lipoproteins such as oxidised LDL [Smith 1995, Sakaguchi 1998, Peiser 
2002]. 
 
Foam cells themselves become activated and start to produce cytokines (IL-1, TNF-α 
and TGF-β), growth factors (insulin-like growth factor-1), proteolytic enzymes and 
reactive oxygen species, leading to more chemotaxis, inflammation, scavenger 
receptor expression and macrophage replication [Libby 2002a, Libby 2002b]. 
However, at the fatty streak stage, atherosclerosis is still potentially reversible. The 
significance of fatty streak formation differs between the carotid and coronary 
arteries, as discussed in subsection J below. 
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D. Progression of Atheroma 
The immune system has a key role in the evolution of an atherosclerotic lesion from a 
fatty streak to a complex plaque. Initially this comprises the more primitive systems 
of ‘innate immunity’, such as the scavenger receptors on macrophages. Innate 
immunity has evolved to fight pathogens, but does not involve the recognition of 
antigens by antibodies. This process is called ‘adaptive immunity’ and this now 
becomes involved. 
 
Antigens are processed by antigen presenting cells (APCs) such as macrophages and 
dendritic cells and presented on their surface to leucocytes such as T cells. In 
atherosclerosis, potential antigens include infectious agents (such as Chlamydia 
pneumoniae), modified lipoproteins, heat shock proteins and beta-2 glycoprotein 1B 
[Binder 2002, Hansson 2002]. Antigenic triggering of T cells, especially CD4+ T 
helper (Th) cells, considerably escalates the inflammatory cascade in plaque. 
 
CD4+ T helper cells are subdivided into Th1 and Th2 subsets. Th1 cells direct cell-
mediated immunity, while Th2 cells direct antibody-mediated immunity. The balance 
between Th1 and Th2 determines the nature of the immune response. Cell-mediated 
immunity has evolved to combat intracellular pathogens such as viruses or Listeria, 
while antibody-mediated immunity combats extracellular pathogens (mainly bacteria) 
through the use of antibody-producing B cells. Cell-mediated immunity (and hence 
Th1 cells) are more important in atherogenesis [Janeway 2005, Libby 2005]. 
 
After activation by APCs, Th1 cells release pro-inflammatory cytokines such as γ-
IFN, TNF-α, lymphotoxin and CD40 ligand) [Mach 1999]. These cytokines activate 
cytolytic CD8+ T cells, which lyse and induce apoptosis in their target cells 
(including macrophages, as well as endothelial and smooth muscle cells) leading to a 
further release of lipid and inflammatory mediators, inducing a cycle of further 
inflammation, cell recruitment and damage [Libby 2002a, Libby 2002b, Geng 2002, 
Littlewood 2003]. There are, however, internal modulations in this process: for 
example, activated Th2 cells are anti-inflammatory, acting through cytokines such as 
Il-10 [Pinderski 2002]. 
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E. The Role of Smooth Muscle Cells 
Smooth muscle cells migrate from the media to the intima in response to chemotactic 
cytokines such as platelet-derived growth factor (PDGF), which also promote smooth 
muscle cell replication. Smooth muscle cells are involved in the healing response to 
plaque events, and replication takes place in bursts, often in response to plaque 
rupture. This ‘healing response’ may in fact lead to plaque expansion, and weakening, 
[Manabe 2002, Clarke 2006], and the lysis and apoptosis of smooth muscle cells is an 
important stimulus for plaque progression [Boyle 2001, Boyle 2003, Littlewood 
2003]. 
 
Evidence from genetic studies has shown that smooth muscle cells in plaque are 
commonly monoclonal (i.e. clonally related to each other), emphasising the 
importance of smooth muscle cell replication in plaque expansion [Murry 1997]. The 
smooth muscle cells throughout the vasculature are a disparate group of cells, with 
different embryological origins. Coronary smooth muscle cells derive from the pro-
epicardial organ, while smooth muscle cells in the upper body derive from 
neuroectoderm, and in the lower body from mesoderm. It has been suggested that 
these different origins alter the response of individual vascular beds to injury [Libby 
2005, Majesky 2007]. 
 
F. The Role of the Extracellular Plaque Matrix 
A plaque is composed of both cells and the extracellular matrix. The extracellular 
matrix is synthesised by smooth muscle cells, and contains collagen, proteoglycans, 
elastin, extracellular lipid and calcium [Williams 2001]. It is broken down by matrix 
metalloproteinases (MMPs) [Newby 2006, Hobeika 2007, Johnson 2007]. In health, 
matrix synthesis and break-down is a balanced process, but it becomes deregulated in 
disease, where it has a multi-faceted influence. 
 
The cytokines PDGF and TGF-β induce excessive matrix generation, while MMPs 
make holes in the underlying fibrin-rich elastic lamina allowing smooth muscle cells 
to migrate to the intima. Experimental overexpression of MMP-inhibitors delays the 
migration of smooth muscle cells in injured arteries [Dollery 1999]. Arterial 
remodelling, as described by Glagov in the coronary circulation, relies on matrix 
proteinases to turn over the extracellular matrix so that the artery can expand outwards 
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[Glagov 1987]. Finally, the mechanical strength of the fibrous cap, a key determinant 
of plaque stability, is related to the collagen metabolism in the plaque. Here, collagen 
synthesis by smooth muscle cells serves to stabilise the plaque, while collagen 
destruction by MMPs has the opposite effect [Sukhova 1999]. In this way, 
macrophage-derived MMPs play a key role in destabilising the fibrous cap, and 
inducing plaque rupture [Libby 1996]. 
 
G. Angiogenesis 
As part of the inflammatory response in atherogenesis, and in response to tissue 
hypoxia in the plaque, angiogenic factors such as vascular endothelial growth factor 
(VEGF) are released. In infection, the purpose of these mediators is to improve the 
delivery of leucocytes and oxygen to assist the immune system in controlling the 
infection. In atheroma their role is controversial. The expression of angiogenic factors 
leads to endothelial migration, and the formation of capillary networks, as well as the 
upregulation of cellular adhesion molecules such as VCAM-1 [Couffinhal 1997, Pipp 
2003]. It has been recently suggested that plaque neovascularisation has the potential 
to aid plaque healing, and can provide a route for reverse cholesterol transport, and 
macrophage departure [Moreno 2009]. However, the improved capillary network also 
has detrimental effects: the improved oxygen and nutrient supply facilitate plaque 
growth, pro-atherogenic leucocytes may more easily enter and leave the plaque, and, 
crucially, the microvasculature weakens the plaque, increasing the likelihood of 
plaque haemorrhage and rupture, of vital importance both for plaque growth, and in 
initiating clinical syndromes [Khurana 2005, Doyle 2007]. Inhibitors of angiogenesis 
have been shown to reduce plaque growth in mice [Moulton 1999], but this is 
controversial amid concern that this approach may prove counter-productive, for 
example by reducing myocardial collateralisation which is protective in CAD [Chyu 
2007]. 
 
Angiogenesis is particularly important in carotid artery atherosclerosis, as plaque 
haemorrhage is far more frequent than in the coronary arteries, possibly because of 
high flow rates and pressures in the lumen and the vaso vasorum (see subsection J 
below) [Virmani 2007]. 
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H. Calcification 
Complex plaque contains areas of calcification. Calcification in the soft tissues may 
occur passively when calcium in precipitated during tissue necrosis. However active 
calcium deposition also occurs in atherosclerotic plaque, in a process similar to bone 
formation.  Bone-type cells, including osteoblasts, osteoclasts and chondrocytes are 
found in plaque, and all the features of osteogenesis have been identified in advanced 
human atherosclerotic lesions in both the coronary and carotid arteries  [Doherty 
2003, Jeziorska 1998]. Inflammatory cytokines such as TNF-α that are found in 
atherosclerotic plaque are known to affect osteoclast activity [Fuller 2002]. 
 
The frequency of calcification is similar in coronary and carotid arteries, with 
maximum calcification found in carotid arteries narrowed by greater than 70% of 
cross-sectional area. In both arterial beds calcification begins in a ‘speckled’ pattern, 
predominantly in areas rich in smooth muscle cells (such as pathologic intimal 
thickening), and at sites of smooth muscle cell loss. Calcium deposition is also found 
at the base of the necrotic core, close to the media. In carotid plaque calcification is 
often fragmented, and may be located deep in the plaque or close to the surface in the 
form of calcified nodules, which are uncommon in coronary artery disease. As 
discussed below in subsection J, juxtaluminal calcified nodules are important because 
they can be responsible for clinical syndromes with adherent thrombus formation. 
These appearances are found in 6-7% of symptomatic carotid plaques, as opposed to 
only 1-2% of plaques in coronary disease [Cirmani 2006, Virmani 2007]. 
 
I. The Focal Nature of Plaque Formation 
Despite the generalised nature of pro-atherosclerotic stimuli, atherosclerotic plaque 
formation is a highly focal process. This has many clinical implications, and so has 
been the object of much research. Branch points in the arterial tree are especially 
prone to plaque formation. The flow dynamics at branch points have been studied, and 
two apparently contradictory stimuli for plaque formation that have been identified 
are: a. low wall shear stress, and b. high oscillatory shear stress (turbulent flow), 
while laminar flow prevents plaque formation [Cheng 2006]. 
 
Wall shear stress is detected by endothelial cells, and they respond to different shear 
stress conditions with different patterns of gene expression [Brooks 2004]. Normal 
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laminar shear stress leads to nitric oxide synthase (NOS) and superoxide dismutase 
expression in endothelial cells. Nitric oxide, as well as being a potent vasodilator, also 
acts as a transcription factor, inhibiting the expression of pro-atherogenic cell surface 
molecules, such as VCAM-1 [Collins 2001]. Increased superoxide dismutase 
expression reduces oxidative stress, reducing pro-atherogenic LDL oxidation. 
 
High oscillatory wall shear stress leads to the upregulation of cell surface molecules 
such as ICAM-1 [Cheng 2006]. ICAM-1 and VCAM-1 expression is found at lesion 
prone sites in mice [Nakashima 1998]. In addition, high oscillatory shear stress may 
upregulate pro-inflammatory and pro-angiogenic genes. Examples include Il-8 
(proinflammatory), placental growth factor (angiogenic) and MMP-1 [Dai 2004].  
 
In the carotid artery, in particular, the greatest atherosclerotic plaque accumulation 
typically occurs on the outer surface wall of the proximal segment of the sinus of the 
internal carotid artery in the region of the lowest wall shear stress. The intimal 
thickness is the least on the flow divider side at the junction between the internal and 
external carotid arterial where wall shear stress is highest [Glagov 1988]. 
 
J. Differences between the Carotid and Coronary Circulations 
A pathological study of 526 symptomatic carotid arterial plaques removed at carotid 
endarterectomy showed that the pathology of culprit carotid plaques is broadly similar 
to that in the coronary circulation, with a high prevalence of fibrous cap rupture, lipid 
core and dense macrophage infiltration [Redgrave 2006]. However, as mentioned 
above, there are several important differences between the arterial beds [Virmani 
2006, Virmani 2007]. The reasons for the differences between the vascular beds are 
partially explained by the much higher blood flow in the carotid circulation, and by 
the shear stresses caused by the carotid bifurcation. 
 
1. Occlusive lumenal thrombosis triggered by plaque rupture is relatively uncommon 
in the carotid circulation, probably because the high blood flow means that plaque 
rupture is more likely to be followed by ulceration and embolisation of plaque 
contents and adherent thrombus. Plaque ulceration is a common finding in carotid 
disease, indicating that plaque contents and possibly adherent thrombus have 
embolised leaving an excavation in the lesion. This is the mechanism of a majority of 
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ischaemic strokes [Virmani 2006], while AMI is usually due to static arterial 
occlusion. In CAD patients who die suddenly, occlusive luminal thrombosis is found 
in 40%, whereas the incidence is 29%, 14%, and 3% after total anterior circulation 
infarction, partial anterior circulation infarction and posterior circulation infarction 
respectively [Burke 2001, Golledge 2000]. Thrombotic occlusion of a carotid artery is 
however more common in the presence of a severe lumenal narrowing as this negates 
the protective effect of high flow rates. When thrombotic occlusion does occur in 
carotid disease, distal propagation of thrombus is important, unlike in CAD [Golledge 
2000]. (Small non-occlusive mural thrombi are commonly found in carotid disease, 
and the formation (and embolisation) of thrombi in the carotid arteries, often in 
association with plaque rupture, are of course of central importance in cerebrovascular 
disease [Spagnoli 2004].) 
 
2. Although plaque rupture is important in both arterial beds, plaque erosion is 
uncommon in coronary disease, while being identified in 10% of symptomatic carotid 
plaques [Virmani 2006]. The precursor lesion for plaque erosion has not been clearly 
defined. However, as well as the typical ‘vulnerable plaque’ with thin fibrous cap and 
necrotic core, it also includes plaques lacking these features, sometimes referred to as 
‘pathological intimal thickening’ [Spagnoli 2004]. Hence a carotid plaque does not 
necessarily need the typical features of vulnerability identified in the coronary 
circulation to be at risk of erosion. 
 
The frequency of plaque rupture versus erosion is different between CVA and TIA. 
Among patients who have cerebrovascular syndromes associated with thrombotically 
active plaque, 90% of those with major stroke have ruptured fibrous plaque and 10% 
erosion, while among TIA patients only 66% have ruptured fibrous plaque and 34% 
erosion [Spagnoli 2004]. 
 
3. Plaque haemorrhage is far more frequent in the carotid circulation [Virmani 2006]. 
This is likely to be due to higher flow rates, as well as higher pressure in the arterial 
lumen and vasa vasorum. 
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4. Calcification is common in both carotid and coronary disease, but the subtype of 
atherosclerosis with calcified nodules is more common in carotid disease at 6-7% 
compared to 1-2% in coronary disease [Virmani 2006, Virmani 2007].   
 
K. Summary 
The process of atherogenesis is complex, owing to the large number of mechanisms 
involved. The handing of lipid in the arterial wall is an important early element. The 
role of the immune system is crucial for the development of plaque, and in this 
context may be considered maladaptive as many of the immune cells and mediators 
involved lead to an increase in the inflammatory cascade. Plaque instability is 
important both in terms of plaque growth and initiating clinical syndromes. Finally, 
considerations of flow dynamics and wall shear stress are important for determining 
the focal nature of the disease, and the differences between different arterial beds. 
 
Chapter 2 Page 43 Atherosclerosis 
 
2.2 EPIDEMIOLOGY OF ATHEROSCLEROSIS 
 
2.2.1 Introduction 
The prevalence of atherosclerosis has increased greatly over the past century and 
ischaemic heart disease is currently the leading cause of death worldwide [Murray 
1997]. Atherosclerosis was comparatively uncommon 100 years ago. At the beginning 
of the 20th century, cardiovascular disease accounted for less that 10% of all deaths 
worldwide. A century later, cardiovascular disease (CVD) accounts for nearly half of 
all deaths in the developed world and 25% in the developing world, and is predicted 
to overtake infectious disease as the main cause of death worldwide by 2020 [World 
Health Organisation (WHO) 2002, Murray 2001].  
 
Figure 2.4 Changing pattern of mortality, 1990 to 2020. Cardiovascular disease 
(yellow) is predicted to be the biggest single cause of mortality even in developing 
economies by 2020. EstMe = established market economies, DevE = developing 
economies, INJ = injury, CVD = cardiovascular disease, ONC = other 
noncommunicable diseases, CMPN = communicable, maternal, perinatal, and 
nutritional diseases. (From Murray 1996, cited in Gaziano 2005) 
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This change in morbidity and mortality is known as the ‘epidemiological transition’. 
Initially three stages were identified:  1. pestilence and famine, 2. receding pandemics, 
3. degenerative and man-made diseases [Omran 1971]. A fourth stage ‘delayed 
degenerative diseases’ was added later, and a fifth ‘obesity’ has been suggested 
[Olshansky 1986]. Many factors are involved in the epidemiological transition, but in 
general the stages can be identified in all countries and populations [Gaziano 2005]. 
 
2.2.2 The Five Stages of the Epidemiological Transition 
When ‘pestilence and famine’ are the leading causes of morbidity and mortality, the 
incidence of cardiovascular disease is necessarily low at 5-10%, mainly 
compromising rheumatic heart disease, other infectious diseases, the  nutritional 
cardiomyopathies, and not atherosclerotic disease. This is the case in parts of sub-
Saharan Africa and Asia today. For example, the average life expectancy in Sierra 
Leone is 34.2 years, by which age there has been little opportunity for the 
development of atherosclerosis [WHO 2002]. An improvement in the health of the 
population will still leave a subsequent burden of morbidity and mortality from 
diseases with a long latent period, such as rheumatic heart disease. 
 
Improving nutrition, combined with public health initiatives, lead to an improvement 
in population health, identified as the second stage: ‘receding pandemics’. Child and 
infant mortality (mainly related to infectious disease and malnutrition) is dramatically 
reduced, and the adult population is also less affected by infectious and nutritional 
diseases. Typically 10-35% of deaths are from CVD. Many regions of China are at 
this stage today, with a national average of 29% of deaths attributable to CVD 
[Murray 1996]. 
 
The third stage, ‘the age of degenerative and man-made disease’, follows on from the 
near total elimination of infectious disease and malnutrition, combined with an 
increase in the prevalence of lifestyle, dietary and social habits that elevate 
cardiovascular risk. Examples include widespread cigarette smoking, a diet high in 
saturated fat and salt, and a high proportion of the population employed in sedentary 
occupations. Many of the former Soviet states exemplify this stage, where the typical 
death rate from CVD is between 35% and 65% [WHO 2002]. 
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The fourth stage, ‘delayed degenerative disease’, occurs when improved lifestyle (in 
particular smoking cessation), and better healthcare, move the onset of CVD to later 
in life. Primary prevention programmes (e.g. entire population blood pressure and 
cholesterol screening), secondary prevention (e.g. aspirin therapy after ischaemic 
stroke) and better treatment of illness (e.g. coronary artery bypass grafting delaying 
morbidity and mortality from coronary artery disease) are all in place, and at this stage 
the age-adjusted CVD mortality rate begins to fall to around 50% of total mortality. 
Great Britain is currently in this stage. 
 
The projected fifth stage, ‘obesity’, has been predicted because epidemiological 
modelling indicates that the current obesity epidemic in the developed world will lead 
to an increase in type II diabetes mellitus, hypertension, dyslipidaemia, and 
consequently an increase in CVD. Already the obesity epidemic which has been 
identified in children has lead to an increased incidence of impaired glucose tolerance 
in childhood [American Diabetes Association 2000, Fagot-Campagna 2000], and the 
yearly rate of reduction in CVD deaths in the United States has decreased [Cooper 
2000].  
 
2.2.3 The Current Situation 
Epidemiological data from the United States show that of a total population of 300 
million, approximately 13 million have CAD: about 8 million have had a myocardial 
infarction, and 7 million have angina. There are 1 million CAD deaths annually, and 
this is the single greatest cause of death in both males and females, accounting for one 
fifth of all deaths and over half of all CVD deaths, and costing the US an estimated 
$100 billion [American Heart Association (AHA) 2004]. 
 
The population-based longitudinal cohort follow-up study of CAD in the town of 
Framingham (Framingham Heart Study) is the most important study of atherosclerosis 
epidemiology in the developed world. The predicted lifetime risk of symptomatic 
CAD (angina or MI) after age 40 is 49% for males and 32% for females [AHA 2004]. 
 
Worldwide, CAD is the greatest single cause of death if infectious disease is 
subdivided [Murray 1997]. CAD deaths are predicted by WHO to increase from an 
incidence of 7.1 million worldwide in 2002, to 11.1 million in 2020 [Bonow 2002]. In 
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the developing world, the incidence of death from all CVD (including CAD and 
stroke) is predicted to double from 9 million in 1990 to 18 million by 2020. This 
increase is driven both by population increases, but also by the predicted transition of 
the majority of developing countries to the third stage of the epidemiological 
transition [Murray 2001, Gaziano 2005]. 
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2.3 CURRENT METHODS OF IMAGING ATHEROSCLEROSIS 
 
2.3.1 Introduction 
In clinical practice, the diagnosis of clinically significant atherosclerosis is suspected 
from a patient’s symptoms, and this suspicion is informed by investigations such as 
electrocardiography (ECG), or exercise testing, combined with the ECG or 
echocardiography. However, methodologies have been developed to image 
atherosclerosis directly, either invasively or non-invasively. These can be further 
divided into purely lumenographic techniques, and those that image the vessel wall 
itself. Vessel wall imaging is important because, although lumenography allows 
stenoses to be identified, the vessel wall is the ‘diseased tissue’ in atherosclerosis. 
Methodologies include angiography, intravascular ultrasound (IVUS), computed 
tomography (CT), ultrasound, positron emission tomography (PET) and 
cardiovascular magnetic resonance (CMR). 
 
 
Figure 2.5 Severe stenosis of the distal left main coronary artery (arrow). From 
Popma 2004.  
 
 
 
Chapter 2 Page 48 Atherosclerosis 
 
2.3.2 Lumenography 
 
A. Invasive Angiography  
Coronary angiography was developed in the 1950s. Initially intravenous contrast was 
injected into the left ventricle or aortic root. In 1959 Sones serendipitously performed 
the first selective coronary angiography, and this rapidly became the technique of 
choice [Sones 1959, Sones 1962]. By enabling the operator to see stenoses in the 
arterial lumen, the effects of atherosclerosis could be clinically assessed. The 
development of selective coronary angiography was of key importance for modern 
clinical cardiology, and is still both the routine method, and the reference standard, for 
making the diagnosis of coronary artery disease. Angiography is an exclusively 
lumenographic technique, but can be combined with (and is an essential precursor to) 
invasive methods of arterial wall imaging such as intravascular ultrasound (IVUS) and 
optical coherence tomography (OCT) (see below). 
 
B. Computed Tomography Coronary Angiography 
Recent developments in technology have meant that CT can now be used to perform 
non-invasive coronary angiography. This form of imaging is called computed 
tomography coronary angiography (CTCA), sometimes loosely referred to as 
‘multislice CT’ because of the requirement to use fast scanners with multiple 
detectors. Technological developments have included an increase in the gantry speed 
to less than 0.5s per rotation, and an increase in the number of detector rows from 4 to 
128, with >1000 slice CT scanners in development. These improvements have 
increased the speed at which images can be acquired (reducing the potential for 
cardiac and respiratory motion artefact) and reduced slice thickness to less than 1mm 
(improving spatial resolution) [Raff 2005, Cordeiro 2006a].  
 
Using 64-slice systems to perform non-invasive coronary angiography, a specificity of 
94-100% for CAD, with a sensitivity of 76-86% has been reported [Cordeiro 2006b, 
Pontone 2007]. The near 100% negative predicative value has established the role of 
CTCA as a ‘rule out’ test, and improvements in sensitivity will, in future, reduce the 
need for additional confirmatory invasive coronary angiography. A major 
technological challenge for CTCA is the presence of calcium in the atherosclerotic 
arterial wall, which can obscure the lumen, leading to a false positive identification of 
Chapter 2 Page 49 Atherosclerosis 
 
coronary stenoses [Hoffmann 2004]. However, increased experience, improved 
scanner technology and automated analysis are helping to overcome this. 
 
Another limitation of CTCA is the radiation dose, which is currently between 9 and 
29 mSv for 64-slice systems. A recent modelling study has estimated that the lifetime 
cancer risk for a standard CTCA study varies from 1 in 3261 for an 80-year-old man 
to as high as 1 in 143 for a 20-year-old woman, although ECG-gating and scanner 
triggering reduced this to 1 in 5017 and 1 in 219 respectively [Einstein 2008]. This 
has made clinicians more reluctant to use CTCA as a simple ‘rule out’ test in low risk 
patients, and the precise role of CTCA in clinical algorithms has yet to be clearly 
defined. 
 
 
 Figure 2.6 Volume rendered CT coronary angiogram of the left coronary artery 
(courtesy of Dr M Rubens). 
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2.3.3 Arterial Wall Imaging 
 
A. Ultrasound (Non-Invasive) 
Non-invasive vascular ultrasound has been used predominantly to image 
atherosclerosis in the carotid arteries, as these are large arteries, and easily accessible 
for imaging. A visual assessment can be made of the presence of plaque, and the 
severity of any stenoses. In addition, Doppler ultrasonography (duplex) can be used to 
further evaluate the severity of stenoses by measuring flow acceleration. Carotid 
ultrasound is routine after a cerebrovascular event or in more elderly patients before 
coronary artery bypass grafting, and has been suggested to screen for cerebrovascular 
disease in at risk populations [Saleem 2008]. Ultrasound has also been used in plaque 
characterisation, and fibrous cap thickness correlated with patient symptoms [Devuyst 
2005]. 
 
However, in terms of atherosclerosis research, the main focus has been carotid intima-
media thickness (C-IMT) [Sankatsing 2005].  The ultrasound transducer is applied to 
the patient’s neck, and B-mode ultrasound is used to measure the distance between the 
lumen-intima interface and the media-adventitia interface of the posterior wall of the 
carotid artery. This is a one-dimensional measurement, although many protocols 
average the measurement along a set length of the arterial wall to improve 
reproducibility. As only the posterior wall of the carotid artery is imaged, the 
asymmetry of the atherosclerotic process may be ignored. There is considerable 
variability in imaging protocols, and the reproducibility of C-IMT is variable, with an 
inter-scan coefficient of variation ranging from 2.6% to 10.2% [Stensland-Bugge 
1997]. This means that to have adequate power, C-IMT studies often involve several 
thousand patients.  
 
Observational, follow up and therapeutic studies have been performed [Sankatsing 
2005]. C-IMT correlates with histology, risk factors for atherosclerosis, and the 
presence of atherosclerosis in the coronary arteries [Pignoli 1986, Poli 1988, Craven 
1990]. Three large studies have indicated that C-IMT is a surrogate marker for 
vascular risk [Chambless 1997, O’Leary 1999, Bots 1997]. It has been used as a 
surrogate end-point in clinical trials in atherosclerosis, for example the recent 
Chapter 2 Page 51 Atherosclerosis 
 
ENHANCE study (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances 
Atherosclerosis Regression) [De Groot 1998, Smilde 2001, Kastelein 2008]. 
 
B. Intravascular Ultrasound 
Intravascular ultrasound (IVUS) is an invasive technique that is used to assess the 
extent of disease in the arterial wall [Popma 2005]. An ultrasound transducer is placed 
at the tip of a cardiac catheter and inserted into the coronary artery. The cross-
sectional anatomy of the arterial wall can be determined, and all three layers 
(endothelium, media and adventitia) are visible [DeMaria 2006]. An IVUS 
examination can detect the presence of plaque, can perform plaque characterisation, 
including the identification of vulnerable or ruptured plaques, and can detect Glagov-
type outward arterial remodelling [Prati 2001, Maehara 2002].  
 
Figure 2.7 IVUS characterization of plaque morphology. A, concentric soft 
plaque; B, Calcification; C, Focal calcification (arrows); D, extensive 
calcification (arrows); E, Adjacent cross sections of a vulnerable plaque show a 
thin fibrous cap (long arrow) and a large lipid core (short arrow). From Popma 
2005. 
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It was IVUS work that identified that patients presenting with acute coronary 
syndromes have an average of two ruptured plaques leading to the concept of the 
‘vulnerable patient’ as described in section 2.1.2 [Riofoul 2002]. One limitation of 
IVUS in the assessment of plaque vulnerability is that the resolution of IVUS (150 to 
300µm) is insufficient to detect thin fibrous caps (50 to 75µm). This limitation has 
been overcome by the use of optical coherence tomography (OCT), which has a 
resolution of 4 to 20µm [Stamper 2006]. Nevertheless, ‘virtual histology’ by IVUS 
has been described, where spectral analysis of the backscatter of the ultrasound signal 
is used to model plaque in three dimensions. This approach has been validated in ex 
vivo coronary arteries, and was successful in identifying lipid rich necrotic cores, 
fibrofatty plaques, and regions of calcification [Nair 2002, Murashige 2005].  
 
As well as plaque characterisation, IVUS has also been used in the quantitative study 
of plaque. Volumetric analysis of IVUS data is able to quantify the degree of 
atheroma present, and this has been used as an endpoint in clinical trials of medical 
therapy to look for atherosclerosis regression, such as the REVERSAL (Reversal of 
Atherosclerosis with Aggressive Lipid Lowering) and the recent ASTEROID (A 
Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived 
Coronary Atheroma Burden) trials [Nissen 2004, Nissen 2006]. For follow-up studies, 
this has the obvious disadvantage that at least two cardiac catheterisations with IVUS 
measurements are required. As well as the radiation dose, IVUS carries a small but 
definite risk of serious procedural complications (arterial occlusion, embolism, 
dissection or thrombus) of 0.4% [Hausmann 2004], which is significant given that the 
REVERSAL trial recruited 502 subjects, and the ASTEROID trial 507 [Nissen 2004, 
Nissen 2006]. 
 
C. Computed Tomography 
Coronary Artery Calcium (CAC) Scoring 
For over 10 years before CTCA was feasible, CT has been used to identify patients 
with significant coronary atherosclerosis by detecting the presence of calcification in 
the coronary arteries, using electron beam CT (EBCT). This technique produces a 
coronary artery calcification (CAC) score, which has been validated as a marker of 
atherosclerotic risk [Achenbach 2005]. CAC scoring can be combined with CTCA 
[Stanford 2004]. 
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CAC scoring has been correlated with histology and validated in post mortem 
coronary arteries, where the presence of calcification has been demonstrated as a more 
sensitive indicator than lumenal narrowing for the presence of atherosclerosis 
[Rumberger 1995, Sangiorgi 1998]. The extent of coronary-artery calcification 
correlates with findings on coronary angiography [Budoff 2002]. The CAC score is 
predictive of future cardiac events [Keelan 2001]. Finally, it has been used as an end 
point in plaque regression trials with statins [Callister 1998]. 
 
Plaque imaging 
More recently CT has been used to attempt to characterise soft (non-calcium 
containing) coronary atherosclerotic plaque, usually in combination with CTCA. 64-
slice CT has a sensitivity of 84% and a specificity of 91% for the detection of non-
flow limiting plaque compared with IVUS [Leber 2005]. In addition, good correlation 
with IVUS has been identified in studies of plaque characterisation [Komatsu 2005, 
Dragu 2008]. Volumetric analysis of plaque is possible [Leber 2005]. In addition 
CTCA has been used to identify Glagov-type outward arterial remodelling [Caussin 
2004]. 
 
D. Positron Emission Tomography 
Positron emission tomography (PET) imaging is a form of non-invasive radionuclide 
imaging which uses positron emitting isotopes. A tracer molecule, labelled with an 
isotope, is injected into the patient and then detected by the scanner. The most 
commonly used tracer is the radioactive glucose isotope 18F-fluorodeoxyglucose 
(18FDG). This is taken up by metabolically active tissue, so that metabolic processes 
can be interrogated at tissue level. 18FDG-PET was originally developed for 
neuroimaging. Currently it is in widespread use for the identification of malignancy. 
In these scans it was noted that almost half of patients had high 18FDG uptake in the 
large arteries, particularly the aorta. This was attributed to the presence of 
metabolically active atherosclerotic plaques, and, in fact, these signals are a common 
source of artefact in PET imaging for malignancy [Yun 2001]. Additionally it was 
already known that PET was sensitive and specific for vascular inflammation in the 
inflammatory vasculitides such as Takayasu’s Arteritis (TA) (see section 3.2.5 for a 
fuller discussion of imaging in TA) [Webb 2004]. 
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The first clinical PET atheroma study imaged 8 patients with an angiographic carotid 
artery stenosis after a recent transient ischaemic attack (TIA). PET was co-registered 
with CT, and showed 18FDG accumulation in plaque ipsilateral to symptoms in all 
patients, which was significantly greater than in plaque on the contralateral side. 
Areas of 18FDG uptake corresponded with dense inflammatory (macrophage) infiltrate 
on histology after subsequent carotid endarterectomy, confirming that PET was 
identifying inflamed plaques [Rudd 2002]. A subsequent larger study confirmed these 
findings, and correlated the degree of 18FDG uptake with the degree of macrophage 
staining in corresponding histological sections [Tawakol 2006]. 
 
PET can also be co-registered with CMR. Currently two separate scans are required, 
and a special cushion is used to maintain identical posture. The images are then co-
registered using anatomical landmarks. This has the potential advantage over PET-CT 
that CMR provides better plaque imaging. In a study of 12 patients with recent TIA 
and an ipsilateral high-grade carotid stenosis, in 7 patients, high 18FDG uptake was 
identified at the site of a CMR-confirmed plaque. In the remaining 5 patients, 18FDG 
uptake in the suspected culprit plaque was low but, in 3 of the 5, a different ipsilateral 
lesion with a high level of 18FDG uptake, but without high-grade stenosis, was 
identified [Davies 2005]. This finding gives an indication of how this technology 
could be used in future to guide patient care, and raises the possibility that current 
guidelines for carotid endarterectomy based purely on percentage stenosis fail to 
address a significant proportion of culprit lesions. 
 
Plaque 18FDG uptake has itself been used as the major endpoint in a randomised 
controlled trial of statin therapy. Patients in whom a plaque with high 18FDG uptake 
was identified on a PET-CT (performed to screen for malignancy) were randomised to 
simvastatin or placebo. On re-imaging at 3 months, there was significantly less 18FDG 
uptake in the target lesion in patients randomised to simvastatin. This was the first 
direct in vivo human evidence that statins reduce plaque inflammation, giving insight 
into how they may act to stabilise plaque. It also indicates how this type of imaging 
could be used in future trials [Tahara 2006]. 
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Figure 2.8. PET, contrast CT, and co-registered PET/CT images in the sagittal 
plane, from a patient presenting with left-sided hemiparesis. (Left) A region of 
18FDG uptake is noted in the neck (arrow). (Middle) CT angiography 
demonstrates a plaque causing stenosis of the right internal carotid artery 
(arrow). (Right) Co-registered PET/CT demonstrating that the region of 18FDG 
uptake corresponds to the plaque. Adapted from Rudd 2002. 
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The main limitation of PET, particularly for serial studies, is radiation exposure. 
18FDG is radioactive, and a typical PET study has a radiation exposure of 
approximately 5 mSv (250 chest X ray equivalents) [European Commission 2001]. 
Apart from the radiation dose, the main limitation of PET is poor spatial resolution, at 
about 5-7mm, which yields a low level of anatomical detail. At this level of 
resolution, with PET alone it is difficult or impossible to distinguish between high 
signal from an inflamed plaque in the carotid artery and, for example, an inflamed 
cervical lymph node. However, as mentioned above, this difficulty has to a large 
extent been overcome by advances in imaging hardware and software that allow PET 
images to be co-registered with another modality with much higher spatial resolution 
(most commonly CT, often in combined PET-CT scanners) [Davies 2006]. These 
difficulties have not yet been overcome in the coronary arteries, because of the small 
size of plaques (area typically less than 10mm2), artefact from cardiac motion, and 
high ‘background’ tracer uptake from the myocardium itself. In spite of these 
difficulties, 18FDG uptake has been demonstrated in the coronaries [Dunphy 2005]. 
Nevertheless, most PET atheroma studies have focussed on the carotid arteries, the 
iliofemoral arteries and the aorta. 
  
Current work is attempting to identify novel tracer molecules for imaging. Labelling 
other molecules allows the process of atherogenesis to be studied in more detail in 
vivo [Davies 2006]. Some work has already been published in humans using 
radiolabelled oxidised LDL, allowing identification of macrophages and foam cells, 
and radiolabelled antibodies and antibody fragments have also been used  [Iuliano 
1996, Shaw 2001]. 
 
E. Cardiovascular Magnetic Resonance 
This is discussed in Chapter 4. 
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2.3.4 Conclusion 
Making a diagnosis of clinically significant atherosclerosis is important in clinical 
practice so that appropriate treatment can be initiated. Lumenal assessment is 
important and often needs invasive testing, especially in CAD. Assessment of the 
arterial wall is of increasing importance in clinical practice and research. This can be 
done invasively (by IVUS or OCT), or non-invasively, especially outside the coronary 
circulation, by ultrasound, CT, PET, or CMR. Quantitative assessment of atheroma 
burden enables clinical studies of atheroma progression and regression with 
therapeutic agents to be performed. CMR offers the opportunity for non-invasive 
serial measurements of atheroma burden without ionising radiation exposure, and so 
is of importance in the study of atherosclerosis. 
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CHAPTER 3 
VASCULAR DISEASE IN THE INFLAMMATORY ARTHRITIDES 
 
3.1 SYSTEMIC LUPUS ERYTHEMATOSUS 
Systemic lupus erythematosus (SLE) is a multisystem, auto-immune, connective 
tissue disorder. The clinical spectrum is broad, including accelerated atherosclerosis 
[D’Cruz 2007]. There is a female predominance of 9:1, with a peak of onset between 
age 20 and 40. The incidence is higher among Asian and African ethnic groups. No 
clear aetiology has been identified, and the genetics are complex.  
 
3.1.1 Diagnostic Criteria 
The consensus criteria for the diagnosis of SLE are those of the American College of 
Rheumatology (Table 3.1) [Tan 1982, Hochberg 1997]. Various objective clinical 
tools have been used to quantify disease severity in SLE. These are the Safety of 
Estrogens in Lupus Erythematosus-National Assessment (SELENA) and the Systemic 
Lupus Erythematosus Disease Activity Index (SLEDAI), often combined as 
SELENA-SLEDAI,[Bombadier 1992, Petri 1998, FitzGerald 1999] the Systemic 
Lupus International Collaborating Clinics/American College of Rheumatology 
Damage Index (SLICC/ACR),[Gladman 1997, Gladman 2000] and the British Isles 
Lupus Assessment Group tool (BILAG)[Symmons 1988]. 
 
3.1.2 Clinical Features 
SLE is an autoimmune condition, but the mechanism of the autoimmunity is itself 
complex. A study of 130 US service personnel who developed SLE, and who had had 
serum stored approximately every second year in the US Department of Defence 
serum repository, showed that in 88 percent of the patients, at least one SLE 
autoantibody tested was present before the diagnosis (up to 9.4 years earlier, mean, 
3.3 years). Often the earliest available serum sample was positive, indicating that 
these measures of time are underestimates. This suggests that autoantibodies alone are 
not responsible for clinical disease.  Antinuclear antibodies (ANA) were present in 78 
percent, anti-double-stranded deoxyribonucleic acid (DNA) antibodies in 55 percent, 
anti-Ro antibodies in 47 percent, anti-La antibodies in 34 percent, anti-Sm antibodies 
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in 32 percent, anti-nuclear ribonucleoprotein antibodies in 26 percent, and 
antiphospholipid antibodies in 18 percent. The appearance of antibodies followed a 
predictable course [Arbuckle 2003].  
 
The incidence of SLE has been estimated at 5.56 per 100 000 in the USA between the 
years of 1980 and 1992. This is a marked increase from an incidence of 1.51 per  
100 000 from 1950-1979, although this may be related to milder forms of the disease 
being recognised [Uramoto 1999]. The incidence in the UK is 3.8 per 100 000 per 
year, with a prevalence of 26.2 per 100 000. The incidence among the white UK 
population is 3.0 per 100 000 per year, whereas it is 10.0 among Asians and 21.9 
among the Afro-Caribbean population, the highest of any population studied so far 
[Danchenko 2006]. 
 
The pathogenesis is unclear. The autoantibodies associated with SLE respond to 
predominantly intracellular antigens. The immune system may be exposed to these 
when cells die. This can occur either due to errors in programmed cell death 
(apoptosis) or in unprogrammed cell death (such as in tissue necrosis). Defective 
uptake of apoptotic cells has been described in SLE. This can lead to endogenous 
intracellular nuclear antigens being exposed on the apoptotic cell surface for 
prolonged periods and subsequent uptake up by macrophages, processing and 
presentation to T and B cells. The usual mechanisms that guarantee ‘tolerance’ of 
endogenous material in SLE have been found to be deranged at various stages, 
leading to autoimmunity [Munoz 2005]. 
 
Linkage studies have found linkage disequilibrium between the locus 1q23.2 and 
SLE. This locus, called the pentraxin locus, contains the genes coding for C-reactive 
protein (CRP) and serum amyloid P component (SAP). CRP itself is involved in 
apoptosis. Mice with targeted deletions of SAP develop an autoimmune lupus-like 
illness [Gillmore 2004]. CRP levels are typically inappropriately low in SLE, and two 
haplotypes at the CRP locus have been significantly associated with reduced basal 
CRP expression (CRP 2 and CRP 4) [Linares 1986]. In addition the CRP 4 haplotype 
was associated with ANA antibody production and clinical SLE [Russell 2004].  
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Table 3.1 ACR criteria for SLE.   
“For the purpose of identifying patients in clinical studies, a person shall be said to have systemic lupus 
erythematosus if any 4 or more of the 11 criteria are present, serially or simultaneously, during any 
interval of observation.” [Tan 1982, Hochberg 1997]. 
 Criterion Definition 
1 Malar Rash Fixed erythema, flat or raised, over the malar eminences, tending to spare the 
nasolabial folds. 
2 Discoid Rash Erythematous raised patches with adherent keratotic scaling and follicular 
plugging, atrophic scarring may occur in older lesions. 
3 Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or 
physician observation. 
4 Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by physician. 
5 Arthritis Non-erosive arthritis involving 2 or more peripheral joints, characterized by 
tenderness, swelling, or effusion. 
6 Serositis a) Pleuritis-convincing history of pleuritic pain or rubbing heard by a 
physician or evidence of pleural effusion 
               OR 
b) Pericarditis-documented by ECG or rub or evidence of pericardial 
effusion . 
7 Renal disorder a) Persistent proteinuria greater than 0.5 grams per day or greater than 3+ if 
quantitation not performed 
               OR  
b) Cellular casts--may be red cell, haemoglobin, granular, tubular, or mixed . 
8 Neurologic 
disorder 
a) Seizures--in the absence of offending drugs or known metabolic 
derangements, e.g., uraemia, ketoacidosis, or electrolyte imbalance  
               OR 
b) Psychosis--in the absence of offending drugs or known metabolic 
derangements, e.g., uraemia, ketoacidosis, or electrolyte imbalance  
9 Hematologic 
disorder 
a) Haemolytic anaemia--with reticulocytosis 
               OR  
b) Leucopenia--less than 4,000/mm3 total on 2 or more occasions  
               OR  
c) Lymphopenia--less than 1,500/mm3 on 2 or more occasions  
               OR  
d) Thrombocytopenia--less than 100,000/mm3 in the absence of offending 
drugs  
10 Immunologic 
disorder 
a) Anti-DNA: antibody to native DNA in abnormal titer  
               OR  
b) Anti-Sm: presence of antibody to Sm nuclear antigen  
               OR  
c) Positive finding of antiphospholipid antibodies based on: 
1). an abnormal serum level of IgG or IgM anticardiolipin antibodies,OR 
2). a positive test result for lupus anticoagulant using a standard method,OR 
3). a false-positive serologic test for syphilis known to be positive for at least 
6 months and confirmed by Treponema pallidum immobilization or 
fluorescent treponemal antibody absorption test. 
11 Antinuclear 
antibody 
An abnormal titre of antinuclear antibody by immunofluorescence or an 
equivalent assay at any point in time and in the absence of drugs known to be 
associated with "drug-induced lupus" syndrome 
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3.1.3 Cardiovascular Disease in SLE 
Cardiovascular disease in SLE includes atherosclerosis, vascular inflammation, 
Raynaud’s phenomenon and a pro-coagulant tendency associated with 
antiphospholipid antibodies. 
 
 a. Coronary artery disease (CAD) 
It was first noted in 1976 that there is a bimodal pattern of death in SLE. An early 
peak (within the first year of diagnosis) was related to nephritis and sepsis. A later 
peak (at around 8 years after diagnosis) was related to premature myocardial 
infarction [Urowitz 1976]. This confirmed the findings of an early necropsy study of 
the hearts of patients with SLE which showed that, in patients treated with 
corticosteroids, there was an excess of atherosclerosis, despite the young age of the 
patients (mean 32 years) [Bulkley 1975].  
 
Overt and subclinical atherosclerosis have been described in SLE [Petri 1992a, Petri 
1992b, Roman 2001, Roman 2003, Selzer 2004, Wolak 2004]. In an SLE cohort in 
Sweden, the risk of myocardial infarction was 9 times that in a control population 
[Jonsson 1989]. A more recent comparison in the US revealed that in females between 
the ages of 35 and 44 with SLE, there was an incidence of myocardial infarction more 
than fifty times greater than in the Framingham dataset [Manzi 1997]. Three case 
control studies have identified accelerated atherosclerosis in SLE, independent of the 
traditional risk factors [Roman 2003, Asanuma 2003, El-Magadmi 2004]. Using 
computed tomography (CT), coronary artery calcification was found in 31% of a 
cohort of 65 patients with SLE compared with 9% of controls. The mean coronary 
artery calcification (CAC) score in patients was 68.9 while in controls it was 8.8. 
These differences were statistically highly significant [Asanuma 2003]. A single 
photon emission computed tomography (SPECT) study showed myocardial perfusion 
abnormalities in 35% of females with SLE who had no prior history of cardiovascular 
disease [Bruce 2000]. 
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b. Carotid Arterial Plaque 
The presence of atherosclerotic plaque in the carotid arteries can be determined non-
invasively by ultrasound or CMR. Many ultrasound-based studies have been 
performed, but none yet by CMR. Identification of carotid plaque is important 
because it indicates that a patient has atherosclerosis. Atherosclerosis is recognised as 
a ‘whole body’ disease, so detecting it in one vascular bed informs the treatment of 
the entire patient, and this is associated with the concept of the ‘vulnerable 
patient’[Naghavi 2003a, Naghavi 2003b, Naghavi 2006].  Other non-invasive 
measures such as carotid intima-media thickness (C-IMT) can be suggestive of 
atherosclerosis, but are not diagnostic. As discussed below, in SLE, C-IMT may not 
be a reliable marker of disease. 
 
Registry data using ultrasound have found a prevalence of carotid plaque of 40% in 
the Pittsburgh registry of 175 females with SLE,[Manzi 1999] and 37% in the Cornell 
registry of 197 sequential outpatients (mean age 44). The incidence among a 
population of age-matched controls was 15% (p<0.001). The relative risk of carotid 
artery plaque was 2.4 times greater among SLE patients (p<0.001). There was excess 
risk in every age group, and the effect was greater the younger the patient, with a 
relative risk of 5.6 times in those less than 40. In a multivariate regression analysis, 
the only factors that were independently associated with the presence of 
atherosclerosis were age, cholesterol and a diagnosis of SLE [Roman 2003]. The 
Cornell registry also showed that the presence of carotid plaque was associated with 
markers of SLE disease severity, these markers indicate the cumulative severity of the 
disease. The association held, even when the damage index was revised to exclude 
confounding conditions that may have been associated with corticosteroid therapy. 
 
In a non-SLE population, the presence of carotid artery plaque is a predictor of future 
cardiovascular events (and is more reliable for this than elevated C-IMT), and the 
identification of atherosclerosis in the carotid or femoral arteries by ultrasound has 
been associated with a three-fold risk of AMI in a prospective registry of 1257 males 
[Belcaro 1996,Salonen 1993].  
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c. Carotid Intima Media Thickness (C-IMT) 
Studies of C-IMT in SLE have not shown a strong correlation between elevated C-
IMT and the presence of atherosclerotic plaque. In fact the opposite has been found to 
be the case. This is surprising as elevated C-IMT is commonly thought of as an early 
marker of atherosclerosis in non-SLE populations: in a study of 1257 males, none 
with SLE, each 0.1mm increase in C-IMT was associated with an 11% increase in risk 
of acute myocardial infarction (p<0.001) [Salonen 1993]. However, in the Cornell 
registry of SLE patients mean C-IMT was 10% less in SLE patients than in age-
matched controls [Roman 2003] and, in the Pittsburg registry, mean C-IMT in SLE 
patients was less than that in the Women’s Healthy Lifestyle Project from the same 
institution (0.68mm vs 0.71mm)[Manzi 1999]. Recent case-control studies in SLE 
found no increase in carotid arterial thickness despite a high frequency of plaques 
[Selzer 2004, Wolak 2004]. However, a case-control study comparing SLE patients 
who had clinical atherosclerosis with SLE patients without atherosclerosis, found C-
IMT was greater in the SLE and atherosclerosis group. This was a small study (26 
patients in each group) and no significant association with risk factors was found 
[Svenungsson 2001]. 
 
d. Endothelial Dysfunction 
Endothelial dysfunction is commonly assessed by flow-mediated dilatation (FMD) in 
the brachial artery [Uehata 1997]. Endothelial dysfunction has been associated with 
virtually all risk factors for atherosclerosis [Celermajer 1993, Celermajer 1994, 
Wiesmann 2004]. Several studies have shown that patients with SLE have evidence of 
endothelial dysfunction. In a study that excluded patients with CVD or significant 
CVD risk factors, FMD was 5% in the SLE population and 12% in the controls. [Lima 
2002]. A more recent study found a median FMD of 5.6% in SLE vs 8.0% in controls. 
These authors performed 5 years of clinical follow up, but found no association 
between clinical event rates and FMD, although numbers were small[Piper 2007]. In a 
less selected SLE cohort, FMD was 3.6% compared with 6.9% in the controls 
(p<0.01). In this cohort, FMD correlated negatively with C-IMT (r = -0.37, p<0.01), 
and this was borne out in a stepwise regression model [El-Magdami 2004]. Hence 
vascular thickening in SLE is correlated with endothelial dysfunction. Impaired 
endothelial function is a feature of vascular inflammation and has been associated 
with primary systemic necrotizing vasculitis [Raza 2000, Filer 2003]. It has also been 
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associated with an exogenously triggered systemic inflammatory response, such as 
after healthy volunteers were administered Salmonella typhi vaccine [Hingorani 
2000]. Anti-inflammatory therapy has been associated with normalisation of 
endothelial function in primary systemic vasculitis [Raza 2000]. 
 
e. Myocardial function 
Ejection fraction and left ventricular (LV) mass were higher and LV hypertrophy 
(LVH) was more common in SLE patients than normal controls. The association 
between LVH and SLE persisted even after other risk factors such as hypertension 
and renal disease had been controlled for. In addition, arterial stiffness as determined 
by radial applanation tomography was a strong determinant of LV mass in SLE 
[Pieretti 2007]. Vascular stiffening is a common finding in SLE, and it has been 
hypothesised that inflammation-mediated vascular stiffening plays a significant role in 
LV structural change in SLE [Roman 2005]. 
 
f. No role for markers of vascular inflammation 
In the general population, elevated serum levels of CRP, ICAM-1 and CD40 ligand 
have been associated with increased vascular risk, but, in SLE, these serum markers 
have been so far unable to predict vascular risk because of the increased baseline level 
of inflammation. In one study the percentage of SLE patients with elevated 
inflammatory markers was: CRP 42%, IL-6 54%, TNF p55 receptor 36%, CD40 
ligand 18%, ICAM-1 65% and VCAM-1 22%; however, there was no association 
between elevated inflammatory markers and carotid plaque [Roman 2003]. 
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3.1.4 Aetiology of Atherosclerosis in SLE 
a. SLE as a vascular risk factor 
There is an excess of conventional vascular risk factors in SLE [Svengungsson 2001]. 
SLE patients have more hypertension than controls (48% v 25%), and are more likely 
to be smokers (35% v 16%) [Asanuma 2003]. The Toronto cohort study of 250 
women with SLE showed a higher incidence of hypertension, diabetes and an earlier 
menopause than in healthy controls. Until recently this was mainly attributed to 
corticosteroid usage, and given as the explanation for the majority of excess 
atherosclerosis in SLE (see section 3.1.4 d below). [Petri 1992a, Petri 1992 b, Petri 
1996]. In the Toronto cohort, the 10 year CV risk calculated using the Framingham 
multiple risk factor assessment was the same for SLE patients and matched controls, 
mainly due to young age (mean 44 years). Given the excess of CV disease in SLE, the 
authors concluded that the Framingham risk factor model does not adequately 
reflected degree of CV risk in SLE [Bruce 2003].  
 
SLE itself is a strong independent risk factor for atherosclerosis. A retrospective 
registry-based study of 263 patients demonstrated a 7.5 times relative risk for 
coronary heart disease after controlling for conventional risk factors using the 
Framingham model. The relative risk of death from myocardial infarction was 17.0, 
and 7.9 for stroke [Esdaile 2001]. A recent study confirmed that SLE disease activity 
is an independent predictor of CAD. Modelling 4094 person-years of follow up 
revealed that, after controlling for all other relevant factors including corticosteroid 
dosing, the degree of lupus activity in the previous year correlated with index events 
of CAD [Karp 2008].  Atherosclerosis is increasingly recognised as a disease of 
vascular inflammation, [Ross 1999] and it seems likely that the high degree of 
vascular inflammation in SLE can accelerate this process.  
 
A distinct risk profile has emerged for atherosclerosis in SLE comprising: elevated C-
IMT, frequently positive lupus anticoagulant, elevated LDL cholesterol, triglycerides 
and lipoprotein(a), elevated alpha 1-antitrypsin and homocysteine levels and 
decreased HDL cholesterol [Svengungsson 2001].  
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b. Autoantibodies 
Autoimmuity is common in SLE, but a higher degree of autoimmunity has been found 
in SLE patients without atherosclerosis. It has been suggested that there are two forms  
of SLE: a less virulent form, with fewer autoantibodies but more atherosclerosis, and 
a more virulent form with more autoantibodies, but less atherosclerosis. In the Cornell 
cohort, SLE patients with carotid plaque were less likely to have autoantibodies 
against ribonuclear proteins (anti-Smith (Sm), RNP, Ro and La). In fact, the presence 
of anti-Sm autoantibodies was the strongest negative predictor for atherosclerosis. 
These authors suggested that the more virulent form of SLE is more likely to receive 
aggressive immunosuppression which may hinder the progression of atherosclerosis. 
The frequency of the most common SLE autoantibody, ds-DNA, was not associated 
with plaque [Roman 2003]. 
 
c. Antiphospholipid Antibodies 
Clinical and experimental evidence supports a link between antiphospholipid 
antibodies and atherosclerosis [Vaarala 1995, Vaarala 2000, Jara 2003]. In 62 MI 
survivors under the age of 45 (none of whom had SLE), 13 (21%) had elevated 
antiphospholipid (anticardiolipin) antibody levels during follow up [Hamsten 1986]. 
Antiphospholipid antibodies are associated with arterial and venous thrombosis; the 
suggested aetiology for atherosclerosis is the antibody-mediated activation of 
endothelial cells [Simantov 1995]. Antiphospholipid antibodies are common in SLE. 
The antiphospholipid antibody syndrome (APS) is typically present in a quarter to a 
third of SLE patients, although some form of antibody positivity can be detected in up 
to 61% of patients [Harris 1983, McMahon 2006].  It is not clear to what extent 
antiphospholipid antibodies are responsible for accelerated atherosclerosis [Manzi 
1999, Petri 2002]. An increased incidence of lupus anticoagulant has been 
demonstrated in SLE patients with CVD compared to SLE patients without 
[Svengungsson 2001]. However, the Cornell registry found no association between 
the incidence of positive antiphospholipid antibodies and plaque; in fact 
anticardiolipin antibody was significantly less common in patients with plaque, and 
there was no difference in patients with lupus anticoagulant [Roman 2003].  
 
Chapter 3 Page 67 SLE and TA 
 
d. Steroids and other therapies 
Data on the role of corticosteroids in atherosclerosis in SLE is divided. In a non-SLE 
population, high dose corticosteroids are associated with glucose intolerance and 
diabetes, central obesity, hypertension and dyslipidaemia- all risk factors for 
atherosclerosis. However, in SLE, vascular inflammation is also associated with 
atherosclerosis, so low dose steroids might be expected to prevent atherosclerosis, as 
has been demonstrated in an animal model of familial hypercholesterolaemia 
[Makheja 1989]. In the Johns Hopkins Lupus Cohort, SLE patients with confirmed 
CAD had a longer mean duration of corticosteroid use (14.3 years versus 7.2 years, p 
< 0.0001), and duration of corticosteroid use was an independent risk factor for CAD 
[Petri 1992a, Petri 1992b]. A recent cohort study of 4094 person-years of follow up 
found that corticosteroid dosing (and SLE activity) independently correlated with the 
incidence of CAD, even after controlling for all other relevant factors [Karp 2008]. 
However, in the Cornell registry, the incidence of previous or current steroid 
treatment was less common among patients with carotid plaque, and the average 5-
year daily steroid dose was lower.  
 
In both cohorts there was less atherosclerosis in patients who had been treated with 
the antimalarial hydroxycholoquine. Hydroxycholoquine reduces cholesterol levels, 
[Petri 1994] but also reduces vascular inflammation through better disease control. 
Disease control seems important as patients with carotid atherosclerosis also have a 
lower incidence of previous cyclophosphamide use [Roman 2003].  
 
e. Lipid Profile 
Dyslipoproteinaemia has been demonstrated in SLE, and in particular a pattern of 
elevated plasma triglyceride and decreased HDL with a normal LDL level [Asanuma 
2003, Borba 1997]. This profile has been associated with CVD in SLE. Lipoprotein(a) 
(Lp(a)) is elevated in SLE. Lp(a) is an independent risk factor for atherosclerosis, 
recruiting inflammatory cells through interaction with the integrin Mac-1 [Borba 
1994]. Patients with SLE and CVD have elevated plasma concentrations of circulating 
oxidised LDL (Ox LDL) compared with SLE patients without CVD [Svenungsson 
2001].   OxLDL has proinflammatory and atherogenic properties [Witztum 1994]. 
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f. Genetic 
Variant alleles of mannose-binding lectin are associated with both an increased risk of 
lupus and arterial thrombus in patients with lupus. The O/O genotype confers a hazard 
ratio of 7.0 compared with the usual A/A genotype [Ohlenschlaeger 2004].  
 
g. Summary 
In a final logistic regression analysis, the disease-related factors that significantly and 
independently correlated with the presence of plaque in SLE were: higher damage-
index score, longer duration of disease, older age at diagnosis, non-treatment with 
cyclophosphamide, and absence of anti-Sm or anticardiolipin antibody. It is important 
that longer disease duration, greater severity of disease and less aggressive 
immunosuppression are all correlated with atherosclerosis in SLE. This is strongly 
suggestive that SLE itself is a potent risk factor for SLE [Roman 2003]. 
 
 
 
3.1.5 Therapy for Atherosclerosis in SLE 
Therapy is directed at controlling inflammation (i.e. the underlying SLE) and also at 
aggressive control of the traditional modifiable cardiovascular risk factors. Guidelines 
have been published for risk factor management in SLE. These suggest that, in much 
the same way as diabetes, SLE should be regarded as a coronary heart disease 
equivalent, with equally stringent therapeutic targets [Salmon 2001].  
 
For lipid management in SLE, even in the absence of atherosclerosis, an LDL 
cholesterol target of <2.6mmol/L has been suggested, but clinical trials are awaited to 
demonstrate the benefit of this approach, and no study has investigated the use of 
statins in SLE [Wajed 2004]. However, a trial has been performed in rheumatoid 
arthritis (RA), another one of the inflammatory arthritides, to assess how the various 
anti-inflammatory actions of statins affect disease activity aside from their 
cholesterol-lowering effect. The TARA (Trial of Atorvastatin in Rheumatoid 
Arthritis) study demonstrated that in 116 patients, randomised to atorvastatin 40mg or 
placebo, statin therapy mediated modest but clinically apparent anti-inflammatory 
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effects as assessed by indices of disease activity, as well as modifying vascular risk 
factors [McCarey 2004]. This study therefore supports the paradigm of the use of 
statins in the context of high-grade autoimmune inflammation. 
 
There is a high prevalence of hypertension in SLE, and in SLE hypertension is 
associated with clinical and subclinical atherosclerosis [Petri 1992a, Manzi 1999]. 
This, combined with the high incidence of renal disease, suggests that aggressive 
hypertension control is mandatory. A blood pressure target of 130/80 mmHg has been 
suggested, but no trial data are available. Because of the renal and atherosclerotic 
disease, it has been suggested that ACE inhibition should play a key role in blood 
pressure management [Wajed 2004]. There has been only one study of ACE inhibition 
in SLE, a descriptive study of captopril therapy in 14 patients with lupus nephritis and 
hypertension from 1984 [Herlitz 1984]. The procoagulant tendency in SLE suggests 
that aspirin therapy would be of additional benefit above that already identified in 
patients with atherosclerosis [Lauer 2002]. A mathematical modelling study has 
suggested that aspirin therapy should be prescribed in all SLE patients, with the 
greatest potential benefit in patients with lupus anticoagulant or antiphospholipid 
antibodies (unless already on warfarin therapy) [Wahl 2000]. In addition, 
identification of diabetes mellitus, good diabetic control, management of obesity and 
smoking cessation have all been suggested as important in SLE on the basis of 
evidence from the non-SLE population [Wajed 2004].   
 
 
3.1.6 Summary 
Accelerated atherosclerosis is an important cause of morbidity and mortality in SLE. 
The aetiology is beginning to be better understood, with the relative roles of 
traditional and disease-specific risk factors being clarified. Little work has been done 
so far on the earlier identification of patients with atherosclerosis, or at risk of 
atherosclerosis, and no clear guidelines exist for primary prevention in patients where 
atherosclerotic disease is not manifest. 
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3.2 TAKAYASU’S ARTERITIS 
Takayasu’s arteritis (TA), first described in 1908, and eponymously named in 1942, is 
a rare, chronic, idiopathic inflammatory disease that principally affects the aorta and 
its primary branches, resulting in a granulomatous panarteritis. Its aetiology is 
unknown. Arteritis may result in stenosis, occlusions and aneurysms of large vessels 
[Shinmi 1942, Hall 1985, Ishikawa 1988, Kerr 1994, Numano 2002]. 
 
3.2.1 Clinical Features 
Typically, TA presents clinically with non-specific systemic symptoms and signs such 
as fever, arthralgia, fatigue, weight loss, headache and rash. The non-specific nature 
of the presentation often leads to a delay in diagnosis. In one retrospective series, 20% 
of patients had remained undiagnosed 3 years after the onset of symptoms. Chronic 
inflammation of the aorta and its major branches including the subclavian, common 
carotid, coronary, pulmonary and renal arteries may result in localised stenoses, 
vascular occlusion, dilatation and aneurysm formation, each of which may cause the 
clinical presentation [Lupi-Herrera 1977, Subramanyan 1989, Kerr 1994a, Kerr 
1994b, Mwipatayi 2005]. Unlike in giant cell arteritis, biopsy material is not 
commonly available. A review of common serological markers (such as ESR or 
CRP), found that no test reliably distinguished between patients with TA and healthy 
volunteers [Hoffman 1998]. In addition to a substantial morbidity, mortality has been 
reported to be as high as 35% at 5 years. However, a small percentage of patients have 
a self-limiting monophasic inflammatory episode which does not require chronic 
immunosuppressive therapy, and does not progress to the occlusive stage. [Kerr 
1994a]. 
 
3.2.2 Diagnostic Criteria 
The most commonly used set of diagnostic criteria are those of the American College 
of Rheumatology (ACR) (Table 3.2). Using a cut off of 3 or more criteria, they have a 
sensitivity of 90.5% and a specificity of 97.8%, compared with the ‘gold-standard’ of 
angiography. The main limitation of the criteria is that they may miss patients with 
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early-stage non-occlusive disease. An alternative set of diagnostic criteria are the 
Ishikawa criteria [Arend 1990, Sharma 1996, Ishikawa 1988]. 
 
Table 3.2 ACR criteria for TA.   
Three or more of the following: [Arend 1990] 
 
 Criterion Definition 
1 Age at disease onset <40 years 
 
Development of symptoms or findings related to TAat age <40 
years. 
2 Claudication of extremities 
 
Development and worsening of fatigue and discomfort in muscle 
of one or more extremity while in use, especially in the upper 
extremities. 
3 Decreased brachial pulse 
 
Decreased pulsation of one or more brachial arteries. 
4 BP Difference 
 
Difference of >10mmHg in systolic BP between arms. 
5 Bruit over subclavian arteries 
or aorta 
 
Bruit audible on auscultation over one or both subclavian arteries 
or abdominal aorta. 
6 Arteriogram abnormality 
 
Arteriographic narrowing or occlusion of the entire aorta, its 
primary branches or large arteries in the proximal upper or lower 
extremities, not due to arteriosclerosis, fibromuscular dysplagia 
or similar causes, changes usually focal or segmental. 
 
2.3.3 Pathology 
The arteritis is characterised by adventitial thickening and cellular infiltration of the 
tunica media, with local destruction of vascular smooth muscle cells and elastin. 
Intimal hyperplasia, the result of myofibroblast proliferation, is followed by fibrosis 
of the tunica media and intima, leading to stenosis and, on occasion, thrombosis 
[Hotchi 1992]. In about 20% of lesions, local destruction of the medial layer 
predominates, and this, combined with an inadequate fibrotic response, results in 
aneurysm formation. Initial inflammatory changes are associated with vasa vasoritis 
and proliferation of the vasa vasorum. These vessels represent the portal of entry for 
inflammatory cells to the vessel wall. Immunophenotypic analysis has identified T 
and B lymphocytes in nodules in the adventitia. T cells co-localise with dendritic cells 
while granulocytes, macrophages and occasional giant cells are also seen [Numano 
2000a, Cid 2000, Inder 2000, Weyand 2003].  
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3.2.4 Presence of Accelerated Atherosclerosis 
As previously noted, diseases associated with chronic inflammation such as SLE and 
rheumatoid arthritis (RA) have been associated with premature atherosclerosis [Manzi 
2000, Bacon 2002, Van 2002]. Accelerated atherosclerosis has been reported in TA, 
most commonly by ultrasound [Maeda 1991, Sun 1996, Taniguchi 1997, Lefebvre 
2000, Park 2001, Meini 2006, Seyahi 2006]. Autopsy reports have shown 
atherosclerosis as well as the changes of TA in the vessels of young TA patients [Hall 
1985, Numano 2000a, Numano 2000b, Numano 2000c]. 
  
One ultrasound study compared 30 females with TA with 45 sex- and age-matched 
patients with SLE, as well as with age-matched normal controls. This showed 
significantly more plaques in both patients with TA (27%) and patients with SLE 
(18%) compared with normal controls (2%). Carotid intima-media thickness (C-IMT) 
was significantly higher in TA (mean 0.95mm) compared with SLE (0.58mm) and 
normal controls (0.59mm), and did not differ between SLE patients and normal 
controls. Two processes are taking place in the arterial wall. Diffuse arterial 
thickening (or sclerosis) may be a feature of atherosclerosis, but is also a feature of 
vasculitis, and is indicated by an increase in C-IMT, while plaque formation is, by 
definition, a marker of atherosclerosis. Imaging can help to differentiate between 
these two processes. They are, however, related: plaque disease in TA is most 
common when the arteritis is most profound [Raninen 2002]. In fact, in the study 
referred to above, carotid plaques were only found if there was involvement of the 
carotid arteries by TA, and 9 of the 10 plaques were present on the same side as the 
TA involvement [Seyahi 2006]. 
  
In TA, inflammatory changes affect the adventitia and the media, whereas in 
atherosclerosis it is the intima that is most involved [Numano 2000a]. Ultrasound is 
unable to distinguish between the intima and media, although CMR does have this 
capability [Pignoli 1988, Salonen 1993, Keenan 2008b]. In addition, ultrasound is 
limited because it can confuse an increase in C-IMT secondary to diffuse vascular 
thickening with atherosclerotic plaque itself [Seyahi 2006]. 
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The aetiologies of atherosclerosis in TA include increased arterial stiffness (especially 
proximally, i.e. in the aorta and carotid arteries), local inflammation, systemic 
inflammation, arterial injury due to the functional stenoses, and turbulent blood flow 
[Raninen 2002]. The excess incidence of coronary disease is not as pronounced as in 
SLE, and when it occurs it usually takes a more proximal or ostial form which is more 
typical of vasculitis rather than systemic inflammation [Park 1989]. It is, however, a 
major clinical challenge when it occurs [Malik 2003].  
 
3.2.5 Role of Imaging 
One major area of progress in the management of patients with TA has been the 
increase in non-invasive imaging. Ideally invasive investigation should be avoided if 
possible for reasons of patient safety and comfort. The most commonly used imaging 
modalities are conventional angiography, magnetic resonance imaging (MRI), 
magnetic resonance angiography (MRA), computed tomography (CT), positron 
emission tomography (PET), CT-PET and ultrasound [Andrews 2004, Andrews 
2007]. Section 2.3 above on atherosclerosis imaging (which is mainly concerned with 
CAD) is also relevant in TA, but what is specific to TA will be addressed here, and 
particularly the imaging of large arteries, both lumen and wall.  
 
a. Conventional angiography 
Angiography, particularly of the aorta and its major branches is the gold standard for 
the diagnosis of TA. It provides high resolution imaging of the vascular lumen, 
pressure gradients across stenoses can be accurately measured, and it gives the 
opportunity for invasive procedures such as stenting. The characteristic pattern of 
disease in TA involves lesions close to the origin of the primary branches of the aorta. 
The earliest lesions are localised narrowings or irregularities of the lumen; these may 
progress to stenosis or complete occlusion (figure 3.1). Vessels may be dilated or 
aneurysmal. ‘Skip lesions’ are also characteristic, where stenoses (or occasionally 
aneurysms) are separated by uninvolved blood vessel. In the most common 
distribution, TA affects the aorta and its branches above and below the diaphragm 
[Kerr 1994a]. In 1997, the International Cooperative Study on TA proposed a five-
type angiographic classification system. Involvement of coronary or pulmonary 
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arteries is designated by adding a C(+) or P(+) to one of the five types (table 3.3) 
[Moriwaki 1997].  
 
Table 3.3 Angiographic classification system for TA.  
From: [Moriwaki 1997]. 
Type Site of Involvement 
I Branches of aortic arch 
IIa Ascending aorta, aortic arch and its branches 
IIb Ascending aorta, aortic arch and its branches and thoracic descending aorta 
III Thoracic descending aorta and/or renal arteries 
IV Abdominal aorta and/or renal arteries 
V Combination of types IIb and IV 
 
However, as a lumenographic technique, angiography is limited at indicating what is 
happening in the vessel wall- this can result in a false negative ‘normal angiogram’ in 
patients with early disease. As an invasive technique it can cause pain and discomfort 
for patients. There is a small but definite complication rate (death, stroke, myocardial 
infarction, access site bleeding and infection). In TA, vascular access may aggravate 
local disease [Malik 2003]. In addition, invasive procedures carry a radiation dose and 
use nephrotoxic contrast media. For all these reasons, invasive angiography is not 
suitable for long-term follow up of TA patients. 
 
b. Magnetic Resonance Imaging/Angiography 
MRI and MRA are key tools in the assessment of large arteries in patients with TA. 
Breath-hold contrast-enhanced three-dimensional MR angiography can be performed 
safely, without arterial puncture and without the use of iodine-based contrast agents or 
radiation. A full arterial survey of major aortic branches and the pulmonary arteries 
can be performed [Andrews 2007]. MRA has been well validated for large arterial 
imaging, for example being used in the assessment of aortic dissection or follow up of 
aortic aneurysms, coarctations and stenoses [Cesare 2000, Bourlet 2000]. Given the 
rarity of TA, there is less data available directly comparing invasive angiography with 
MRA in TA. In one study of 55 supra-aortic arterial segments (in 7 patients) MRA 
had a sensitivity of 95% and a specificity of 96% for arterial stenosis or occlusion 
compared to digital subtraction angiography (DSA) [Cantu 2000]. 
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The main limitation of MRI is availability, and it remains relatively time-consuming, 
operator-dependent and expensive. In addition, recently a rare adverse effect of 
gadolinium-based MR contrast materials has been identified, a rare condition called 
nephrogenic systemic fibrosis (NSF), characterised by the formation of connective 
tissue in the skin which becomes thickened, coarse and hard, sometimes leading to 
contractures and joint immobility and sometimes with systemic involvement. NSF has 
been reported only in patients with renal insufficiency, particularly those with end-
stage renal disease. Approximately 300 cases of NSF have been identified worldwide, 
and over 200,000,000 doses of gadolinium contrast have been administered to 
patients. Different gadolinium-based agents have different safety profiles. 
[Marckmann 2006, Grobner 2006].  However it must be emphasised that MR contrast 
agents have a much superior safety profile to iodinated contrast used in CT. 
 
Although MRA is the main MR-based form of imaging used in TA, arterial wall 
imaging is of increasing interest. This is usually performed using spin echo sequences. 
As the whole of the vessel wall is seen, early thickening can be identified. Areas of 
vascular inflammation can be visualised with newer imaging protocols such as STIR 
(Short T1 Inversion Recovery) which indicate tissue oedema. In addition, inflamed 
tissues take up gadolinium-based MR contrast agents which increase signal on 
subsequent imaging. These techniques can also be used in the chronic phase to 
confirm disease quiescence, or to look for other areas of disease activity. Chapter 5 
discussed the use of MR to image the arterial wall, in particular atherosclerotic 
plaque.  
 
Early diagnosis is vital in TA, given the frequent diagnostic delay (see section 3.2.1 
above), and the severe complications of untreated disease. The combination of MRI 
and MRA has been reported as having equal diagnostic accuracy as invasive 
angiography. MRI (tissue characterisation) and MRA are, in fact, replacing invasive 
imaging for the diagnosis of TA [Choe 1999, Steeds 2006]. In summary, contrast-
enhanced MRI and MRA have an important role in early diagnosis, activity 
determination, and follow-up of TA patients. 
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Figure 3.1 Magnetic resonance angiogram of a 23-year old female with 
Takayasu’s Arteritis. The right subclavian (1), left common carotid (2) and left 
subclavian (3) arteries are occluded. 
 
c. Ultrasound 
Like MRI, high resolution Doppler ultrasound can detect vascular thickening before 
lumenal stenosis. In addition, it has the advantage that it is cheap and widely 
available. However it is highly operator dependent. While excellent for imaging the 
carotid and vertebral arteries in the neck, the depth of soft tissue limits its ability to 
image the aorta, the proximal subclavian arteries, and the intrathoracic course of the 
carotid arteries. The classical appearance is the so-called ‘Macaroni sign’, because the 
artery appears diffusely severely narrowed, secondary to generalised thickening of the 
arterial wall, as opposed to the focal appearances seen with atherosclerotic plaque 
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(figure 3.2) [Maeda 1991, Meini 2006]. Ultrasound has a better than 95% correlation 
with invasive angiography and MRA for severe lesions in the carotid arteries. 
Elevated ultrasound C-IMT has been used as an early marker of disease. Ultrasound 
has shown increased arterial ‘stiffness’ in TA. Ultrasound appearances correlate with 
disease activity as assessed by erythrocyte sedimentation rate (ESR), CRP and CT 
lumenography [Cantu 2000, Park 2001, Schmidt 2002, Schmidt 2005, Ng 2006]. The 
changes can be large: in Park’s study, the mean thickness of actively inflamed arteries 
was 3.3 mm, compared with 1.6 mm for inactive lesions. In addition, vessel 
echogenicity and the presence of intramural arteries have been suggested as possible 
markers of disease activity. A reduction in wall thickness has been demonstrated by 
ultrasound in response to therapy or associated with disease quiescence, but no studies 
have so far shown that therapy can be guided by ultrasonography [Schmidt 2002, 
Kissin 2004]. 
 
Figure 3.2 Ultrasound assessment of carotid intima-media thickness (C-IMT) in 
Takayasu’s arteritis. The diffuse and homogeneously increased IMT can be seen 
in both near (1) and far (2) arterial walls (*) (adapted from [Seyahi 2006]). 
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 d. Computed Tomography 
Like MRA, CT angiography can identify stenotic large arterial lesions. Also, like MRI 
and ultrasound, CT can identify vessel wall thickening before the lumen becomes 
stenosed [Park 1995, Yamazaki 2002]. CT is of high utility diagnostically, especially 
if MRA is not available. It has been used for longitudinal follow up, but its utility is 
limited by the radiation dose [Paul 2001]. The typical effective dose is 8mSv, which is 
the equivalent of 400 chest X rays, or 3.6 years of natural background radiation 
[European Commission 2001]. In addition, CT angiography requires the use of 
nephrotoxic iodinated contrast agents. 
 
e. Positron Emission Tomography  
18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) uses the uptake 
of radioactively labelled glucose to identify metabolically active tissue. Clinically, 
PET imaging is most commonly used for tumours, but it can also identify 
inflammation, as in TA [Zhuang 2002, Love 2005]. For an inflamed artery to generate 
enough signal to be visible on a PET image, it must, in addition, be thickened to at 
least 4mm. Small studies have suggested that PET has a role to play in the diagnosis 
and management of TA [Andrews 2004], and a study of 18 TA patients showed it to 
have a specificity of 100% with a sensitivity of 92% for active disease compared with 
standard clinical criteria [Webb 2004]. PET has been used for serial follow up, which 
is appealing as vascular inflammation is the primary target of therapy [Scheel 2004]. 
PET has compared favourably with MRI [Meller 2003]. PET is limited by spatial 
resolution, however this can be overcome to some extent by co-registration with CT, 
and combined PET-CT scanners [Kobayashi 2005]. A further limitation, particularly 
in elderly patients, is that areas of atherosclerosis also exhibit 18F-FDG uptake, 
although typically the distribution and pattern are different [Tatsumi 2003]. PET also 
exposes the patient to ionising radiation, and finally availability is low.  
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3.2.6 Therapy 
Therapy of vascular disease in TA is divided into immunosuppression, management 
of cardiovascular risk, and specific interventional therapy for vascular stenoses, 
occlusions or aneurysms. 
 
a. Immunosuppression 
Because of small patient numbers, there is little randomised trial data in TA. 
However, immunosuppression is the mainstay of treatment, and therapy with 
corticosteroids is a near universal. Published data suggest that steroids are associated 
with an improvement in systemic symptoms and a fall in ESR in almost all patients, 
and disease remission can be achieved in about half. Other agents include 
azathioprine, methotrexate and cyclophosphamide which are used as ‘steroid-sparing’ 
therapy, and in patients who do not respond to corticosteroids [Hall 1985, Shelhamer 
1985, Kerr 1994a]. Newer agents under investigation include tumour necrosis factor 
alpha (TNFα) antagonists [Hoffman 2004]. 
 
b. Cardiovascular Risk 
As mentioned above, patients with TA, like most patients with inflammatory 
arthritides, are at increased risk of atherosclerosis. Aggressive primary and secondary 
prevention are important, with control of all risk factors. In addition, it is possible that 
the pleiotropic (non-cholesterol related) actions of HMG-CoA reductase inhibitors 
(statins) may include an anti-inflammatory action in the arterial wall, which may 
indicate an additional role in vasculitis [Mason 2003, Schonbeck 2004]. 
 
c. Intervention 
Surgical intervention in TA can be complicated by restenosis, occlusion, dehiscence 
and aneurysm formation. The restenosis and occlusion rate at 1 year has been reported 
to be up to 30% [Liang 2004]. The safety profile of surgery in TA is reasonable: in a 
large series of 106 patients with TA from Japan, 73.5% of patients undergoing surgery 
for complications of TA were alive at 20 years. A subgroup analysis suggested that 
surgery improved survival in patients with more severe disease, while worsening it in 
patients with a lower grade of severity [Miyata 2003]. There is a clinical consensus 
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that, if possible, surgery should be performed when the disease is quiescent to 
minimize the risk of surgical dehiscence [Andrews 2007]. 
 
 
3.2.7 Summary 
As in SLE, accelerated atherosclerosis is a feature of Takayasu’s Arteritis. However, 
the more fulminant course of TA means that the clinical features of the arteritis tend 
to dominate. In addition, there is considerable overlap between the clinical features of 
atherosclerotic disease and the arteritis itself. However, atherosclerotic disease itself is 
a major cause of morbidity and mortality in TA. Noninvasive imaging allows the 
earlier identification of atherosclerotic disease, and it is to be hoped that the earlier 
initiation of secondary prevention may improve outcomes in TA. 
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CHAPTER 4 
CARDIOVASCULAR MAGNETIC RESONANCE 
 
4.1 BASIC PRINCIPLES OF MAGNETIC RESONANCE AND IMAGE CREATION 
4.1.1 Introduction and History 
Magnetic resonance imaging (MRI), relies on the properties of the nuclei of hydrogen 
atoms (protons) when placed in a strong magnetic field and exposed to radiofrequency 
(RF) energy. A series of developments have occurred over the last 70 years, starting 
with an improved understanding of the physics involved, and leading to the routine 
clinical scans available today. Several of the discoveries along the way have been 
recognised by the award of a Nobel prize. 
 
The phenomenon of nuclear magnetic resonance (NMR) was first described in 
molecular beams in 1938 [Rabi 1938]. Then, in 1946, two groups described NMR in 
solid matter. For this work, Felix Bloch and Edward Mills Purcell were awarded the 
Nobel Prize in physics in 1952 [Bloch 1946; Purcell 1946]. In 1948 Bloembergen 
developed the concept of relaxivity [Bloembergen 1948]. The discovery of the effect 
of the local environment on relaxation times led to the field of nuclear spectroscopy 
[Proctor 1950]. NMR developed side-by-side advances in spatial localisation and in 
image reconstruction, mainly in computed tomography (CT), which led to the award 
of the Nobel Prize in medicine to Sir Godfrey Hounsfield and Alan Cormack in 1979. 
These developments enabled the first clinical NMR image to be acquired by 
Mansfield in 1977, and he was subsequently awarded the 2003 Nobel Prize in 
medicine for his discovery, along with Paul Lauterbur [Mansfield 1977]. 
 
NMR entered clinical practice in the early 1980s. The technique was renamed 
magnetic resonance imaging (MRI) in 1984 to indicate to patients that there was no 
ionising radiation involved, and for cardiovascular imaging the name Cardiovascular 
Magnetic Resonance (CMR) is now standard [NMR progress report 1984, Pennell 
1999]. 
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Initial developments were dominated by neuroimaging, with attempts at cardiac 
imaging frustrated by respiratory and cardiac motion. The development of ECG-
gating helped to overcome the problem of cardiac motion.  Using the R wave of the 
ECG to trigger the scanner, image data could be acquired at the same time point in the 
cardiac cycle over multiple cycles and combined to increase the signal-to-noise ratio 
(SNR) to interpretable levels [Lanzer 1984]. The problem of respiratory motion was 
initially addressed by respiratory gating, so that images were only acquired at the 
same point in the respiratory cycle, but subsequent increases in the speed of data 
acquisition have meant that a typical cardiac image can now be acquired in the space 
of a single breath-hold.  
 
At first only still images (such as spin echo images) were acquired. Subsequent 
developments with gradient echo imaging led to moving images, using sequences 
such as FLASH (fast low angle shot) [Frahm 1986]. Improvements in hardware led to 
the development of FISP (fast imaging with steady-state precession) giving 
improvements in SNR and blood-myocardium contrast [Oppelt 1986]. This is typical 
of the process of advance in MRI, in that developments incorporate advances in 
magnet, gradient, coil and sequence technology. These elements are discussed 
individually below.  
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4.1.2 Physics of CMR  
 
a. Protons 
The theoretical foundation of magnetic resonance imaging [Weishaupt 2003] is based 
on the properties of the proton. Protons are able to absorb and emit radiofrequency 
energy. The hydrogen nucleus is a single proton. As the human body is 80% water, it 
contains an abundance of hydrogen nuclei. The proton is a positively charged particle. 
It has the property of spin, and generates a magnetic dipole. The dipole is a vector 
quantity (a magnitude and direction). Under normal conditions, outside of an applied 
magnetic field, the magnetic dipole vectors of protons in tissue are randomly 
orientated. Hence the net magnetisation vector of a tissue (designated M) is zero. 
However, if an external magnetic field (designated B0) is applied, the magnetic vector 
of each proton becomes aligned with the field, either parallel with the direction of the 
field (low energy state), or opposite to the direction of the field (anti-parallel, a high 
energy state). There is a small excess of nuclei aligned parallel to the field, leading to 
a net magnetisation vector (M0) in the direction of the field B0. This direction is 
designated the z axis, so the component of net magnetisation in this direction is 
designated Mz (figure 4.1).  
 
Figure 4.1 In an external magnetic field, nuclei align parallel or anti-parallel to 
the field. There is a small excess of nuclei aligned parallel, leading to the vector 
M0. Courtesy of Dr M Tanner (adapted). 
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b. Precession 
As well as their own internal spin, in a magnetic field the proton’s dipole rotates 
around the direction of the applied field. This is called precession (figure 4.2). The 
precessional frequency is related to the strength of the applied field. This relationship 
is described by the Larmor equation. 
 
υ = (γ/2π) B0 
where: 
υ =  the precessional or Larmor frequency (Hz). 
γ =  the gyromagnetic ratio (Hz/Tesla). This is a constant for a given nuclear 
isotope, and for hydrogen nuclei it is 42.57 Hz/T. 
B0 =  the external field strength (Tesla). 
 
Figure 4.2 The proton’s dipole rotates around the direction of the applied field 
(B0). Courtesy of Dr M Tanner (adapted). 
 
 
c. Resonance 
If a radiofrequency (RF) pulse at the precessional (resonant) frequency is transmitted 
to protons in a magnetic field they absorb the energy. Rather than precessing 
randomly, the protons precess in phase after excitation. The radiofrequency energy 
induces some protons to ‘flip’ their magnetic vector, increasing the proportion of 
protons aligned anti-parallel to B0, moving the tissue to a higher energy state. For 
these two reasons, M is no longer aligned with B0. The ‘flip angle’ is the angle that 
the radiofrequency pulse induces between M and B0. It is determined by the amplitude 
B0 
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and duration of the RF pulse. When a RF pulse with a flip angle of 90º is applied, 
there is no net magnetisation vector parallel or antiparallel with the field B0, so the 
magnetisation vector Mz = 0. Instead M is in the transverse plane (designated xy), 
where it precesses at the Larmor frequency (Mxy). The magnitude of the vector Mxy is 
subsequently determined by the extent to which the protons precess in phase with 
each other. It is the vector Mxy that induces the signal in the receiver coil (figure 4.3). 
 
Figure 4.3 The rotating vector Mxy induces a signal in the receiver coil. Courtesy 
of Dr M Tanner (adapted). 
  
 
 
d. Relaxation 
After the RF pulse is turned off, the precessing protons return to equilibrium at their 
baseline position; this process is called relaxation. Relaxation has two components: 
longitudinal relaxation and dephasing. In both, the hydrogen nuclei are moving from a 
higher energy state to a lower energy state, so energy is released. Longitudinal 
relaxation means the net magnetisation vector M increasing in the z-axis (Mz). This is 
known as ‘T1 recovery’ (figure 4.4). The nuclei transfer energy to the surrounding 
tissue or lattice, so T1 recovery is also called ‘spin-lattice relaxation’. The rate of 
recovery is exponential, and the recovery time constant T1 is derived from the 
equation of exponential recovery: 
 
M(t) = M0  -  dM0 e –t/ T1 
 
T1 is the time it takes for 1-1/e (63%) of the perturbation in the longitudinal 
magnetization to recover. For soft tissue this is typically of the order of 1 second. 
 
B0 
Mxy 
X 
Z 
Y 
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Figure 4.4 T1 Recovery. The vector M returns to Mz. Courtesy of Dr M Tanner 
(adapted). 
 
After the RF pulse is switched off, the precessing protons start to move out of phase 
with each other (dephasing). This leads to a reduction in the magnitude of Mxy. 
Dephasing occurs for two reasons. Firstly, the nuclei exchange energy with each 
other, a process known as ‘spin-spin’ or T2 relaxation, which is exponential (figure 
4.5). The time constant T2 indicates the time taken for 1-1/e (63%) of the magnitude 
of the vector M to be lost, and is typically of the order of 100ms. However, the 
observed rate of dephasing is greater than that expected from spin-spin interaction 
alone. Small variations in the strength of the magnetic field (called field 
inhomogeneities) lead to variations in the precessing frequencies of individual 
protons, and this also causes dephasing. The combination of decay due to field 
inhomogeneities and spin-spin interaction is termed T2* decay. T2* is therefore 
always shorter than T2.  T1 and T2 are constant for a given tissue, and differ between 
tissues. 
 
Figure 4.5 T2 Decay. The vector Mxy returns to zero. Courtesy of Dr M Tanner 
(adapted). 
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4.1.3 Basic Components of a MRI Scanner 
a. Magnet 
The magnet is the primary component of the MRI scanner. The magnet generates a 
strong, homogeneous and stable magnetic field within the bore of the scanner. 
Typically, non-homogeneities in the field within the scan region should be less than 3 
parts-per-million. Virtually all clinical CMR is performed with an MRI scanner based 
around a superconducting magnet, although historically, and for other applications, 
permanent and resistive magnets have been used. Superconducting magnets can 
generate high field strength with high stability. A superconductor is a substance that 
loses its resistance to electrical current under certain conditions (usually very low 
temperature). MRI scanners use an alloy of niobium and titanium that loses its 
resistance at 4K (-269ºC). Liquid helium is used to reach this temperature, so a chiller 
is required which reduces helium boil-off. 
 
Field strength is measured in Tesla (T). Higher magnetic field strengths increase the 
signal-to-noise ratio (SNR), increasing the resolution and decreasing imaging time; 
however they are also more expensive. The common platform for cardiac imaging has 
a field strength of 1.5T, although some applications such as plaque imaging and 
perfusion are being developed at 3T. In general, any application that is limited by 
SNR benefits from increased field strength. Imaging at higher field strength has its 
own challenges, for example increased artefact with FISP gradient echo. 
 
b. Gradients 
The gradient system is used to modify the magnetic field within the bore of the 
magnet. This is done to alter the frequency and phase of the protons (see below). The 
magnetic gradients are generated by three orthogonal coils, orientated in the x, y and z 
axes. These coils are resistive electromagnets powered by amplifiers which allow 
rapid and precise adjustments to field strength and direction. Advanced whole-body 
gradient systems are capable of producing gradients up to 50mT/m. As there are 3 
orthogonal coils, and as they can be combined together, a gradated field can be 
generated in any direction, meaning that imaging can be performed in any plane. 
Stronger gradients increase resolution and reduce scan time. Faster switching also 
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reduces scan time. However these are limited by peripheral nerve stimulation which 
occurs with combined high gradient strength and frequent switching.  
 
c. Radiofrequency system 
RF transmission coils are antennae which produce radiofrequency energy. They are 
used to excite the protons in the tissues being imaged. The radiofrequency 
transmission system consists of a RF synthesiser, power amplifier and a transmitting 
coil. Typical peak power output is up to 15kW, with an average power output of 
300W.  
 
d. Receiver coils 
Receiver coils are antennae which receive the signal emitted by the precessing 
magnetisation in the tissue. The magnetic vector in the tissue causes a current to flow 
in the receiver coil by induction. The signal is greatest if the coil is close to the tissue 
being imaged; such coils are called ‘surface coils’ (Figure 4.6). The current induced in 
the coil is amplified before image reconstruction. Multi-element phased array coils are 
capable of acquiring multiple channels of data in parallel. These can reduce imaging 
times. They use specially adapted ‘parallel imaging’ sequences which replace some of 
the spatial encoding originating from the magnetic gradients with the spatial 
sensitivity of the different coil elements.  
 
Figure 4.6 A surface coil of the type used in CMR for a cardiac study. 
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e. Image reconstruction system. 
Images are constructed from the radiofrequency echoes that have been received by a 
computer, which decodes the spatial and magnitude information contained within the 
echo, and displays this information in a visual form. 
 
 
4.1.4 Image Acquisition 
a. Slice Select 
In order to generate an image from a tissue in a scanner, it is necessary to know how 
much signal is coming from each point within the scanner. In conventional MRI this 
is done by selecting a ‘slice’ to be imaged (i.e. a 2-dimensional (2D) plane with a 
defined thickness), and then encoding the data within the slice along both transverse 
axes by ‘frequency encoding’ and ‘phase encoding’. The general principle behind this 
encoding is that gradient coils can be used to alter the magnetic field strength within 
the static external magnetic field (B0). They can do this in any direction. A graded 
change in field strength within the magnet leads to a gradient in the precessional  
frequency of protons along the axis of the change in field strength. Hence RF pulses 
of differing frequencies will excite different parts (or ‘slices’) of the tissue. The ‘slice 
select gradient’ is applied perpendicular to the desired imaging plane, and the initial 
RF pulse is of a sufficiently narrow range of frequencies (the ‘bandwidth’) to excite 
only a slice of a predetermined thickness. Any resulting signal will come only from 
that slice, and the remainder of the tissue remains unexcited. 
 
 
 
b. Frequency encoding 
Frequency encoding is used during the readout period to spatially encode along one of 
the transverse axes. During the ‘echo’, when the signal is being received, a gradient is 
applied in one direction across the selected slice (the ‘frequency encode’ or ‘readout’ 
gradient). This gradient causes the signal being returned from the slice to differ in 
frequency from one side to the other. This is turned back into spatial / signal intensity 
information by a process called a Fourier transformation, giving values for signal 
intensity along the frequency encode direction. 
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c. Phase encode 
The third dimension is called the ‘phase encode’ direction. A gradient (the phase 
encode gradient) is applied along the other transverse axis (perpendicular to the 
frequency encode gradient) many times between the slice select gradient and the 
readout gradient, with varying magnitudes. This alters the phase of the precessing 
protons by a set amount depending on their position along the phase encode axis. 
Hence the phase of a signal in the readout indicates its position in the phase encode 
direction. The phase/magnitude data is turned into spatial/magnitude data by a further 
Fourier transformation. The spatial resolution in the phase encode direction depends 
on how many times the phase encode gradient is applied, but typical values for 
cardiac imaging are 128 or 256. 
 
 
d. k-space 
Signal acquisition is in reality acquired into a mathematical matrix known as ‘k-
space’. The k-space formalism was introduced independently in 1983 by both 
Ljunggren and Tweig  [Ljunggren 1983, Tweig 1983]. k-space is typically rectangular 
with two perpendicular axes centred in the centre. By convention, the vertical axis of 
k-space diagrams corresponds to the phase encode direction. Lines of readout 
acquired after small or zero phase encode gradients occupy the centre of the phase 
encode axis, whereas the lines at both extremities of the phase axis are filled after the 
application of greater phase encoding steps. The horizontal axis corresponds to the 
frequency encode direction. Here the centre of the axis corresponds to data acquired at 
the centre of an echo where all protons are in phase (and hence of maximum 
amplitude), whereas the rephasing and dephasing portions of an echo are placed at 
either extremity of the frequency axis. Each line of k space corresponds to a different 
phase encode step. The central lines of k space, acquired after shallow phase encode 
steps, have a large amplitude. They contain the majority of image contrast (i.e. signal-
to-noise). The lines at either side of k space on the phase axis have small amplitude 
and these lines are responsible for high spatial frequency detail (i.e. resolution). 
Advanced MRI techniques reduce scan time by filling k-space in novel and efficient 
ways, for example by spiral or radial k-space trajectories. 
 
Chapter 4 Page 91 Principles of CMR 
 
 
e. 3-Dimensional (3D) Imaging 
In 3D imaging, the approach described above is modified in that rather than selecting 
a narrow slice (e.g. 2mm), an entire volume of tissue is selected (the ‘slab’). Typical 
slab thicknesses are between 20 and 200mm. In 2D imaging, slices are necessarily 
thin to obtain good resolution, so the number of excited protons is low, and so is the 
resulting signal. A large number of cardiac cycles are needed to build up sufficient 
signal to form an image (SNR). In 3D imaging, because an entire volume is being 
excited, SNR is high, reducing imaging time and improving resolution. However the 
individual slices need to be subsequently reconstructed from the 3D volume. This is 
done by an addition phase encode step in the z axis. This has been refined further with 
the ‘volume selective’ 3D technique [Feinberg 1985, Crowe 2003]. 
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4.2 SEQUENCES USED IN CMR 
An imaging sequence can be considered the “orchestral score” of the scanner, and is 
the combination of radiofrequency pulses and applied gradients that leads to image 
generation. Many sequences have been optimised for cardiac and vascular imaging. 
There is a broad distinction between sequences which produce still images (e.g. spin 
echo) and those for moving images (e.g. gradient echo). Different sequences have 
different tissue contrast weightings (e.g. T1 and T2) [Weishaupt 2003]. 
 
4.2.1 Spin Echo 
Spin echo sequences are used throughout the body to acquire still images. A first 
slice-selective RF pulse with a flip angle of 90º is applied, flipping the magnetization 
vector Mz into the transverse plane (xy).  Then, for the reasons given above, the 
protons begin to dephase. A 180º pulse in now applied. This has the effect of 
‘refocusing’ the dephased protons, so that they are not now moving out of phase, but 
back into phase. As they rephase, the magnitude of the magnetization vector Mxy 
increases, leading a to a signal peak – this is called the ‘spin echo’. The spin echo 
occurs at the echo time (TE), which is equal to twice the time between the 90º and 
180º pulses (figure 4.7). 
 
Figure 4.7 Spin echo. After a 90° pulse, the precessing protons begin to dephase. 
A 180° pulse at time t causes them to rephase at time 2t (TE) leading to the 
signal. Courtesy of Dr M Tanner (adapted). 
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The refocusing 180º pulse eliminates the contribution that field inhomogeneities make 
to dephasing (T2* decay). The effect of spin-spin interaction on dephasing (T2 decay) 
is, however, left unaltered. Hence the magnitude of the resulting echo is dependent on 
the T2 of the tissue. If a series of refocusing 180º pulses is applied, the decay in the 
signal over successive 180º pulses is equal to T2. The value of TE determines the T2 
contrast of the image (figure 4.8). 
 
Figure 4.8 When a sequence of 180° pulses is applied, the decay in the measured 
signal is equal to T2. Courtesy of Dr M Tanner (adapted).  
 
After the pulse sequence has been applied and the signal acquired, a delay is required 
to allow sufficient recovery of signal in the z direction to enable further echoes to be 
generated (T1 recovery). The time between successive pulse series is the repeat time 
(TR), so TR alters the T1 contrast of the image.  
 
The final image is built up by adding together the data acquired across a number of 
image acquisitions, increasing the signal and hence ‘signal-to-noise’ ratio (SNR). The 
imaging time can be reduced by acquiring more k-space lines during each acquisition. 
This is referred to as fast spin echo (FSE) imaging. Multiple spin echoes are acquired 
using additional 180º pulses, and each is preceded by a different phase encode step. 
The number of 180º pulses is the echo train length (ETL). An ETL of 7 reduces the 
imaging time by seven-fold. However, with longer ETLs, T2 decay leads to low levels 
of signal at the end of the echo train, so for each imaging application an optimum 
setting exists.  
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For a tissue to generate signal in spin echo imaging it must be stationary, or at least at 
the same place each time an image is acquired. In cardiac and vascular imaging this is 
accomplished by ECG-gating so the image is acquired in the same part of each 
cardiac cycle. For the same reason, solid tissue is of high signal, while flowing blood 
is of low signal, so in CMR spin echo images are often referred to as ‘dark blood’ 
images.  
 
4.2.2 Gradient Echo 
In order to acquire moving images, a sequence is required that does not depend on 
delays to allow T1 recovery, as in spin echo. In gradient echo (GRE), the initial RF 
pulse is of a lower flip angle than in spin echo (typically 8º to 35º). Mz is only 
partially flipped into the transverse plane, so some longitudinal magnetisation remains 
in the z axis, which is available to be flipped by subsequent repeats, even if TR is 
short. The GRE sequence can thus be repeated rapidly. With repeated RF pulses, 
longitudinal magnetization reaches an equilibrium, enabling near-constant readout. 
  
A second difference from spin echo is that, to generate a signal, no 180° pulses are 
used. Instead only the gradient coils are used to generate the echo. After the initial RF 
pulse, the frequency encode gradient is switched on. This leads to dephasing: 
‘gradient defocusing’. Then the frequency encode gradient is switched to opposite 
polarity, leading to rephasing, and hence the echo: ‘gradient echo’ (figure 4.9). This 
has the advantage that it is much quicker than 180º refocusing, but the disadvantage 
that as there is no 180º refocusing, GRE is susceptible to artefact from field 
inhomogeneity (susceptibility artefact). To overcome this, TE is usually short. An 
example of a GRE sequence is FLASH (Fast Low Angle Shot) [Frahm 1986].  
 
Image acquisition time can be further reduced by using a ‘segmented’ sequence. A 
‘spoiler gradient’ which destroys residual transverse magnetization is applied after 
each readout, enabling multiple phase-encoding steps to be rapidly acquired. This is 
particularly important in cardiac imaging where reduction in scan time has allowed 
moving images to be acquired within a single breath-hold, and in real-time. A further 
refinement development in GRE is the steady state free precession (SSFP) sequence 
[Oppelt 1986]. In conventional GRE, the phase encode and frequency encode steps 
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dephase the precessing protons. In SSFP, the phase coherence of transverse 
magnetisation is rephased, so the phase coherence of transverse magnetisation is 
maintained between RF pulses, and imaging occurs when all transverse and 
longitudinal components of magnetisation are in steady state. This sequence is faster 
than FLASH, and has improved blood:myocardium and fat:myocardium contrast  over 
standard GRE. 
 
Figure 4.9 Gradient echo. The echo is generated by dephasing and then 
rephrasing precessing protons using the frequency encode gradient. Courtesy of 
Dr M Tanner (adapted). 
 
In GRE images, blood is of high signal and myocardium of intermediate signal, so 
they are referred to as ‘bright blood’ images. SSFP is the standard GRE sequence in 
current clinical use for CMR. 
 
 
 
4.2.3 Summary 
Many different MRI sequences are available. They have been optimised for different 
applications. Spin echo is a basic MRI sequence that is used in CMR for obtaining 
static images, for example for anatomical display or tissue characterisation. Gradient 
echo sequences are faster but more prone to artefact. In CMR they are generally used 
to obtain cines. Sequence development is always ongoing. 
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CHAPTER 5 
CMR OF THE ATHEROMATOUS PLAQUE:  
CURRENT ACHIEVEMENTS, ANTICIPATED DEVELOPMENTS,  
CLINICAL APPLICATION 
 
5.1 INTRODUCTION 
Atherosclerosis is the predominant cause of death and disability in the developed 
world today. Vessel wall imaging by cardiovascular magnetic resonance (CMR) is a 
relatively new technique for imaging atherosclerosis. It is used to identify and 
characterise atherosclerotic plaque (particularly in terms of vulnerability to rupture), 
and to assess for plaque progression or regression, particularly in response to 
treatment. Much of the work that is described here involves the carotid arteries, but 
CMR is now starting to image the coronary artery vessel wall.  
 
Investigations for coronary artery disease (CAD) either indicate the functional 
importance of flow-limiting coronary stenoses (eg exercise electrocardiography), or 
involve lumenography (eg coronary angiography). The presence of lumenal stenoses 
implies thickening of the arterial wall, so when a diagnosis of clinically significant 
atherosclerosis is made, the atherosclerosis itself remains invisible. Arterial wall 
imaging by cardiovascular magnetic resonance (CMR) aims to make atherosclerosis 
visible. 
 
5.1.1 Rationale for Vessel Wall Imaging 
It is well established that atherogenesis begins many years, even decades, before 
arterial stenoses develop, as the famous study of US soldiers in Vietnam demonstrated 
[Macnamara 1971]. The first steps of the process, such as fatty streak formation, were 
identified in these young soldiers at post-mortem, at a stage when they could not be 
identified in vivo by coronary angiography. When an atherosclerotic plaque forms in 
the arterial wall, and then begins to increase in size, it does not immediately start to 
intrude on and narrow the arterial lumen. Initially, the artery adapts, or ‘remodels’ 
outwards to make room for the plaque. In 1987, Glagov demonstrated this 
phenomenon in a series of left main stem coronary arteries at post mortem [Glagov 
1987]. He showed that in mild to moderate atherosclerosis, the coronary lumen area 
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increased with the amount of plaque present, so the greater the area of plaque, the 
greater the lumen area. The artery had remodelled outwards. However, in more severe 
disease, as plaques progressed further in size, eventually the coronary lumen did 
become compromised. The point when the plaque began to intrude on the lumen 
occurred when about 40% of the vessel cross-section was occupied with plaque. The 
clear implication of this work was that many patients with ‘normal’ coronary 
angiograms on lumenography had clinically significant atherosclerosis in the arterial 
wall (Figure 5.1) [Keenan 2008a].  
 
Figure 5.1 Glagov remodelling in the carotid artery in vivo. (1) MR angiogram. 
Targeted maximal intensity projection (MIP) of the right carotid artery 
bifurcation showing a 20-30% stenosis of the proximal right internal carotid 
artery. (2) a T1-weighted dark blood image longitudinal to the carotid 
bifurcation shows the plaque to be much larger than it appeared on the 
angiogram. (3 and 4) T1 and T2 weighted images perpendicular to the internal 
carotid artery show a large eccentric atherosclerotic plaque. The true degree of 
stenosis is 70%. In (4) the fibrous cap can be differentiated as an area of high 
signal adjacent to the lumen (adapted from [Keenan 2008a]). 
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5.1.2 Which plaques rupture? 
This ‘silent’ atherosclerosis of the arterial wall became of greater interest when it was 
appreciated that a high proportion of myocardial infarctions were caused by the 
rupture of shallow, non-flow limiting plaques that might well be ignored on coronary 
angiography. It had generally been thought that atherosclerotic plaques grew by stages 
until eventually they occluded the arterial lumen. The paradigm was that angiography 
could identify patients ‘at risk’ of events by identifying high-grade stenoses. 
However, a case series of patients with myocardial infarction who had had a previous 
angiogram and were them re-studied at the time of the infarction showed that in 78% 
of the patients the culprit lesion was less than 70% stenosed at the time of the 
previous angiogram, and in many cases much less than 70% [Ambrose 1988]. This 
revealed further limitations of lumenography.  
 
 
Figure 5.2 T1-weighted fast spin echo CMR image. Longitudinal section through 
the carotid bifurcation, indicating the slice positions for vessel wall imaging in 
the carotid bifurcation. A typical pilot image used to acquire a series of images 
such as in Figure 5.3. 
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5.1.3 Atheroma Imaging by CMR 
What has been described so far has concentrated mainly on coronary artery disease 
(CAD) as this is the paradigm atherosclerotic disorder, and has been the most 
intensively studied. However, CMR arterial wall imaging has concentrated on the 
carotid arteries as they are large, relatively immobile, and near the surface CMR. As 
discussed above in section 2.1.3, the carotid artery is a good but imperfect model for 
CAD. CMR arterial wall imaging was first described ex vivo in 1982 with iliac artery 
specimens [Serfaty 2001], and clinical studies were soon performed [Herfkens 1983]. 
Over the last 25 years development has been rapid, following advances in MRI 
scanner, hardware and software technology (Figures 5.2 and 5.3). As well as the 
carotid and iliac arteries, the aorta has also been studied, and more recent work has 
begun to examine the coronary artery wall. 
 
Plaque imaging has been extensively validated. This was done initially by imaging ex 
vivo arteries, and comparing images with histology (Figure 5.4). However, the 
majority of this work has involved imaging patients’ carotid arteries before carotid 
endarterectomy, and then comparing the images with histological images of the 
excised plaque. Many studies of this type have been performed, and they have refined 
the accuracy of carotid CMR for characterising carotid plaque morphology and 
composition.  
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Figure 5.3 T1-weighted fast spin echo CMR images. A series of 20 contiguous 
slices through the carotid bifurcations bilaterally. The carotid arteries are 
arrowed in image 1. 
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5.2 PLAQUE CHARACTERISATION BY CMR 
The understanding that plaque composition is as important as plaque size in causing 
clinical events led to efforts to characterise plaque. A large plaque with a thick fibrous 
cap and a small lipid core may be stable and unlikely to rupture and cause vessel 
occlusion, which contrasts with a smaller plaque with a thin fibrous cap, a large lipid 
core and areas of dense neovascularisation and inflammation which may be more 
unstable. CMR is an ideal tool for plaque imaging because its high degree of soft 
tissue contrast means that lipid and fibrous tissue can be distinguished.  
 
Using only T2-weighted imaging, Serfaty was able to classify ex vivo plaque 
according to the American Heart Association classification with a sensitivity of 
between 67% and 90% and a specificity of between 85% and 100% [Serfaty 2001]. 
The first study to attempt to characterise plaque in vivo was performed in 1996. 
Toussaint demonstrated an excellent correlation between in vivo and ex vivo T2 
relaxation times for areas of fibrous cap and lipid core in carotid plaque of 6 patients 
undergoing endarterectomy, showing that the ex vivo work was clinically applicable  
[Toussaint 1996]. The ability of CMR to discriminate between tissue components was 
not fully utilised as only one contrast weighting (T2) was used. Imaging the same 
tissue several times with different contrast weightings, and then combining the 
information enables a much greater degree of tissue characterisation to be performed. 
This process is called multi-contrast, or ‘multi-spectral’ imaging. Algorithms have 
been drawn up to combine information from several scans. An example is shown as 
Table 5.1. 
 
Table 5.1 Signal characteristics of different tissues by CMR. 
 
Sequence Weighting Signal Intensity by Tissue Component 
 Fibrous Cap Lipid Core Calcification Thrombus 
T1 Intermediate High Low Variable 
T2 Intermediate Low Low Variable 
Proton Density Intermediate High Low Variable 
Time of Flight Intermediate Low Low Variable  
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5.2.1 Multispectral Imaging 
By improving tissue characterisation, multispectral MRI provides better lesion-type 
classification. A large and typical study by Cai, looking at the carotid arteries of 60 
patients before endarterectomy, showing that multispectral CMR correlates well with 
the AHA classification with an accuracy of 80.2%. Sensitivity ranged from 67% to 
84%, with specificity between 90% and 100% [Cai 2002]. The standard AHA plaque 
classification was adapted for CMR (Table 5.2), (Figures 5.5 and 5.6).  
 
Table 5.2 Conventional and Modified AHA Classification of Atherosclerotic 
Plaque (adapted from [Cai 2002]).  
Plaque 
Type 
Histological appearance  CMR plaque 
type 
CMR appearance 
Type I initial lesion with foam cells 
Type II fatty streak with multiple foam cell layers 
Type I -II near-normal wall thickness, no calcification 
Type III preatheroma with extracellular lipid pools Type III diffuse intimal thickening or small eccentric 
plaque with no calcification 
Type IV atheroma with a confluent extracellular lipid 
core 
Type V fibroatheroma with possible calcification 
Type IV–V plaque with a lipid or necrotic core 
surrounded by fibrous tissue 
Type VI complex plaque with possible surface defect, 
haemorrhage, or thrombus 
Type VI complex plaque with possible surface defects, 
haemorrhage, or thrombus 
Type VII calcified plaque Type VII calcified plaque 
Type VIII fibrotic plaque without lipid core Type VIII fibrotic plaque without lipid core and with 
possible small calcifications 
 
 
5.2.2 Fibrous Cap Thickness and Integrity 
Fibrous cap rupture is the key event in the development of many of the clinical 
syndromes of atherosclerosis. The first CMR study to try to assess fibrous cap 
integrity was performed ex vivo in 1998. Using carotid endarterectomy specimens, 
Winn showed that CMR was 90% specific for identifying the presence of a fibrous 
cap, and 98% specific for detecting cap rupture, but the sensitivities were much lower 
(37% for presence of cap and 12% for identification of rupture) [Winn 1998]. For a 
non-invasive method of plaque imaging, however, a high degree of sensitivity is 
essential, as the technique needs to reliably identify patients with unstable plaque. 
Fortunately progress has been made over the last decade, and improvements in 
resolution and multispectral imaging have enabled the thickness of the fibrous cap to 
be measured in vivo, giving an indication of plaque stability. In a study of 22 
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endarterectomy patients, CMR classification of fibrous cap as intact or ruptured 
correlated with histology with a sensitivity of 89% and a specificity of 96%. When 
plaques were subdivided into “intact and thick” or “intact and thin” or “ruptured”, 
CMR findings were 89% accurate [Hatsukami 2000]. 
 
Figure 5.4. Ex vivo correlation of carotid plaque histology with CMR. (A) High 
resolution T1-weighted fast spin echo CMR of an ex vivo carotid artery – 
transverse section immediately above the carotid bifurcation, external carotid 
artery to the left and internal carotid artery to the right. Two plaques are 
present, one with a thin/ruptured fibrous cap (large arrow), the other with a 
thick fibrous cap (small arrow). (B) Matched hematoxylin and eosin (H&E) 
histological section. 
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5.2.3 Lipid-Rich Necrotic Core 
The presence of a lipid core is another marker of a vulnerable plaque. The size of the 
lipid core is also important, and may itself be an endpoint in therapeutic trials. In 101 
sections from 18 endarterectomy patients, the sensitivity and specificity of CMR for 
lipid-rich necrotic core were 98% and 100% respectively. However, this analysis 
excluded lipid-rich necrotic cores that were subsequently found on histology to 
contain intra-plaque haemorrhage. If these plaques were included, sensitivity and 
specificity dropped to 85% and 92% respectively. Plaque haemorrhage is a challenge 
for CMR, but an important marker of instability [Yuan 2001]. Quantification of lipid 
core by CMR correlates well with histology [Cai 2005]. 
 
Technological developments may aid the identification of lipid components. Recently 
a diffusion-weighted CMR sequence has been demonstrated ex vivo to have improved 
contrast-to-noise ratio (CNR) for lipid core versus fibrous cap as compared with a 
conventional T2-weighted sequence. This diffusion-weighted sequence now needs to 
be validated in vivo [Qiao 2007]. 
 
5.2.4 Plaque Haemorrhage / Thrombus Imaging 
As well as the thickness of the fibrous cap and the presence of a lipid-rich necrotic 
core, another indicator of plaque rupture or instability is the presence of haemorrhage 
or thrombus. If a haemorrhage has occurred into a plaque, then by definition the 
plaque is unstable. Adherent lumenal thrombus is also a sign of instability as it 
indicates that the plaque is in some way disrupted. Plaque haemorrhage is not a one-
off event leading to vessel occlusion and a clinical syndrome. Although this does 
occur, small plaque haemorrhages can occur silently. Intraplaque haemorrhage is 
implicated in plaque growth and is a strong stimulus to repair (which leads to plaque 
expansion), inflammation and neovascularisation, weakening the plaque further. 
Thrombus has iron-containing breakdown products of haemoglobin, which have 
paramagnetic contrast properties. However, CMR of intraplaque haemorrhage 
presents a particular challenge because the signal intensity of the haemorrhage varies 
widely depending on its age. As is shown in table 5.3, a recent haemorrhage can be of 
high signal in all four of the common CMR weightings, while an old haemorrhage can 
be of low signal on all weightings, making it difficult to distinguish from calcification. 
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In spite of these difficulties, Chu was able to identify intraplaque haemorrhage with a 
sensitivity of 90% and a specificity of 74% in 27 endarterectomy patients. Intraplaque 
haemorrhage was present in 77% of locations sampled [Chu 2004]. Haemorrhage into 
an atherosclerotic plaque can be subdivided into haemorrhage into the necrotic core 
without rupture of the fibrous cap, and haemorrhage or thrombus formation adjacent 
to the lumen (usually associated with a ruptured cap). This distinction has proved 
useful because haemorrhage without fibrous cap rupture has not been associated with 
clinical events whereas rupture with juxtalumenal thrombus or haemorrhage has, 
because it indicates ongoing instability (erosion, rupture, ulceration) of the fibrous 
cap. CMR was able to differentiate between these two lesion types with 96% 
accuracy. In this study, the overall sensitivity and specificity of CMR for detection of 
thrombus had improved to 96% and 82% respectively [Kampschulte 2004]. 
 
5.2.5 Use of Contrast Agents 
In addition to multispectral imaging, the use of extrinsic intravenous contrast has 
improved plaque characterisation by CMR. The standard contrast agent is gadolinium 
bound to a chelate. Gadolinium is a rare earth metal. It has a short T1 time constant, 
which relaxes water molecules that comes into its proximity, leading to high signal 
intensity on T1 weighted sequences. Gadolinium is commonly used for MR 
angiography (MRA), which is often performed in patients with carotid artery disease. 
It is also routinely used in CMR for imaging myocardial infarction and fibrosis. After 
injection, the contrast initially remains in the vascular space and so can demonstrate 
areas of vascularity in plaque, a marker of vulnerability. After the initial vascular 
phase, gadolinium chelate moves into the extracellular space, being more 
concentrated in areas where the extravascular space is expanded, such as in scar 
tissue, or the fibrous cap. In Cai’s study of lipid rich necrotic core and fibrous cap 
(referred to above), intravenous gadolinium contrast was used to improve tissue 
characterisation between the fibrous cap and the lipid core. After contrast, different 
types of fibrous cap could be differentiated. 56% of sections had collagen-rich fibrous 
caps. Of these, all those with moderate gadolinium enhancement were assessed 
histologically to be stable, whereas all those with strong enhancement after contrast 
has evidence of neovascularisation or inflammatory infiltrate. Of the 44% of patients 
with fibrous cap made of loose matrix, all had strong gadolinium enhancement 
(Figure 5.7) [Cai 2005]. 
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Table 5.3 MRI/Histology Criteria: Intraplaque Haemorrhage. Adapted from 
[Chu 2004].  
   MRI 
Age of 
Haemorrhage 
Erythrocytes Histology T1W T2W / PDW TOF 
Fresh Intact with 
intracellular 
methaemoglobin 
 
Lymphocytes 
Neutrophils 
Scattered macrophages 
Hyperintense Hypointense/ 
Isointense 
Hyperintense 
Recent Lytic with 
extracellular 
methaemoglobin 
Macrophage clusters 
Giant cells 
Cholesterol crystals 
Peripheral angiogenesis 
Hyperintense Hyperintense Hyperintense 
Old Amorphous Amorphous debris 
with hemosiderin  
No inflammatory 
reaction 
Hypointense Hypointense Hypointense 
 
 
Figure 5.5. Very early plaque on the posterior aspect of the right internal carotid 
artery. T1-weighted image (left) and T2-weighted image (right). The fibrous cap 
can be seen, overlying an area of calcification which is of low signal on both T1- 
and T2-weighted images. 
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5.3 CLINICAL CORRELATION 
The developments in plaque imaging over the last ten years have been rapid,and 
several studies have begun to show how a clinical role for this technology may 
develop, of which three are described here for illustration. A study of fibrous cap 
rupture correlated carotid scan appearances with clinical history in 53 patients. 
Patients identified by CMR as having a ruptured fibrous cap were more likely to have 
had a transient ischaemic attack (TIA) or stroke than those with an intact, thick cap. 
Of patients with a ruptured plaque by CMR, 70% had symptoms, compared with 7% 
of patients with intact, thick caps. Compared with patients with thick fibrous caps, 
patients with ruptured caps were 23 times more likely to have had a recent TIA or 
stroke [Yuan 2002]. As well as fibrous cap thickness, intraplaque haemorrhage has 
been correlated with clinical events, and also plaque growth. Of 29 patients with 
carotid plaque who were followed by serial CMR over 18 months, 14 had intraplaque 
haemorrhage by CMR at baseline. In these patients, vessel wall volume and lipid rich 
necrotic core volume increased, but they stayed the same or reduced in patients 
without haemorrhage. In addition, plaques with haemorrhage were more likely to 
develop new plaque haemorrhages during follow up (43% versus 0%), because of 
ongoing plaque instability, indicating that plaque haemorrhage is a marker of 
vulnerable plaque [Takaya 2005]. Plaque haemorrhage has been correlated with 
clinical events in a larger study of 154 patients with asymptomatic 50-79% carotid 
stenosis by ultrasound. There were 12 anterior circulation cerebrovascular events 
ipsilateral to the index carotid plaque over a mean of 38 months of follow up after the 
CMR study. The hazard ratio (HR) for cerebrovascular accident (CVA) was 17.0 for 
plaque with thin or ruptured fibrous cap, and 5.2 for intraplaque haemorrhage, with an 
increase in hazard ratio of 2.6 for every 10mm2 increase in intraplaque haemorrhage 
area. There was also an increase in HR of 1.6 for every 10% increase in the plaque 
percentage of lipid-rich or necrotic core [Takaya 2006]. 
 
Current guidelines for carotid endarterectomy are based on percentage stenosis as 
assessed by ultrasound. The North American Symptomatic Carotid Endarterectomy 
Trial (NASCET) criteria state that carotid endarterectomy should be recommended to 
patients with symptomatic carotid stenosis of 70% to 99% [NASCET 1991]. The 
CMR studies show that these criteria are a rather blunt tool for patient selection for an 
operation that carries considerable risks. Patients with unstable plaque but less than 
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70% stenosis are excluded, while patients with greater than 70% stenosis and stable 
plaque are recommended for surgery. In these patients the unstable plaque may be 
further down the common carotid artery (as recent MR-PET work has shown). 
Improving patient selection for surgery improves outcomes as those most likely to 
benefit are operated, while those who are unlikely to benefit are excluded. CMR 
carotid plaque assessment has a key role to play in patients with TIA and stroke.  
 
In the longer term, and with wider availability, this approach may prove of clinical 
use in other patients currently assessed by carotid ultrasound, such as older patients 
being worked up for coronary artery bypass grafting. The ideal is to identify patients 
before symptoms develop. The numbers of ‘at risk’ patients are so large that a CMR-
based screening program for unstable carotid plaque is not feasible. However, if 
reliable serum markers of plaque instability were available, the prospect would be 
more appealing. Recent practice in the United States, following the Asymptomatic 
Carotid Atherosclerosis Study (ACAS) was to offer carotid endarterectomy to patients 
with a carotid stenosis of between 60% and 99%, who had had no symptoms [ACAS 
1995]. In this trial, the event rate in the unoperated cohort was only 11% at 2.7 years, 
and it has been estimated that 40 operations were needed to prevent 1 stroke. Given 
that of the 150,000 endarterectomies performed in the United States each year, at least 
half are done for stenoses that have never been symptomatic, it is clear that CMR 
could have a clinical role [Rothwell 2004]. 
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Figure 5.6 T1-weighted fast spin echo CMR image. A moderate plaque is seen in 
short axis (A) and in long axis (B) at the carotid bifurcation (long arrow). The 
origin of the external carotid artery can be seen (arrowhead). The plaque is of 
uniform intermediate signal indicating fibrous tissue. This is a very typical site 
for plaque development.  
 
Figure 5.7 T1-weighted fast spin echo CMR image before (A) and after (B) 
gadolinium contrast. A large eccentric plaque in the right common carotid artery 
is shown (large arrows). Two small areas enhance after contrast administration 
(small arrows), suggesting regions of increased vascularity and possible plaque 
instability. 
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5.4 THERAPEUTIC STUDIES WITH CMR ENDPOINTS 
As well as plaque characterisation, CMR plaque imaging parameters have been used 
as the primary endpoints in clinical trials. Although a research application, these are 
some of the most exciting developments in the field of atherosclerosis research. 
Studies of this type have been among the first to show atherosclerosis regression. 
Similar studies with coronary intravascular ultrasound (IVUS) require repeated 
cardiac catheterisation, with the associated risks, contrast dose and radiation exposure. 
External ultrasound studies may be limited by less than optimal reproducibility, 
usually requiring more patients. Quantitative studies require a method of reproducibly 
measuring the degree of atherosclerosis present. This is done for MR images by 
tracing the outer and inner arterial walls, and so measuring the lumen and vessel wall 
areas. This can be done for one ‘slice’ placed perpendicularly to an artery, ideally near 
a landmark (such as the carotid bifurcation) so that it can be easily repeated in 
subsequent studies. Each slice has a predetermined thickness (usually 2mm in the 
carotid), so that, if several contiguous slices are acquired then the lumen and wall 
volume of an artery can be modelled along a set length of the artery. Increased 
sampling increases accuracy, and also reproducibility. (Figure 5.8) 
 
The first example of a study of this type showed that simvastatin caused regression of 
atherosclerotic lesions in the aorta and carotid arteries of 18 patients followed for one 
year by CMR [Corti 2001]. At two years, the results were expressed in terms of vessel 
wall thickness (similar to an ultrasound intima-media thickness (IMT)), and vessel 
wall area. There had been a 16% reduction in aortic vessel wall thickness (at the 
thickest point), and a 16% reduction in vessel wall area. There was no change in 
vessel wall thickness at the thinnest point. The same was found in the carotid artery, 
with a 19% reduction in vessel wall thickness, and an 18% reduction in the vessel 
wall area. Again there was no difference in vessel wall thickness at the thinnest part. 
This illustrates a strength of the technique in that differential change around the 
arterial wall can be measured, which is not possible with the standardised ultrasound 
technique. Simvastatin caused the vessel wall area to reduce by nearly one fifth. The 
reduction in vessel wall area was not matched by a similar increase in lumen area. In 
fact the increase in lumen area was comparatively modest at +6% in the aorta and 
+5% in the carotid. The arterial wall remodelled outwards in response to 
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atherosclerosis, and in response to atherosclerosis regression, the vessel wall remodels 
inwards, with the lumen left comparatively unaffected [Corti 2002].  
The power of this technique can be shown by a further study of plaque regression in 
patients randomised to simvastatin 80mg or 20mg. Although only 27 patients were 
randomised, the study demonstrated significant results in 6 months. Comparable 
ultrasound studies need to recruit many more patients and with longer follow-up . 
Imaging the thoracic aorta, the authors showed a 12% reduction in plaque volume 
with high dose statin, with no significant change in lumen volume. So if this study 
had been performed with a purely lumenographic technique, the results would have 
been negative [Lima 2004]. 
 
 
Figure 5.8 The user interface of a semi-automated software solution used to 
model the carotid arterial wall at the bifurcation (AtheromaTools, a plug in of 
CMRTools, CVIS Ltd, London). This sort of analysis is essential for quantitative 
work, such as studies of plaque regression. 
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With improvements in imaging, studies of plaque regression are now starting to focus 
on individual plaque components rather than the simpler measure of overall vessel 
wall volume, area or thickness. An example of this approach is the Orion study. In 
this study comparing 40mg against 5mg rosuvastatin, the authors measured the carotid 
artery wall volume, but also the volume of the lipid core. The interim results show a 
reduction of the lipid core volume of 35.5%, although this did not quite achieve 
significance (p=0.06) [Saam 2005b]. Nevertheless, the approach seems likely to bear 
fruit, as reduction in the lipid core not only indicates plaque regression, but may also 
indicate stabilisation.  
 
 
 
 
 
5.5 CORONARY VESSEL WALL IMAGING 
The majority of the CMR work described so far has focussed on the carotid artery 
partly because it is comparatively easy to image. The coronary artery is a more 
difficult target, but is of considerable interest to cardiologists. The coronary arteries 
are difficult to image by CMR because they are small, tortuous, not near the surface, 
and because they move with cardiac and respiratory motion. A coronary artery may 
have an external diameter of 5mm, and yet move 5cm with inspiration. CMR 
techniques are not yet sufficiently good to image the coronary artery wall with a 
single shot imaging technique, and therefore the image needs to be built up over a 
number of cardiac cycles, for each of which the heart and the diaphragm need to be in 
the same position. The first paper to demonstrate that CMR could characterise the 
coronary artery wall was published in 2000. The images were acquired during a 
breath-hold and imaging was performed over between 12 and 18 cardiac cycles. A fat 
suppression pre-pulse was used to reduce signal from the fat around the coronary 
artery so that the vessel wall could be clearly seen. Using coronary angiography as the 
gold standard, the authors demonstrated that CMR was able to identify a normal thin-
walled vessel, and an eccentric plaque [Fayad 2000].  More recently, the first large 
study showing the clinical utility of this approach has been published. In this study, 
CMR coronary artery vessel wall imaging was performed on 136 patients with type I 
diabetes, not previously known to have cardiovascular disease [Kim 2007]. 
Diagnostic quality coronary artery CMR images were obtained from 96% of patients. 
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These authors did not correlate CMR findings with angiography as a gold standard 
because angiography was not indicated in this cohort. Instead they measured the 
coronary artery wall thickness and the presence of stenoses by CMR and correlated 
these with diabetic nephropathy as indicated by proteinuria as an indicator of severity 
of diabetes. Coronary artery stenoses were identified in 10% of patients with 
nephropathy, and 0% of patients without. Also, the maximum right coronary artery 
wall thickness was 2.2mm in patients with nephropathy and 1.6mm in those without. 
Both differences were statistically significant. The authors describe this approach as 
measuring coronary plaque burden. Previously, coronary artery calcification (CAC) 
scoring by CT was also described in a similar way. A limitation of CAC is that the 
test is normal unless calcification is present in the coronary arteries, so soft plaque 
may be missed. However, the use of multidetector CT (250 or more detectors) now 
provides images of coronary plaques, which includes those which are not calcified, 
but at a significant radiation burden. Using CMR to assess the general degree of 
thickening of the coronary arteries, is an appealing way of assessing the coronary 
plaque burden. Therapeutic studies assessing plaque regression in the coronary 
arteries may be possible.  
 
 
 
 
5.6 NEWER APPROACHES 
CMR provides good anatomical detail of atherosclerotic plaques, but it may be useful 
to combine CMR with other techniques which map functional and metabolic changes. 
Two methods used are multi-modality imaging, and molecular imaging. 
 
5.6.1 Positron Emission Tomography 
(Also see section 2.3.3 D) 
Positron emission tomography (PET) imaging uses a radioactive glucose isotope (18F-
fluorodeoxyglucose -18FDG), which is taken up by metabolically active tissues after 
injection. Originally used in the assessment of malignancy and in neuroimaging, high 
signal was frequently identified from atherosclerotic plaques, particularly in the aorta, 
which were metabolically active and so took up 18FDG. The low amount of 
anatomical detail and comparatively poor spatial resolution meant that detailed plaque 
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characterisation was not possible, but this has been overcome by combining PET and 
CMR (or CT), allowing the fusion of anatomical and functional data. The images are 
combined by co-registration, where the patient is maintained in a constant position 
between scans, and various anatomical landmarks are identified on both scans. In a 
study of 12 patients with recent TIA and an ipsilateral high-grade carotid stenosis, 
CMR identified a lesion with high 18FDG uptake at the site of the stenosis in seven 
patients (58%). In the remaining 5 patients, 18FDG uptake in the targeted lesion was 
low. In 3 of these 5 patients, MR-PET identified another different lesion with a high 
level of 18FDG uptake, but without high-grade stenosis, in a vascular territory 
compatible with the patients’ TIA [Davies 2005]. This adds further credence to the 
paradigm that guidelines for carotid endarterectomy based purely on percentage 
stenosis fail to address a significant proportion of culprit lesions. This conclusion can 
be extrapolated to the coronary arteries. 
 
Plaque 18FDG uptake has itself been used as the endpoint in a trial of statin therapy. 
Patients in whom a plaque with high 18FDG uptake was identified on a PET-CT 
(performed to screen for malignancy) were randomised to simvastatin or placebo. On 
re-imaging at 3 months, there was significantly less 18FDG uptake in the target lesion 
in patients randomised to simvastatin. This was the first in vivo imaging 
demonstration in humans of statins reducing plaque inflammation, giving insight into 
how they may act to stabilise plaque. It also indicates how this type of imaging could 
be used in future trials [Tahara 2006]. 
  
5.6.2 USPIO 
Another approach is the use of molecular contrast agents. Ultra-small 
superparamagnetic iron oxide (USPIO) particles have the combined properties of 
being taken up by macrophages, and of being visible by CMR, as iron particles cause 
low signal intensity on CMR images. Macrophages are present in inflamed (and 
therefore vulnerable) plaque. Therefore, USPIO-related signal drop out on CMR may 
indicate zones of plaque inflammation. When USPIOs were injected into 30 patients 
pre carotid endarterectomy, signal loss was detectable in plaque in 24 of the 27 
patients with analysable images. When this was compared with the presence of 
USPIOs in plaque at histology post surgery, CMR had a sensitivity and specificity of 
93% and 64% respectively for the presence of USPIOs [Trivedi 2006]. More recent 
Chapter 5 Page 115 CMR of the Atheromatous Plaque 
 
 
 
work has used USPIOs to show that plaque inflammation is unrelated to the degree of 
stenosis [Tang 2008a]. However, in a small study, USPIO-related signal drop out was 
concordant with plaque inflammation as visualised by 18FDG PET [Tang 2008b]. 
 
Recently a USPIO-derived variable has been used as the end-point of a randomised 
trial comparing high- and low-dose atorvastatin in patients with a carotid arterial 
stenosis that accumulated USPIO at baseline. High-dose atorvastatin significantly 
reduced USPIO-related signal while low-dose did not. Furthermore this study 
achieved a positive result after only three months of therapy, and needing only 47 
patients. This study shows the power of USPIO plaque inflammation imaging in 
therapeutic studies in atherosclerosis, particularly for the evaluation of potential new 
therapeutic agents [Tang 2009].  
 
Larger studies of USPIO-enhanced imaging are now required to assess what benefit 
direct imaging of plaque inflammation can have on clinical decision-making, and 
more therapeutic trials should be designed utilising this technology. Furthermore, 
USPIOs are only one of a host of new cellular and molecular imaging agents which 
are set to have a profound influence on life sciences research and clinical practice 
over the next decade. 
 
 
 
 
5.7 CONCLUSION 
CMR arterial wall imaging is a new addition to the array of tools available to image 
atherosclerosis. It is non-invasive, uses no ionising radiation, is not limited to 
lumenography, and has advantages over ultrasound. Detailed atherosclerotic plaque 
characterisation is currently possible in the carotid artery, and has been correlated 
with clinical events. In research, CMR arterial indices have been used as the primary 
endpoints of therapeutic trials in atherosclerosis, and have been used to demonstrate 
plaque regression. Coronary artery wall imaging is also possible. Multimodality 
imaging, such as MR-PET, and molecular imaging are currently under active 
development and will further increase the importance of non-invasive imaging in the 
management of atherosclerosis. 
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CHAPTER 6 
METHODS 
  
In the five clinical studies described in this thesis (Chapters 7-11), the main focus was 
cardiovascular magnetic resonance (CMR) derived carotid artery wall parameters. 
The methods used are described in sections 6.1 and 6.2. A separate protocol, 
comprising both CMR and histology, was used for the study of post-mortem carotid 
arteries (Chapter 7) which is given in section 6.3. Finally, in the studies of patients 
with inflammatory arthritidies (Chapters 10 and 11), a CMR assessment was made of 
endothelial function, and a routine CMR cardiac study with gadolinium contrast was 
performed. The relevant methodologies are described in sections 6.4 and 6.5.  
 
6.1 ASSESSMENT OF CAROTID ARTERY WALL VOLUME 
The history of and background to the development of CMR arterial wall imaging is 
discussed in Chapter 5. This section will focus on the technical aspects and imaging 
parameters. 
 
6.1.1 Hardware for Imaging 
Scanner 
All the scans described in this thesis were performed using a 1.5 Tesla CMR scanner. 
For the studies of normal volunteers and patients (Chapters 8-11) a Siemens Sonata 
(Siemens, Erlangen, Germany) was used, however, for the study of post mortem 
carotid arteries (Chapter 7) a Siemens Avanto was used. All in vivo studies were gated 
to the electrocardiogram (ECG). 
 
Coils 
For all scans on volunteers and patients, purpose-built bilateral four channel phased-
array carotid surface coils were used (Machnet BV, Eelde, the Netherlands). In 
addition, a specially designed vacuum head and neck cushion was used for 
immobilization, and subjects were positioned so that their neck was at the isocentre of 
the magnet (figure 6.1). All subjects were given ‘in-the-ear’ ear plugs to protect their 
hearing. 
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Figure 6.1 For carotid vessel wall imaging, bilateral surface coils are used with a 
vacuum cushion designed to aid immobilisation. 
 
 
6.1.2 Imaging Protocol 
Gradient echo bright blood localisers were rapidly acquired in all 3 orthogonal planes 
to locate the patients head and neck within the scanner. A stack of time-of-flight 
(TOF) images was then acquired perpendicular to the long axis of the carotid arteries 
as identified on the localisers. A saturation band was placed cranial to the imaging 
volume so that only blood flowing in the caudo-cranial direction would be of high 
signal. The TOF images were used to identify the carotid bifurcation on each side. 
Then a low resolution T1-weighted fast spin echo (FSE) image was acquired through 
the bifurcation on each side; this was defined as a plane running through three points: 
one in the common carotid artery, one in the internal carotid artery and one in the 
external artery (figure 6.2). A second image was then acquired perpendicular to this in 
the common carotid artery. These images were used to rapidly assess for the presence 
of any carotid plaque, to determine the location and orientation of the carotid artery 
for further imaging, and to verify optimal coil position. This was defined as when the 
carotid bifurcation was in the middle of the area of high signal underlying the coil. If 
the coil was too high or too low, it was repositioned, and imaging was recommenced. 
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Using these localising images, the subsequent high resolution images as appropriate 
for the study in question were then acquired (figure 6.3). 
 
 
Figure 6.2 A T1-weighted fast spin echo (FSE) localiser of the carotid bifurcation, 
showing the common carotid (CCA), the internal carotid (ICA) and the external 
carotid (ECA) arteries.  
 
 
 
6.1.3 Two Dimensional (2D) Fast Spin Echo Sequence 
The 2D fast spin echo (FSE) sequence is the conventional sequence used for arterial 
wall imaging [Keenan 2008b]. Using the localiser images described above, a 
contiguous stack of high-resolution T1-weighted FSE images was acquired 
perpendicular to the carotid artery, in the same orientation as the TOF images. For 
each side, slices were acquired from 20mm below the carotid bifurcation to 20mm 
above. Slice thickness was 2mm and 20 contiguous slices were acquired for each side 
centred on the bifurcation, giving 40mm of longitudinal coverage per artery (figure 
6.3).  
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Sequence parameters were: field of view (FOV) 110mm read x 65mm phase (up to 
30% bigger phase FOV depending on patient size), pixel size 0.43mm x 0.43mm, 
ECG-gated to every cardiac cycle with end-diastolic triggering, TE 9.6ms, echo train 
length 9 with a readout time of 76ms, band width 230 Hz/pixel, 4 averages. Dark 
blood preparation was used with the inversion time (TI) determined by average R-R 
interval. The scan time per slice was 68 RR intervals (1 minute 8 seconds at a heart 
rate of 60 per minute). This sequence (unmodified) was also used for the post mortem 
carotid artery study in Chapter 7. 
 
 
Figure 6.3 The FSE localisers are used to acquire a contiguous stack of 20 high 
resolution T1-weighted FSE images perpendicular to the carotid artery. 
 
 
 
6.1.4 Three Dimensional (3D) Fast Spin Echo Sequence 
In Chapter 9, the 2D sequence described above is compared with a 3D sequence. This 
was developed by Crowe and co-workers at the CMR unit at the Brompton Hospital 
[Crowe 2003, Crowe 2005a, Crowe 2005b, Crowe 2006]. Their work had shown that 
this technique could potentially give high resolution images with a large reduction in 
scan time compared with the 2D technique. In addition they demonstrated good 
reproducibility, with a coefficient of variation of 4.5% [Varghese 2005a; Varghese 
2005b]. However, further preparatory work revealed that the long imaging time (c. 10 
minutes) required for the sequence as described in the 2003 paper led to frequent 
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movement artefact, even when the 2005 modification to attempt to eliminate artefact 
from swallowing was incorporated. Therefore, in the current thesis the sequence was 
modified by making the slab smaller (16mm depth), reducing the imaging time to an 
average of just over 3 minutes per slab. This substantially reduced movement artefact. 
To obtain adequate longitudinal coverage, several contiguous slabs were acquired. 
 
In Chapter 9 the imaging parameters were: slab thickness: 16mm, encompassing 8  x 
2mm slices (and a further 50% slice oversampling, used to prevent wraparound in the 
z axis), FOV 110mm read x 65mm phase, imaging matrix 256 x 152 (giving true pixel 
size of 0.43mm x 0.43mm, interpolated to 0.21mm x 0.21mm during reconstruction), 
ECG-gated to every cardiac cycle with end-diastolic triggering, TE 13ms, echo train 
length 9, readout time 113ms, bandwidth 150 Hz/pixel, 1 average. Black blood double 
inversion recovery (DIR) was used with an inversion time set at 537ms for all heart 
rates. The scan time per slab was 203 RR intervals. At a heart rate of 60 per minute, 
this was equivalent to 3 minutes 23 seconds for 8 slices. 
 
In Chapter 7 the 3D sequence used to image the post mortem carotid arteries at high 
resolution was of the same design, but optimised to maximise resolution in an ex vivo 
setting where scan time is unimportant.  
 
 
6.1.5 Image Analysis 
Dedicated software to analysed carotid artery images was developed by Dr Varghese 
at the Royal Brompton Hospital CMR Unit working with Dr Merrifield of the Visual 
Information Processing Group, at the Department of Computing, Imperial College. 
This software has been validated for this application [Varghese 2006]. The software is 
called Atheroma Tools, and it functions as a plug-in of CMRtools (Cardiovascular 
Imaging Solutions, London, UK), a commercial software solution for the analysis of 
CMR images. 
 
For both 2D and 3D sequences in vivo and ex vivo, Atheroma Tools was used to 
derive carotid artery volumes. For each slice, the operator contours the internal and 
external carotid arterial surfaces. The software then measures the lumenal and 
adventitial areas for each slice and, using the slice thickness and number of slices, 
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converts these into a lumenal and adventitial volumes. Subtracting the lumenal 
volume from the adventitial volume derives the wall volume (figure 6.4). Wall 
volume, lumenal volume and total vessel (adventitial) volume are the main variables 
measured in the projects described in this thesis. This data has also been presented as 
the wall/outer wall (W/OW) ratio: the wall volume expressed as a percentage of the 
total vessel volume, an index of arterial thickening [Saam 2005a]. 
 
All images were analysed by a single reader. However, using the same technique, Dr 
Varghese in our group showed that this methodology has a coefficient of variation of 
4.5% [Varghese 2005a, Varghese 2005b]. 
 
 
Figure 6.4 Atheroma Tools software. (A) The user interface, (B) close up of 
contours, (C) 3D reconstruction of carotid bifurcation (CC=common carotid, IC 
= internal carotid, EC = origin of external carotid (not analysed)). 
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6.2 ASSESSMENT OF CAROTID ARTERY DISTENSIBILITY 
 
6.2.1 Background 
Arterial distensibility is a measure of vascular health. With progressive atherosclerotic 
disease arteries become stiffer and less compliant, and a reduction in carotid, radial 
and aortic distensibilities have been correlated with coronary atherosclerosis 
[Giannattasio 2007].  Arteries also become stiffer with ageing. These changes have 
been attributed to an increase in the proportion of collagen fibres over elastin fibers, 
as well as the fracturing of elastic lamellae [Samila 1981]. Previous assessment of 
arterial distensibility has used ultrasound [Hansen 1995, Schmidt-Truckass 1999]. 
However, the improvement in temporal resolution of cine CMR suggested that similar 
data to ultrasound could be acquired by CMR, so we incorporated a cine image on 
each side perpendicular to the common carotid artery to assess distensibility. Other 
groups have also started to use this approach: for instance a measurement of arterial 
distensibility has been used as part of a multi-faceted CMR assessment of vascular 
health [Lee 2008]. In terms of definitions, arterial distensibility is defined as the 
measured change in arterial area from end-diastole to end-systole, while compliance is 
the degree of change in arterial area for a given change in arterial pressure. 
 
6.2.2 Image Acquisition 
Using TSE localiser images, a single gradient echo cine image was acquired 
perpendicular to the common carotid artery on each side to assess arterial 
distensibility. This was a standard prospectively ECG-gated balanced steady state free 
precession (SSFP) sequence, with sequence parameters FOV 105mm x 52mm, flip 
angle 60, bandwidth 977 Hz/pixel, giving a voxel size of 0.66 x 0.82 x 6mm.  
 
6.2.3 Image Analysis 
The cine image manually contoured at end-diastole and end-systole for each side, and 
the percentage distensibility was calculated. Of note, data on arterial compliance were 
not derived as these require blood pressure to be measured in the scanner and this 
facility was not available on the scanner used for this study.  
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6.3 MEASUREMENT OF CAROTID ARTERY WALL PARAMETERS IN POST 
MORTEM SPECIMENS 
 
6.3.1 Background 
Although carotid arterial wall CMR is well established for quantitative studies of 
atherosclerosis, and has been used as an end point for randomized trials,[Corti 2001, 
Corti 2002] little basic validation work has been performed. Previous studies had 
validated plaque compositional analysis ex vivo,[Martin 1995] but no study has 
measured carotid artery volumes by CMR in ex vivo arteries, and then measured the 
volume by histology as a basic validation.  
 
6.3.2 Tissue Acquisition and Preparation 
Colleagues in the pathology department and bereavement office at the Royal 
Brompton Hospital identified recently deceased patients who were to undergo post 
mortem examination. All adult patients were considered eligible, excluding on safety 
grounds those with serious communicable diseases. Full approval was obtained from 
the institutional ethical committee, and all local tissue handling procedures were 
followed. In all cases, written informed consent was obtained from the next of kin. 
During necropsy the carotid arteries were removed from the patient, with the aim of 
obtaining at least 20mm of axial length above and below the carotid bifurcation. The 
arteries were washed, all adherent soft tissue was removed, and they were fixed in 
10% formaldehyde for a minimum of 24 hours. They were then prepared for imaging 
by removing the external carotid artery and trimming the internal carotid artery and 
common carotid artery to a standard length of at most 30mm above and below the 
carotid bifurcation. 
 
6.3.3 Image Acquisition 
Imaging was performed in a standardized manner. Two sequences were used. The 
first was the standard clinical sequence used in our institution for carotid arterial wall 
imaging (a 2D fast spin echo sequence) [Keenan 2008e]. The second was a three 
dimensional fast spin echo sequence with a small field of view, optimized for 
maximal resolution as a form of internal control [Keenan 2008c]. 
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All imaging was performed at room temperature. Some changes in plaque 
characteristics have been described with cooling from body temperature. The main 
changes are related to the physical properties of plaque components, such as a 
decrease in the T2 relaxation time of lipid, but this was of limited importance as this 
was not a study of plaque characterization; however a small increase in plaque size 
has been observed with cooling [Dalager-Pedersen 1999, Rhodes 2007].  
 
Figure 6.5 T1-weighted FSE scout image showing right and left ex vivo carotid 
arteries. CCA = common carotid artery, ICA = internal carotid artery, ECA = 
truncated origin of external carotid artery. 
 
 
 
After being taken out of formaldehyde, the arteries were dried for 5 minutes on tissue 
paper. The arteries were then supported by means of a 2 mm diameter length of 
plastic fiber-optic cable inserted down the common carotid and internal carotid lumen, 
which was in turn secured at either end in a specially constructed box for imaging. For 
each patient, both arteries were imaged simultaneously. The arteries were imaged in 
air. The box was air-tight to prevent excessive drying of the specimens. Standard 
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phantoms were placed on both sides of the box containing the arteries to give 
adequate signal for automatic scanner adjustments to take place. A 1.5T scanner was 
used (Siemens Avanto, Erlangen, Germany), with a 2cm small loop surface coil 
secured under the artery box (figure 6.5) 
 
Sequence Parameters: 2D T1-weighted 2D FSE 
Field of view (FOV) 110mm read x 65mm phase, imaging matrix 256 x 150, TE 
9.6ms, echo train length 9, readout time of 76ms, bandwidth 230 Hz/pixel, 4 averages, 
TR 1000ms, with a fat saturation pre-pulse. Pixel size was 0.43mm x 0.43mm, and 
slice thickness was 2mm. Contiguous images were acquired covering the full length 
of both arteries. Scan time per slice was 67s. 
 
Sequence Parameters: 3D multi-slab volume-selective T1-weighted FSE 
Slab thickness 32mm (with a further 50% slice oversampling used to prevent 
wraparound in the z axis), FOV 50mm read x 20mm phase, imaging matrix 256 x 
105, TE 15ms, TR 900ms, echo train length 7, readout time 105ms, bandwidth 130 
Hz/pixel, 1 average, with a fat saturation pre-pulse. True voxel size was 0.195mm x 
0.190mm x 1mm (partition phase-encode), as 32 partition phase-encode steps were 
used through the slab thickness, with the slab reformatted into 1mm thick slices. Scan 
time per slab was 10 min 48 seconds. 
 
6.3.4 Image Analysis 
Image analysis was performed as described in section 6.1.5 for in vivo images to 
derive luminal volume, adventitial volume and wall volume for each artery by each 
technique.  
 
6.3.5 Slide Preparation and Analysis 
After being decalcified for 9 days in ethylenediaminetetraacetic acid (EDTA), carotid 
arteries were embedded in paraffin wax using standard techniques, and sectioned 
every 1mm along the length of the vessel with a section thickness of 4µm per section. 
The sections were stained using hematoxylin and eosin (H&E), and slides were 
prepared (figures 6.6 and 6.7). Using a Nikon 80i microscope, with a 5 megapixel 
digital camera connected to a PC, images were analyzed using NIS-Elements (Nikon 
Instruments, Japan). This software performs automated boundary detection and, 
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calibrated to the microscope, was used to measure the luminal and adventitial area of 
the arterial sections, and, subtracting them, the wall area. The operator was blinded to 
the CMR analysis. Histological specimens were considered suitable for analysis if a) 
the tissue slice was complete circumferentially, and b) the endoluminal surface was 
intact. Tissue sections were excluded if histological processing had produced severe 
artefact. 
 
Figure 6.6 H&E Histological sections through the common carotid artery in 
three subjects. (A) No atheroma is present. (B) A shallow eccentric plaque is 
present, with fibrous cap (FC) and lipid core (LC) noted. (C) A moderate-sized 
eccentric plaque with a thick fibrous cap overlying the lipid core.   
 
6.3.6 Sequence Comparison and Slice Matching 
Comparison was made between the clinical (2D) CMR sequence and both the high 
resolution (3D) CMR sequence, and histological data. The main aim was to compare 
volumes but, as slice matching was performed, area data for individual slices could 
also be compared. Slice matching between 2D and 3D CMR datasets was performed 
using the z coordinate of the CMR scan. Slice matching between 2D CMR and 
histology was made primarily using the longitudinal position of each slice which had 
been noted during processing but, for an additional validation, visual assessment was 
performed using features including: overall shape of lumen and wall, the presence and 
shape of atheromatous plaque, and the presence of plaque components [Yuan 2001]. 
Where there was no histological section to map to a CMR section (because of 
disruption during histological processing) that slice was excluded from the CMR 
volumetric analysis. Volume and area data were then compared between 2D and 3D 
techniques, and between the 2D technique and histology (figure 6.8). 
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Figure 6.7 H&E Histological sections through the carotid bifurcation in two 
subjects. (A) Minimal intimal thickening is present in the internal carotid artery 
(arrows). (B) Two large plaques are present in the internal carotid artery. Both 
contain areas of calcification (arrows). 
 
Figure 6.8  An example of slice matching; the arrow indicates an area of plaque 
matched between the 2D sequence (left), the 3D sequence (centre), and the 
histological section (right).  
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6.4 ASSESSMENT OF ENDOTHELIAL FUNCTION 
 
6.4.1 Introduction 
Endothelial dysfunction is an early feature of cardiovascular disease, and has been 
associated with all major cardiovascular risk factors [Celermajer 1993, Celermajer 
1994, Rong 1998, Weisman 2004]. Endothelial function can be assessed by measuring 
to what extent an artery (usually the brachial artery) dilates in response to reactive 
hyperaemia. Brachial artery reactive hyperaemia is conventionally induced by 
inflating a sphygmomanometer cuff placed distally around the forearm to 20mmHg 
above systolic blood pressure for five minutes, thus rendering the forearm ischaemic. 
When the cuff is released, tissue ischaemia leads to dilatation of the resistance 
arterioles in the forearm and increased flow in the brachial artery. The increase in 
flow is detected as increased shear by the endothelium, inducing it to release 
mediators such as nitric oxide (NO) which cause dilatation of the brachial artery itself. 
This is termed flow mediated dilatation (FMD), and it is quantified by measuring the 
size of the brachial artery before and after the cuff inflation. As FMD is an 
endothelium-mediated process, the degree of dilatation is an indicator of the function, 
and so health, of the endothelium. When FMD is used as a measure of endothelial 
function, it is conventional also to assess endothelial independent vasodilatation, and 
this is done by measuring the change in the size of brachial artery in response to 
sublingual glyceryl trinitrate (GTN). 
 
FMD has traditionally been measured by ultrasound [Celemajer 1992]. It was first 
described and validated by CMR in 2002 by Dr Sorensen in the CMR unit at the 
Royal Brompton Hospital [Sorensen 2002]. This study also showed that BAR by 
CMR has superior reproducibility to ultrasound; the CMR technique has the 
advantage that it measures the arterial area whereas ultrasound measures a diameter, 
which has been identified as inaccurate as the artery is usually oval-shaped [Ong 
2002].  The CMR technique has been used as an end point in randomised clinical 
trials [Tanner 2007]. Non-invasive measurements of FMD in the brachial artery have 
been correlated with invasive measures of endothelial function in the coronary 
arteries, and endothelial dysfunction is associated with early atheroma formation and 
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has been linked to an increase in future cardiac events [Takase 1998, Schachinger 
2000, Suwaidi 2000].  
 
6.4.2 Methodology 
In studies of endothelial function described in this thesis (Chapters 10 and 11), a 
previously validated CMR endothelial function protocol was used [Sorensen 2002]. A 
2cm small loop surface coil was placed over the brachial artery (figure 6.9). The right 
brachial artery was used, although the left was used in patients with Takayasu’s 
arteritis if the right brachial artery was known to be occluded proximally. A cross-
sectional image of the brachial artery was acquired. Then the artery was occluded 
distal to the coil for 5 minutes by inflating a blood pressure cuff on the forearm to 20 
mmHg above systolic pressure. On release of the cuff, the artery was scanned 
immediately and at 1-minute intervals up to 5 minutes after cuff deflation. Then, for 
assessment of endothelium-independent dilatation, 400µg of sublingual glyceryl 
trinitrate was given, and the artery was imaged every minute until maximal dilatation 
had taken place, or a maximum of ten minutes had been reached (figure 6.12). 
 
 
Figure 6.9 A 2cm small loop surface coil applied to the right brachial artery for 
the CMR assessment of endothelial function. 
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A segmented FLASH gradient echo sequence was used with the following imaging 
parameters: 8 views per segment; TE 14 ms; field of view 7x3.5 cm; matrix size 
256x128, pixel size 0.27x0.27 mm, and acquisition time 12 cardiac cycles; and ECG-
gating with trigger delay to image at end diastole. 
 
Figure 6.10 Assessment of endothelial function by brachial artery reactivity 
(BAR). The area of the brachial artery is traced before (A) and after (B) the 
induction of forearm hyperaemia. The increase in area is due to flow-mediated 
dilatation (FMD). 
 
 
 
 
Using CMRTools software, the cross-sectional area of the artery was calculated at 
baseline and at 1 minute after induction of reactive hyperaemia, and the percentage 
FMD was calculated as the percentage change in area (figure 6.10). Similarly, cross-
sectional area was measured before GTN, and at maximal dilatation after GTN, and 
the percentage change in area was expressed as endothelium independent dilatation. 
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CHAPTER 7 
VALIDATION OF ARTERIAL WALL MAGNETIC RESONANCE  
USING HUMAN POST MORTEM CAROTID ARTERIES  
 
7.1 Introduction 
Cardiovascular magnetic resonance (CMR) of the carotid arterial wall has emerged as 
a useful technique in the non-invasive assessment of atherosclerosis [Keenan 2008b]. 
As well as qualitative studies of plaque composition, quantitative studies of the 
carotid arterial wall have been performed, and show promise for future clinical trials 
in atherosclerosis [Yuan 2001, Corti 2001, Keenan 2008e]. While ultrasound-derived 
measurements are generally one dimensional (1D) using carotid intima media 
thickness (C-IMT), CMR provides a three-dimensional (3D) means to determine 
carotid arterial wall volume. Different sequences have been used including contiguous 
2-dimensional (2D) turbo spin echo (TSE) images and newer  3D methods [Crowe 
2003]. These sequences have recently been compared in normal subjects [Keenan 
2008c]. However, little data exist to assess the accuracy of these techniques for wall 
volume measurement using ex vivo tissue specimens.  
 
Early proof-of-principle work imaged arteries ex vivo to show that CMR could 
identify plaque components, but without assessment of arterial dimensions [Crooks 
1982, Gold 1993, Martin 1995]. The only report to measure carotid artery dimensions 
ex vivo studied the effect of temperature and formaldehyde fixation, but no 
histological measurements were made, and no validation was performed [Dalager-
Pedersen 1999. When CMR has been used in the morphometric analysis of carotid 
artery plaque, it has been validated by comparing CMR images with histological 
sections obtained at carotid endarterectomy [Yuan 2001]. CMR was initially 
performed ex vivo on plaques removed at surgery, and then in vivo on patients before 
plaque extraction [Winn 1998, Serfaty 2001, Toussaint 1996]. When CMR has been 
used for quantitative modelling of the carotid bifurcation, the only validation that has 
been performed is inter-scan reproducibility [Varghese 2005a, Varghese 2005b, Saam 
2005].  
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The aim of this study therefore was to provide a two-way validation of the most 
commonly used 2D TSE method for arterial wall volume assessment. Using ex vivo 
human carotid arteries, a standard clinical 2D sequence was validated against both a 
high resolution 3D TSE sequence, and against histological data. 
 
7.2 Methods 
With full ethical permission from the institutional ethical committee, and written 
informed consent from the next of kin, 20 carotid arteries were removed from 10 
cadavers during necropsy. The arteries were harvested with the aim of obtaining at 
least 2cm of axial length above and below the carotid bifurcation. After washing and 
removing adherent soft tissue, the arteries were fixed in 10% formaldehyde for a 
minimum of 24 hours. The arteries were then trimmed to a standard length of at most 
3cm above and below the carotid bifurcation. The external carotid artery was 
removed, leaving the common carotid artery, the carotid bifurcation and the internal 
carotid artery. 
 
7.2.1 Image Acquisition 
These details are given in chapter 6.3.3. 
 
7.2.2 Image Analysis 
The images were analyzed as previously described in vivo [Varghese 2006]. In brief, 
datasets of contiguous slices were obtained for each carotid artery by both 2D and 3D 
techniques. 2D and 3D datasets were analyzed in a random order by a single 
experienced observer who was blinded to subject details and histological data. Using 
Atheroma Tools (a plug-in of CMRtools, Cardiovascular Imaging Solutions, London, 
UK) the internal and external carotid artery surfaces were contoured manually for 
each image. The software then automatically derived the lumenal area, the wall area, 
and the total (adventitial) area. Using the slice thickness, the area data were summated 
to measure the lumenal volume, wall volume, and total volume for each artery by 
each technique. 
 
7.2.3 Slide Preparation and Analysis 
These details are given in chapter 6.3.5. 
Chapter 7 Page 133 PM Carotids 
 
7.2.4 Sequence Comparison and Slice Matching 
Four comparisons were made. Overall volumetric data (lumenal volume, wall volume 
and total volume) were compared between 2D and 3D datasets. Secondly, using the z 
coordinate, individual slices were matched between 2D and 3D and compared. As 2D 
slice thickness was 2mm while 3D slice thickness was 1mm, each 2D slice was 
compared with the mean of the two corresponding 3D slices. 2D slices were matched 
to histological slices. As part of the process of histological preparation, the 
longitudinal position of each slice had been noted and this was the primary data used 
for matching. However as it was anticipated that there would be some tissue 
disruption and shrinkage during processing, as an additional validation, slice matching 
was verified by a visual assessment comparing histological sections and MR images. 
Features used for visual matching included: overall shape of lumen and wall, the 
presence and shape of atheromatous plaque, and the presence of plaque components 
(Figure 7.1a-c). The process used followed that for analysis of endarterectomy 
specimens previously described by Yuan et al [Yuan 2001]. Matching was performed 
by an experienced reviewer. As for the 2D v 3D comparison, the lumenal volume, 
wall volume and total volume by histology and by CMR were compared for each 
artery. In addition, lumenal area, adventitial area and wall area were compared 
between matched histological and CMR slices. 
 
7.2.5 Statistics & Ethics 
To derive R2, a simple linear regression was performed for: a) lumenal, wall and total 
volume between 2D and 3D datasets for each whole artery; b) lumenal, wall and total 
area between 2D and 3D  for each slice; c) volumes between 2D and histology 
datasets; d) areas between 2D and histology datasets. Scatterplots were drawn with a 
line of identity to examine for systematic bias, and Bland-Altman plots were 
performed. A t-test could not be used as samples were not independent (2 arteries 
from each patient, ≈20 slices per artery). Instead, a mixed effects linear regression 
model was used to derive mean, confidence intervals and p values. Patient and then 
artery were both added as random effects to account for the hierarchical structure of 
the data. Visual inspection of the data showed that all measurements were skewed; 
therefore the natural log transformation was used, and the results are presented as 
geometric means. All analysis was carried out using Stata 10 (StataCorp, Texas, 
USA). Statistical significance was considered present if p<0.05. 
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Figure 7.1. Examples of matched 2D (low resolution), 3D (high resolution) and 
histological images, demonstrating some features used for matching.  
A) Shallow atheromatous plaque containing an area of low signal intensity 
(arrow).  
 
B) Eccentric atheromatous plaque, with fibrous cap (arrow).  
 
C) Complex plaque at the carotid bifurcation (arrows). 
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7.3 Results 
The 10 patients (20 arteries) had a mean age of 62.5 years (range 21-85 years, 7 
males). For all arteries the full protocol of 2D CMR (clinical sequence), 3D CMR 
(high resolution sequence), and histological sectioning was performed. All CMR 
images were interpretable. Data comparing volumes by 2D and 3D CMR techniques 
are shown in table 7.1 and figures7.2 and 7.6. Comparison of the 2D and 3D 
techniques showed high correlation for lumenal (R2=0.99), wall (R2=0.96), and total 
(R2=0.99) volumes. Lumenal volume was equivalent between measures, wall volume 
by 2D was 7% greater than by 3D (p<0.01), and total volume by 2D was 4% greater 
(p<0.01). 
 
The 2mm thick 2D slices (N=420), derived from the 20 arteries (mean 21 slices per 
artery), were matched with corresponding pairs of 1mm thick 3D slices. The slice area 
comparison data are shown in table 7.1 and figures7.3 and 7.6. There was good 
correlation between the datasets (lumen R2=0.97, wall R2=0.92, total R2=0.97). 
Measurements for lumenal area and total area were equivalent (lumen p=0.98, total 
p=0.29), while wall area was 7% greater by 2D (p=0.03). 
 
Of the 2D CMR slices, 331 of 420 (79%) were matched with histological sections that 
were suitable for analysis (figure 7.1). The main reason for failure to match was 
disruption of the histological section in processing. Volumetric data derived from the 
matched sections are shown in table 7.2 and figures7.4 and 7.6. CMR volumes 
correlated well with histology (R2=0.95 to 0.97). All CMR volumes were between 
10% and 14% greater than microscopy measurements (p<0.01). 
 
The area measurements are given in table 7.2 and figures 7.5 and 7.6. There was a 
high correlation between the measurements (R2=0.86 to 0.91). CMR areas were 
between 10% and 15% greater than microscopy areas (p<0.01). 
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Table 7.1. Comparison of vessel wall measurements for ex vivo carotid arteries 
between a clinical 2D CMR sequence and a 3D high resolution validation 
sequence. Results are expressed as geometric mean ± CI, with p value derived 
from mixed effects linear regression modelling.  
 2D  3D p Mean difference as percentage of 
mean absolute value [%] 
Lumen Volume 889 ±287  880 ±284 0.54 1 
Wall Volume 982 ±344  916 ±320 <0.01 7 
Total Volume 1901 ±589  1826 ±566 <0.01 4 
     
 
Lumen Area 18.7 ±5.3  18.9 ±5.1 0.98 1 
Wall Area 21.1 ±6.3  19.7 ±5.6 0.03 7 
Total Area 40.9 ±11.0  39.6 ±10.3 0.29 3 
 
 
Table 7.2. Comparison of vessel wall measurements from evaluable sections of ex 
vivo carotid arteries as performed by a clinical 2D CMR sequence and by 
microscopy validation. Results are expressed as geometric mean ± CI, with p 
value derived from mixed effects linear regression modelling.  
 2D  Histology p Mean difference as percentage 
of mean absolute value [%] 
Lumen Volume 354 ±110  308 ±95 <0.01 14 
Wall Volume 388 ±140  351 ±127 <0.01 10 
Total Volume 750 ±242  665 ±215 <0.01 12 
     
 
Lumen Area 19.5 ±5.0  16.8 ±4.3 <0.01 15 
Wall Area 21.5 ±6.4  18.9 ±5.9 <0.01 11 
Total Area 41.7 ±11.3  36.6 ±9.9 <0.01 13 
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Figure 7.2 Comparison between 2D clinical CMR sequence and high resolution 
3D CMR sequence for measuring wall volume and lumenal volume in the carotid 
artery. Scatterplots with line of identity (left) and Bland-Altman plots with lines 
indicating mean difference and 95% confidence limits (right). Wall volume (top) 
and lumenal volume (bottom). 
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Figure 7.3 Comparison between 2D clinical CMR sequence and high resolution 
3D CMR sequence for measuring wall area and lumenal area in the carotid 
artery. Scatterplots with line of identity (left) and Bland-Altman plots (right). 
Wall area (top) and lumenal area (bottom). 
Chapter 7 Page 139 PM Carotids 
 
Figure 7.4 Comparison between 2D clinical CMR sequence and histology for 
measuring wall volume and lumenal volume in the carotid artery. Scatterplots 
with line of identity (left) and Bland-Altman plots with lines indicating mean 
difference and 95% confidence limits (right). Wall volume (top) and lumenal 
volume (bottom). 
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Figure 7.5 Comparison between 2D clinical CMR sequence and histology for 
measuring wall area and lumenal area in the carotid artery. Scatterplots with 
line of identity (left) and Bland-Altman plots (right). Wall area (top) and lumenal 
area (bottom). 
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Figure 7.6. Box and whisker plots comparing carotid arterial volume and area 
measurements  by 2D and 3D CMR sequences (left), and 2D CMR and histology 
(right). Lumen, wall and total (adventitial) volume and area measurements are 
shown. The filled boxes represent the inter-quartile range (IQR): the bottom and 
top of the box being the 25th and 75th percentile respectively. The whiskers 
represent the upper and lower adjacent values (lower adjacent value = 25th 
percentile – 1.5 x IQR; upper adjacent value = 75th percentile + 1.5 x IQR). Any  
datapoints outside these ranges are plotted individually. The skewed nature of 
the data can be appreciated. 
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7.4 Discussion 
The purpose of this study was to validate the accuracy of quantitative CMR carotid 
arterial imaging, using a conventional T1-weighted 2D TSE vessel wall clinical 
imaging sequence. The comparators chosen were histology (as this has been 
conventionally regarded as the gold standard) and CMR at very high resolution, using 
a 3D sequence (a sequence that can only be run ex-vivo). The results of the clinical 
2D sequence were good against both comparative standards, with high correlation for 
all parameters measured.  
 
Lumenal volume was equivalent between the 2D and 3D scans, but adventitial (+4%) 
and wall volumes (+7%) were slightly higher by the 2D clinical sequence. The most 
likely reason for this small overestimation is improved tissue discrimination and 
reduced partial volume effects with the high resolution 3D sequence allowing more 
accurate contouring of the adventitial boundary. A previous in vivo study comparing 
clinical 2D and 3D sequences found that the 2D technique measured the lumenal 
volume as 5% greater than with 3D, and this difference was attributed to greater blood 
signal near the vessel wall with 3D. Ex vivo there is no blood signal, and this 
difference has disappeared, supporting this interpretation. In vivo, the adventitial 
volume was 1.7% greater with the 2D technique, and this is in keeping with the 
present study [Keenan 2008c].  
 
The agreement between the 2D CMR sequence and microscopy was also good (R2 
between 0.95 and 0.97), however, the 2D CMR measures were slightly greater 
(between 10% and 15%). Knowing that the 3D agreement with the 2D CMR data is 
superior to this, it seems likely that this larger difference comes from changes to the 
tissue during histological processing. Processing involves many steps: decalcification 
(in EDTA), dehydration (in ethanol), clearing (in xylene), embedding (in paraffin), 
slicing (on a microtome), slide preparation, removal of paraffin (with xylenes, 
alcohols and water) and staining. The degree of shrinkage has been measured for the 
different stages: 1-2% for dehydration, 2-5% for clearing and 5-10% for paraffin 
infiltration [Iwadare 1984]. Taken together, dehydration, clearing and paraffin wax 
embedding typically results in a shrinkage of 13% [Boonstra 1983]. This magnitude 
of change is in keeping with the findings of the current study. It is important to note 
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that although fixing samples in formaldehyde typically results in a shrinkage of 
between 3% and 32% in tissue dimensions, this is not relevant to the current 
comparative study as all specimens were fixed in formaldehyde before any imaging or 
measurements were performed [Reimer 2005, Girerd 1994].  
 
This study provides further validation for the quantitative approach to CMR 
atherosclerosis imaging, by yielding firm comparative data between a clinical CMR 
sequence and gold standard measurements. Such comparisons have been performed 
for ultrasound measurements of intima-media thickness (IMT) in the radial artery, 
although the correlation was poor, with a correlation coefficient (R2) of 0.38, with 
ultrasound measurements being consistently higher than the histological 
measurements, as in the current study [Girerd 1994]. Validation of ultrasound-derived 
variables in pigs has been better, with R2 values of 0.69 to 0.78 [Rodriguez-Macias 
2001]. 
 
In conclusion, quantitative CMR vessel wall volume measurement shows increasing 
promise in atherosclerosis research, and in particular for the assessment of new 
treatments for atherosclerosis. The high degree of inter-study reproducibility means 
that studies of plaque regression may be carried out with smaller sample sizes than by 
ultrasound, and this is appealing for trial design and costs particularly in mechanistic 
studies [Varghese 2005a]. Validating the accuracy of the CMR technique provides 
additional support for this methodology in atherosclerosis research. 
 
Chapter 8 Page 144 Ageing in Normal Subjects 
 
CHAPTER 8 
DETERMINATION OF THE NORMAL SAMPLE RANGE OF CAROTID  
ARTERY WALL VOLUME AND DISTENSIBILITY BY AGE AND SEX   
BY A 2-DIMENSIONAL CMR METHOD 
 
8.1 INTRODUCTION 
Vessel wall imaging yields insights into the atherosclerotic disease process, 
particularly in its early stages, and for this purpose it is preferable to lumenal 
angiography. Arterial wall imaging has commonly been performed by B-mode 
ultrasound and, for non-invasive studies, the carotid artery is usually selected as it is 
large and near the body surface. In post-mortem series, carotid atherosclerosis 
correlates with coronary artery disease [Mathur 1963]. A standardized ultrasound 
measure of the degree of atherosclerosis in the carotid artery is the intima-media 
thickness (C-IMT), which correlates with histology, risk factors for atherosclerosis, 
the presence of atherosclerosis, and the likelihood of future vascular events [Pignoli 
1986, Poli 1988, Craven 1990, O’Leary 1999]. It has been used as a surrogate end-
point in clinical trials in atherosclerosis [De Groot 1998, Smilde 2001]. However, the 
reproducibility of C-IMT is variable, with an inter-scan coefficient of variation 
ranging from 2.6% to 10.2% because of variation in the way images are acquired and 
measured [Stensland-Bugge 1997]. C-IMT is also a one-dimensional measurement, 
usually taken of the posterior carotid artery wall, which may ignore the asymmetry of 
the atherosclerotic process. 
 
Carotid vessel wall imaging by cardiovascular magnetic resonance (CMR) does not 
have these limitations, as it can be performed in any plane with no near field artefacts, 
and constant resolution throughout the imaging plane. A large series of contiguous 
images can be acquired along the length of the artery and combined into a three-
dimensional model, which allows complete interrogation of the volume extent of wall 
thickening. CMR has been validated against histology from patients imaged before 
carotid endarterectomy, it can assess plaque stability, and abnormal appearances have 
been correlated with clinical events. It correlates well with ultrasound C-IMT 
measurements. [Cai 2002, Hatsukami 2000, Yuan 2002, Mani 2006]. Inter-study 
reproducibility is good, with coefficients of variation between 3.5 % and 5.8%, which 
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allows therapeutic studies with CMR endpoints to be performed with significantly 
fewer subjects than by ultrasound [Corti 2001, Saam 2005a, Varghese 2005a, 
Varghese 2005b]. However, CMR is a newer technique than C-IMT, and experience 
of its use is still relatively limited. 
 
Age is the single greatest risk factor for atherosclerosis [Anderson 1991]. The effect 
of modifiable risk factors has been extensively studied, but it is important to 
understand the effect of normal ageing (including age-related atherosclerosis) in order 
to go on to evaluate the relative effects of modifiable risk factors. To our knowledge, 
no CMR study has yet described the changes of normal carotid arterial wall ageing. 
Therefore, the aim of this study was to perform CMR carotid arterial wall imaging in 
healthy subjects free of atherosclerotic risk factors across a wide range of ages in 
order to study the normal arterial ageing process, and to derive age-specific normal 
sample data.  
 
 
8.2 METHODS 
 
8.2.1 Normal subjects 
An advertising campaign was used to attract volunteers with the aim of prospectively 
recruiting 100 healthy volunteers between 20 and 69 years, with 10 per sex per 
decade. Volunteers with a previous history of cardiovascular disease, or a history of a 
major modifiable risk factor for atherosclerosis, or taking any cardiovascular 
medication were excluded, as were volunteers with a contraindication to CMR. Each 
volunteer completed a health questionnaire, and a full physical examination (including 
blood pressure and cardiac auscultation) and electrocardiogram (ECG) were 
performed. Blood was sent for serum glucose and lipid profile. Any volunteers who 
were current or former smokers, diabetic, hypertensive or hyperlipidemic, or who had 
a positive family history of premature vascular disease were excluded, as were 
subjects with an abnormal ECG. Subjects who reported no cardiovascular risk factors, 
but were nonetheless found to have elevated blood pressure, elevated total cholesterol 
to HDL ratio (>5), elevated triglycerides, or elevated random glucose were excluded 
from the study, and referred to their own physician for further management. 
Thresholds for elevated serum glucose or hypertension were taken from standard 
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consensus reports [Expert Committee 2003, Chobanian 2003]. Patients were excluded 
if they had a lipid profile that indicated that they would be at increased risk of 
cardiovascular disease (total cholesterol / HDL >5) in accord with the Framingham 
risk factor model, and with British Guidelines [Joint British Societies 2005]. ECG 
normality was defined using a standard reference, using the Sokolow-Lyon criteria for 
LVH [Mirvis 2005, Sokolow 1949] Each subject’s 10-year percentage coronary risk 
was calculated using the Framingham dataset [Anderson 1991].  
 
8.2.2 CMR 
Carotid CMR was performed using a 1.5T scanner (Siemens Sonata, Erlangen, 
Germany) and a purpose-built bilateral four-channel phased-array carotid surface coil 
(Machnet BV, Eelde, the Netherlands) was used, with a specially designed head and 
neck cushion for immobilization. A contiguous stack of high-resolution T1-weighted 
fast spin echo images was acquired approximately perpendicular to the longitudinal 
axis of both common carotid arteries and centered on the carotid bifurcation 
bilaterally (figure 8.1). Slice thickness was 2mm, and 20 contiguous slices were 
acquired for each side, giving 40mm of longitudinal coverage per artery. The 
coverage of common carotid and internal carotid artery on the left and right sides was 
identical at 20mm above and below the bifurcation; for subjects where the 
bifurcations were not at the same level, the scan was extended to ensure that 20mm of 
longitudinal coverage was obtained above and below the bifurcation on both sides.  
 
Typical sequence parameters for T1-weighted fast spin echo images were: field of 
view (FOV) 110mm read x 65mm phase (up to 30% bigger phase FOV depending on 
patient size), pixel size 0.43mm x 0.43mm, ECG-gated to every cardiac cycle with 
end-diastolic triggering, TE 9.6ms, echo train length 9 with a readout time of 76ms, 
bandwidth 230 Hz/pixel, four averages. Dark blood preparation was used with the 
inversion time (TI) determined by average R-R interval. The scan time per slice was 
68 RR intervals. The scan time to acquire 20 slices was therefore 1360 RR intervals. 
At a heart rate of 60 per minute, this is equivalent to 22.7 minutes, plus any delay that 
might have occurred between slice acquisitions, or because of slice repetitions. In 
addition, a single cine image was acquired perpendicular to the common carotid artery 
on each side to assess distensibility. This was a standard prospectively gated balanced 
steady state free precession (SSFP) sequence, with sequence parameters FOV 105mm 
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x 52mm, flip angle 60, bandwidth 977 Hz/pixel, giving a voxel size of 0.66 x 0.82 x 
6mm, with a scan time of 9 RR intervals.  
 
 
Figure 8.1 Carotid artery imaging. Left:  T1-weighted fast spin echo images 
acquired perpendicular to a normal right carotid artery with a slice thickness of 
2mm, with in-plane resolution of 0.43x 0.43mm. Images 1-3 show the common 
carotid and images 4-6 show the bifurcation into internal carotid artery (straight 
arrows) and adjacent external carotid artery (curved arrows). Right: Computer 
modeled 3-dimensional reconstruction of the carotid artery in a normal subject 
showing the adventitial and lumenal surfaces of the common carotid (CC) and 
internal carotid (IC) arteries (the external carotid (EC) is truncated at its origin). 
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8.2.3 Analysis 
A single experienced investigator, who was blinded to all clinical data, analyzed all 
the MR images using dedicated software (Atheroma Tools, a plug-in of CMRtools, 
Cardiovascular Imaging Solutions, London, UK). The internal and external carotid 
artery surfaces were manually contoured for each slice giving the lumenal area and 
the total vessel area, as previously described (figure 8.1) [Varghese 2006]. Using this 
methodology, the inter-study reproducibility in our institution is known to be 4.5% 
[Varghese 2005a, 2005b]. 
 
In cases where flow suppression was incomplete, there was sufficient separation 
between the flow signal and the vessel wall to allow them to be distinguished, and this 
was facilitated by the 3D semi-automated modeling of the analysis software (figure 
8.2). Using the slice thickness, the software calculated the lumen and wall volume for 
each slice, and summated them to produce a 3D model from which the lumen volume, 
wall volume and total vessel volume were derived for the standardized 40 mm length. 
The total wall volume was also expressed as a percentage of the total vessel volume 
(wall/outer wall or W/OW ratio). The cine image perpendicular to the common 
carotid artery was manually contoured at end diastole and end systole for each side, 
and the percentage distensibility was calculated.  
 
8.2.4 Subjects with coronary artery disease 
In order to determine if this technique differentiated between normal volunteers and 
patients known to have atherosclerosis, 10 patients (all males, 61.4 years, range 50-
69) with triple vessel coronary artery disease awaiting coronary intervention, but with 
no history of cerebrovascular disease and unknown carotid artery status were also 
scanned using the same research protocol. Although these patients were not known to 
have carotid arterial disease, there was a high degree of expectation that disease 
would be found. 
 
8.2.5 Statistics and ethics 
Linear regression analysis was performed to quantify the strength of association 
between the measured variables and age. These data were used to derive normal 
sample reference ranges according to age by regression analysis, with 95% confidence 
intervals and Z-scores. All data are presented as mean values of left and right carotid 
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artery. The study was approved by the institutional review committee, and all subjects 
gave written informed consent.  
 
 
Figure 8.2 A. User interface for software used to quantitatively analyze carotid 
artery images (Atheroma Tools, a plug-in of CMRtools, Cardiovascular Imaging 
Solutions, London, UK). B. Detail of A. demonstrating manual contours on a 
sample image (T1-weighted fast spin echo perpendicular to a normal right 
carotid artery, slice thickness 2mm, in-plane resolution 0.43x 0.43mm). C. 
Computer modeled three-dimensional reconstruction of the carotid artery in a 
normal subject showing the adventitial and lumenal surfaces of the common 
carotid (CC) and internal carotid (IC) arteries (the external carotid (EC) is 
truncated at its origin). 
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Table 8.1. Baseline characteristics of normal subjects studied (mean ± 95% CI). 
 
 20-29 
years 
30-39 
years 
40-49 
years 
50-59 
years 
60-69 
years 
Males 
Height  [m] 1.80 
(1.78, 
1.84) 
1.82 
(1.78, 
1.86) 
1.76 
(1.71, 
1.81) 
1.79 
(1.75, 
1.82) 
1.75 
(1.71, 1.80) 
Weight  [kg] 70.7 
(66.0, 
75.0) 
78.3 
(73.0, 
83.6) 
81.8 
(72.0, 
91.6) 
79.7 
(73.4, 
86.0) 
79.3 
(71.4, 87.2) 
Body surface area  [m2] 1.88 
(1.80, 
1.95) 
1.99 
(1.90, 
2.07) 
1.99 
(1.85, 
2.13) 
1.99 
(1.90, 
2.08) 
1.96 
(1.85, 2.07) 
Systolic blood pressure  
[mmHg] 
121 
(115, 126) 
124 
(119, 130) 
125 
(119, 131) 
125 
(119, 131) 
127 
(121, 132) 
Diastolic blood pressure  
[mmHg] 
73 
(67, 79) 
77 
(72, 82) 
78 
(75, 81) 
81 
(78, 83) 
77 
(72, 81) 
Total cholesterol 
[mmol/L] 
4.8 
(4.4, 5.2) 
4.9 
(4.2, 5.5) 
4.7 
(4.3, 5.1) 
5.5 
(4.9, 6.0) 
5.4 
(5.0, 5.8) 
10 year CAD risk [%] 0.4 
(0.2, 0.6) 
1.4 
(0.9, 1.9) 
3.9 
(3.1, 4.7) 
8.5 
(6.7, 10.2) 
13.0 
(10.8, 15.1) 
Females 
Height  [m]  1.66 
(1.62, 
1.71) 
1.67 
(1.63, 
1.71) 
1.66 
(1.63, 
1.69) 
1.67 
(1.62, 
1.72) 
1.65 
(1.60, 1.69) 
Weight  [kg]  61.4 
(56.8, 
66.0) 
61.3 
(54.3, 
68.3) 
68.9 
(62.6, 
75.2) 
64.6 
(60.5, 
68.7) 
61.0 
(57.1, 64.9) 
Body surface area  [m2] 1.68 
(1.61, 
1.76) 
1.68 
(1.57, 
1.79) 
1.78 
(1.69, 
1.87) 
1.73 
(1.66, 
1.79) 
1.67 
(1.60, 1.74) 
Systolic blood pressure  
[mmHg]  
116 
(109, 124) 
109 
(103, 116) 
115 
(108, 123) 
122 
(116, 128) 
124 
(120, 128) 
Diastolic blood pressure  
[mmHg]  
72 
(68, 76) 
71 
(65, 76) 
75 
(71, 79) 
73 
(70, 76) 
74 
(70, 77) 
Total cholesterol 
[mmol/L] 
4.6 
(4.2, 5.1) 
4.9 
(4.4, 5.3) 
4.7 
(4.3, 5.1) 
5.5 
(5.1, 5.9) 
5.6 
(5.0, 6.2) 
10 year CAD risk [%] 0.0 
(0.0, 0.0) 
0.1 
(0.0, 0.3) 
1.6 
(0.9, 2.4) 
3.0 
(2.1, 3.8) 
4.0 
(3.5, 4.4) 
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8.3 RESULTS 
 
Of 122 volunteers, 22 (16 male and 6 female) were excluded because of cardiac risk factors 
(14), significant carotid artery plaque (6), and claustrophobia (2). The remaining 100 subjects 
were distributed equally with 10 per sex per decade. The demographics are presented in table 
8.1. All CMR datasets were suitable for analysis.  
 
The results for carotid artery lumen volume, carotid artery wall volume, total carotid artery 
volume and W/OW ratio for normal volunteers in each decile are presented in table 8.2, 
averaged for left and right, and divided by sex. Within subjects, the overall degree of 
correlation between left and right carotid arterial parameters was high (lumen volume R2 = 
0.62, wall volume R2 = 0.77, total vessel volume R2 = 0.68, W/OW R2 = 0.58, p < 0.0001 for 
all). In males, vessel wall volume, carotid lumen volume, total vessel volume and W/OW 
ratio were all significantly positively associated with age (table 8.2, figures 8.3 and 8.4).  
 
In females, vessel wall volume, total vessel volume and W/OW ratio were significantly 
associated with age, but lumen volume was not (table 8.2, figures 8.3 and 8.4). Of note, in 
females two phases were identified: the first from the third to the fifth decades, when there 
was an increase in wall volume, lumen volume and total vessel volume; the second between 
the fifth and seventh decades, when wall volume remained constant, with a reduction in 
lumen and total vessel volume. Relationships were generally weaker in females than in males. 
The statistical relationships were not strengthened by indexing the variables for body surface 
area (BSA). Arterial distensibility decreased in males from 25.8% in the third decade, to 
11.1% in the 7th (R2 = 0.30, p<0.01, figure 8.5). Reduced distensibility was significantly 
correlated with increasing wall volume (R2=0.17; p<0.001), total vessel volume R2=0.09; 
p=0.003) and W/OW (wall volume R2 = 0.14; p<0.001). There was also a significant decrease 
in distensibility with age in females, from 19.1% to 13.8% (R2 = 0.10, p<0.01), and the 
reduced distensibility was significantly associated with increased arterial wall volume (R2 = 
0.04; p<0.05). 
 
The ten patients with coronary artery disease (CAD) all had atherosclerotic plaque in the 
carotid arteries. The W/OW ratio was significantly increased compared with sex and age 
matched subjects (44.0% versus 34.0%; p=0.001). The lumen volume was significantly 
smaller in CAD patients. The difference between the patients with CAD and the normal male 
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subjects was assessed by the area under the curve (AUC) method, using Z-scores generated 
from the normal volunteers. There was a high degree of separation between the Z-scores of 
these two patient groups, with an AUC for W/OW ratio of 0.95 (95% CI: 0.90 - 1.00, 
p<0.001); and an AUC for lumen volume of 0.84 (95% CI: 0.70 - 0.98, p<0.001). 
 
 
  
Table 8.2. Carotid artery volumes by age decile showing mean and 95% confidence 
intervals. Correlation coefficient (R2) and p value are given for correlation with age. 
Data are presented as mean of left and right carotid arteries. (W/OW = Wall/Outer Wall 
Ratio). 
 
 20-29 years 30-39 years 40-49 years 50-59 years 60-69 years R2 p  
 
  Males     
Lumen volume   
[mm3] 
1657 
(1532, 1781) 
1660 
(1534, 1786) 
1713 
(1563, 1863) 
1842 
(1680, 2004) 
2011 
(1795, 2228) 
0.14 <0.001 
Wall volume   
[mm3] 
671 
(622, 720) 
760 
(723, 798) 
861 
(790, 932) 
898 
(836, 959) 
1083 
(966, 1200) 
0.43 <0.001 
Total vessel 
volume [mm3] 
2327 
(2160, 2494) 
2420 
(2271, 2570) 
2574 
(2358, 2790) 
2740 
(2549, 2930) 
3094 
(2779,3409) 
0.26 <0.001 
W/OW ratio  
[%] 
29 
(28, 30) 
32 
(30, 33) 
34 
(33, 34) 
33 
(31, 35) 
35 
(33, 37) 
0.25 <0.001 
 
  Females     
Lumen volume  
[mm3] 
1228 
(1144, 1312) 
1348 
(1210, 1486) 
1576 
(1414, 1738) 
1467 
(1371, 1563) 
1369 
(1289, 1448) 
0.03 0.10 
Wall volume  
[mm3] 
531 
(506, 556) 
604 
(558, 651) 
682 
(629, 735) 
692 
(658, 726) 
690 
(656, 724) 
0.26 <0.001 
Total vessel 
volume [mm3] 
1759 
(1653, 1865) 
1952 
(1770, 2135) 
2258 
(2047, 2468) 
2159 
(2038, 2280) 
2059 
(1954, 2164) 
0.07 0.006 
W/OW ratio  
[%] 
30 
(30, 31) 
31 
(30, 32) 
30 
(29, 32) 
32 
(31, 33) 
34 
(33, 35) 
0.21 <0.001 
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Figure 8.3 Graphs of carotid artery wall volume plotted against age with regression line 
and normal sample range (2 standard deviations above and below regression line). Male 
(left), female (right).  
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Figure 8.4 Graphs of carotid wall volume normalized to total vessel volume (W/OW 
ratio) plotted against age with regression line and normal sample range (2 standard 
deviations above and below regression line). Male (left), female (right). 
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Figure 8.5 Graphs of carotid distensibility in male and female normal subjects against 
age (mean of left and right). There is a significant decrease in distensibility with age that 
is more prominent in males, which parallels the increasing wall volume with age 
identified in figure 8.3 (p<0.001). 
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8.4 DISCUSSION 
 
There is little data using CMR to study the normal ageing process in human carotid arteries. 
Our data show that in healthy subjects of both sexes without conventional risk factors for 
atherosclerosis, the carotid artery wall volume and W/OW ratio increase with age. The carotid 
artery wall volume for males increases by 61% from the 3rd decade to the 7th decade, and this 
effect is also present in females (30% increase) but is of lesser magnitude. The carotid wall 
volume increases proportionately more than the lumen volume (male +21%, female +11%), or 
the total vessel volume (male +33%, female +17%). The increase in wall volume with age is 
correlated positively with the increase in lumen volume, and negatively with distensibility. 
Two phases were observed in females. The first (up to the fifth decade) represents outwards 
arterial remodeling, while the second (fifth decade onwards) represents lumenal narrowing. 
This reflects the findings of other studies, such as a large post mortem study of females who 
suffered sudden cardiac death, which found outward arterial remodeling without loss of 
lumenal area in women under 50, and lumenal narrowing in women over 50 [Burke 1998]. 
For some of the statistical relationships the correlation coefficients are relatively small (e.g. 
0.26 for wall volume in females). This indicates that 26% of the observed variation in wall 
volume between individuals can be explained by differences in their age; as is expected other 
factors are involved. These data therefore indicate the relative contribution of ageing to the 
observed variation.  
 
Together, these findings indicate significant changes in arterial morphology and 
haemodynamics with ageing. These changes are likely to represent a combination of ‘normal 
ageing’ and subclinical atherosclerosis, as age itself is the major risk factor for atherosclerosis 
{Anderson 1991]. These data form a useful baseline for further quantitative CMR studies of 
atherosclerosis in the arterial wall, which could incorporate assessments of arterial sclerosis as 
well as the formation of atheromatous plaques. We found W/OW to be a useful measure 
because it allows comparison to be made between carotid CMR scans with different numbers 
of slices, where absolute values become meaningless.  
 
Arterial remodelling with ageing has been previously described by ultrasound in the carotids, 
with arterial wall thickening and reduced compliance [Hansen 1995, Schmidt-Trucksäss 
1999]. The increase in vessel wall thickness is predominantly due to intimal thickening, and it 
is known that the arterial intima thickens with age [Gamble 1993, Homma 2001]. Many 
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processes are involved, such as smooth muscle cell migration from the media [Orlandi 2006].  
Glagov et al. proposed that the artery dilates to accommodate the increase in wall thickness 
[Glagov 1987]. As well as intimal thickening, there is a change with ageing in the elastin and 
collagen fibers of the arterial wall. Elastin fibers decrease in number, with an increase in 
collagen fibers, as well as fracturing of elastic lamellae [Samila 1981]. As elastin fibers are 
more distensible, the artery becomes less compliant and dilates. The dilation has been 
regarded as a physiological mechanism to enable the heart to discharge the stroke volume into 
arterial tree without an excessive rise in afterload, or as a response to many years of cyclic 
stress [Schmidt-Trucksäss 1999]. With arterial dilation, wall shear stress decreases. Reduced 
wall shear stress has been implicated in the etiology of vessel wall thickening, so this may, in 
turn, contribute to intimal thickening [Gnasso 1996]. Although ultrasound is valuable in the 
study of atherosclerosis, CMR has additional benefits of contiguous perpendicular arterial 
imaging allowing robust 3D modeling of the arterial wall with good longitudinal coverage. 
This ensures complete assessment of the vessel wall where atherosclerosis is both 
discontinuous and typically asymmetrical.  
 
In subjects known to have CAD but with unknown carotid status, we found significant 
increases in total vessel wall volume and the W/OW ratio. In the small sample examined, the 
W/OW ratio correctly allocated an individual subject to either ‘normal’ or ‘CAD’ groups with 
95% certainty. However, no general conclusions can be drawn from the abnormal subjects as 
only ten patients were studied. This group was included solely to illustrate the use of this 
methodology and the potential use of the normal sample ranges, and future studies should 
address other abnormal populations in more detail. In a small multicenter study of patients 
known to have carotid plaque, Saam et al. found a mean W/OW ratio of 58%, and that W/OW 
was reproducible with an intraclass correlation coefficient of 0.97 [Saam 2005a]. Therefore, 
W/OW ratio increases in established atherosclerosis, and may be useful as a marker of 
vascular risk. 
  
This study has several potential weaknesses. The applicability of this technique in clinical 
practice is unknown. The normal population studied represents individuals who in general are 
fitter than clinical patients; imaging of clinical patients is more challenging: movement 
artefacts are more common, and the body habitus of overweight patients can make carotid 
imaging difficult. Abnormal subjects were included to illustrate how this methodology can be 
used in clinical practice, but this was a small group comprising only male patients. 
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In conclusion, CMR shows carotid arterial wall volume increases with age, which is 
associated with reduced distensibility. These changes represent a combination of age-related 
changes, and the changes of pre-clinical atherosclerosis. These age-indexed normal sample 
3D data will be useful for further CMR studies focused on the early sclerotic component of 
atherosclerosis. 
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CHAPTER 9  
COMPARISON OF 2D AND MULTI-SLAB 3D MAGNETIC RESONANCE  
TECHNIQUES FOR MEASURING CAROTID WALL VOLUMES 
 
 
9.1 INTRODUCTION 
Cardiovascular magnetic resonance (CMR) is a good technique for assessing 
atherosclerosis in the carotid artery, with much development over the last 15 years in 
plaque characterization and assessment of the structure and function of the arterial 
wall [Hatsukami 2000, Corti 2001, Cai 2002, Yuan 2002, Leeson 2006, Mani 2006]. 
Quantitative carotid wall imaging typically requires a stack of two dimensional (2D) 
images which can be contoured and analyzed. Acquisition protocols vary, but scan 
times of the order of 1 hour are common in order to cover an adequate length of the 
carotid artery with contiguous slices. Long scan times limit the applicability of the 
technique. As scan times increase, patient comfort and acceptability decrease, and 
patient movement increases, leading to image degradation from movement artefact 
[Boussel 2006]. Long scan times also limit the feasibility of using carotid MR in large 
clinical studies. To reduce the scan time, a localized 3 dimensional (3D) fast spin echo 
(FSE) sequence for carotid artery imaging has been developed and validated [Crowe 
2003, Crowe 2005a, Crowe 2005b, Crowe 2006, Varghese 2005a, Varghese 2005b].   
 
In conventional 3D imaging, rather than a single slice, a slab of tissue is excited by 
the radiofrequency (RF) pulse. Spatial encoding is performed in three dimensions by 
using additional phase-encoding in the direction perpendicular to the selected slab, 
along with an additional dimension of Fourier transformation for image reconstruction 
[Botnar 2001]. 3D images have inherently higher signal-to-noise ratio (SNR), so 
fewer cardiac cycles are needed than with 2D in order to produce similar image 
quality at the same voxel size. In theory, the SNR advantage of 3D over 2D is √N 
where N is the number of 3D phase-encode steps in the partition direction. Using 
perpendicular 90 and 180 degree selection gradients, the 3D slab can be defined in 2 
dimensions, leaving the tissue outside unexcited; hence the field of view (FoV) can be 
reduced in the primary phase encode direction without leading to wraparound. The 
reduced FoV enables fewer phase encoding steps to be used to spatially resolve that 
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direction, leading to a reduced imaging time [Crowe 2003, Feinberg 1985, Luk-Pat 
1999]. 
 
Two other 3D techniques for arterial wall imaging are 3D GraSE (Gradient and spin 
echo) [Luk-Pat 1999] and more recently 3D balanced SSFP (steady-state with free 
precession). The SSFP sequence has performed well in terms of contrast to noise 
ratio. It has been used with DIR black blood preparation [Koktzoglou 2007a], and also 
with DEFT (driven equilibrium Fourier transform) diffusion preparation [Koktzoglou 
2007b]. It has been modified to include a swallowing navigator [Koktzoglou 2007c]. 
These papers have reported large reductions in scan time for 3D compared with 2D 
(88% [Koktzoglou 2007a] and 89% [Koktzoglou 2007b]). However, if comparable 
methods of ECG gating had been used, the time saving would have been 
approximately 66%. In addition, the variability between 2D and 3D has been reported 
as the difference between 3D and the mean of 2D and 3D, expressed as a percentage 
of the mean. The more usual method of expressing the difference between 3D and 2D 
as a percentage of the mean, indicates that 3D lumen area was on average 15.2% less 
than by 2D, and wall area was 9.4% less. 
 
As well as 3D techniques, 2D techniques with multi-slice readout have been 
developed. Reading out several slices simultaneously increases coverage and so 
reduces scan time. TI can be a challenge as it varies for each slice, but this can be 
overcome with interleaving [Song 2002, Parker 2002]. By most methods the number 
of slices that can be simultaneously acquired is limited to 4 by specific absorption rate 
(SAR) limits, saturation effects and blood flow artefact [Yarnykh 2003, Itskovich 
2004]. A more recent method called REX-DIR (rapid extended coverage-DIR), has 
been developed which can acquire up to 10 slices; this uses a rapid acquisition with 
relaxation enhancement pulse sequence (RARE) [Mani 2004]. 
 
The purpose of this study was to compare a multi-slab 3D volume selective fast spin 
echo cardiovascular MR sequence with a routine 2D FSE sequence for quantification 
of carotid wall volume. 
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9.2 METHODS 
9.2.1 Subjects 
An advertising campaign was used to attract volunteers with the aim of recruiting 100 
healthy volunteers between 20 and 70 years, with 10 per sex per decade. 122 
applicants were screened to identify the 100 normal subjects who did not have a 
history of cardiovascular disease, and who were free of cardiac risk factors on a 
questionnaire, physical examination, electrocardiogram (ECG), and on blood tests for 
serum glucose and lipid profile. No volunteers had a contraindication to MR. Any 
volunteers who were diabetic, hypertensive or hyperlipidemic were excluded. The 
study was approved by the institutional review board, and all subjects gave written 
informed consent after the nature of the study had been fully explained. 
 
9.2.2 Image Acquisition 
Carotid artery imaging was performed on each volunteer using 2D and 3D techniques 
sequentially in a single scanning session. A 1.5T scanner (Siemens Sonata, Erlangen, 
Germany) and a purpose-built bilateral four channel phased-array carotid surface coil 
(Machnet BV, Eelde, the Netherlands) were used, with a specially designed head and 
neck cushion for immobilization. The 2D imaging protocol was performed first. For 
this, a contiguous stack of high-resolution T1-weighted fast spin echo images was 
acquired approximately perpendicular to the paths of both the carotid arteries over 
40mm and centered on the carotid bifurcation bilaterally. Slice thickness was 2mm, 
and 20 contiguous slices were acquired for each side, giving 40mm of longitudinal 
coverage per artery. Typical sequence parameters for T1-weighted fast spin echo 
images were: field of view (FoV) 110mm read x 65mm phase (up to 30% bigger 
phase FOV depending on subject size), imaging matrix 256 read x 152 phase (up to 
198) (giving pixel size 0.43mm x 0.43mm, interpolated to 0.21mm x 0.21mm during 
reconstruction), ECG-gated to every cardiac cycle with end-diastolic triggering, TE 
9.6ms, echo train length 9 with a readout time of 76ms, bandwidth 230 Hz/pixel, 4 
averages. The 2D technique was zonal in that saturation pulses were used to suppress 
signal from the selected slice anterior and posterior to the FoV to prevent wraparound; 
however, the lower SNR of the narrowed phase encode FOV required 4 averages, in 
comparison to the 2 averages more typically required for 2D carotid imaging at 1.5T, 
and the scan time per 2D slice was approximately the same as a full-FOV 2D slice 
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would have been.  Dark blood preparation was used with the inversion time (TI) 
determined by average RR interval [Fleckenstein 1991]. The scan time per slice was 
68 RR intervals. The scan time to acquire 20 slices was therefore 1360 RR intervals. 
At a heart rate of 60 per minute, this is equivalent to 22.7 minutes, plus any delay that 
might have occurred between slice acquisitions, or because of slice repetitions.  
 
For the 3D imaging protocol, a previously described method was used for the 3D 
acquisition [Crowe 2003]. The protocol was modified to reduce the length of 
individual scans, so 3 contiguous 3D slabs were acquired; the 3 slabs were used to 
reduce movement artefact which can be a problem with longer scans [Boussel 2006]. 
The slab thickness was 16mm encompassing 8 slices and a further 50% slice 
oversampling was used to prevent wraparound in the z axis. Typical sequence 
parameters were: FoV 110mm read x 65mm phase, imaging matrix 256 x 152 (giving 
true pixel size of 0.43mm x 0.43mm, interpolated to 0.21mm x 0.21mm during 
reconstruction), ECG-gated to every cardiac cycle with end-diastolic triggering, TE 
13ms, echo train length 9, readout time 113ms, bandwidth 150 Hz/pixel,  
1 average. The 3D slab was resolved into 2mm thick slices to give voxel size identical 
to the 2D technique. Black blood double inversion recovery (DIR) was used with an 
inversion time set at 537ms for all heart rates. The scan time per slab was 203 RR 
intervals. The scan time to acquire 3 slabs (24 slices) was therefore 609 RR intervals. 
At a heart rate of 60 per minute, this was equivalent to 10.2 minutes. There was no 
delay between slab acquisitions and, in particular, no 3D scans were repeated for 
movement artefact. 
 
9.2.3 Image Analysis 
From both the 2D and 3D stacks of images, datasets of 20 contiguous slices were 
obtained for each carotid artery, centred on the bifurcation. Window and level setting 
were identical for all datasets. All 2D and 3D datasets were reviewed by a single 
observer with 3 years of carotid MR experience. The observer was blinded to subject 
details and the images were analyzed in a random order, using the same methodology 
for both. Dedicated software was used, as previously described (Atheroma Tools, a 
plug-in of CMRtools, Cardiovascular Imaging Solutions, London, UK) [Varghese 
2006]. Briefly, the internal and external carotid artery surfaces were contoured 
manually for each image. The software then derived the lumenal area and the total 
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vessel area for each slice, and summated the data from the 20 slices to produce a 3D 
model of the carotid bifurcation for both techniques. From these models, lumen 
volume, wall volume and total vessel volume were derived for the imaged volume 
(40mm of longitudinal coverage). The total wall volume was also expressed as a 
percentage of the total vessel volume (wall/outer wall or W/OW ratio) as previously 
described [Saam 2005a]. 
 
For the first 30 subjects, signal-to-noise ratio (SNR) was determined by tracing the 
lumenal and adventitial borders of a matched representative slice of the right common 
carotid artery for both 2D and 3D acquisitions. The mean signal was measured, and 
this was divided by the mean signal for a standardized region of air in the same slice.  
 
9.2.4 Statistics 
The values derived for each variable by 2D and 3D techniques were plotted against 
each other, and the line of identity was plotted to characterize any systematic bias. 
Bland-Altman plots were performed to look for strength of association and for 
systematic bias. Linear regression was also performed to derive the R2 correlation 
coefficient. As there were two measurements from each subject (left and right 
arteries), in order to avoid confounding in the regression analysis, this was performed 
with a mean of left and right values for each parameter on each subject. In addition, a 
t-test was performed to look for any significant difference between 2D and 3D 
measurements. The mean difference between 2D and 3D values for each variable was 
expressed as a percentage of the mean absolute value of the variable, indicating the 
true magnitude of the difference between the two measurements. The difference in 
SNR between 2D and 3D was determined, and a t-test was performed to assess the 
significance of this difference.  P <0.05 was considered statistically significant. 
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9.3 RESULTS 
 
Of 122 volunteers, 22 (16 male and 6 female) were excluded. The reasons for 
exclusion were as follows: 14 were found to have cardiac risk factors, 6 had 
significant carotid artery plaque, and 2 were unable to tolerate the scan due to 
claustrophobia. The remaining 100 subjects were spread equally with 10 per gender 
per decade. Full datasets were obtained on all 100 subjects, and 100% of datasets 
were suitable for analysis, providing data on 200 carotid arteries. Sample 2D and 3D 
images are shown in figure 9.1. Data acquired using the 2D and 3D techniques for 
lumen volume, wall volume, total vessel volume and wall/outer wall (W/OW) ratio 
are presented in table 9.1, along with results of the linear regression analysis, while 
the differences between 2D and 3D are presented in table 9.2. The data are shown 
graphically in figures 9.2 and 9.3.  
 
The 3D technique measured both the total vessel volume and lumen volume as 
smaller than by 2D, and the wall volume and W/OW ratio as larger.  There was good 
correlation between the 2D and 3D models for total vessel volume, lumen area, and 
wall volume, but the correlation for the W/OW ratio was weaker. Using the t-test, 
there were statistically significant differences between the values for each variable by 
2D and 3D (P<0.05). 
 
SNR was determined by 2D and 3D for the first 30 subjects. The mean SNR for 2D 
was 4.5, compared with 9.1 for 3D, an improvement of 2.1-fold. A t-test was 
performed showing that this difference was significant (P<0.001). 
 
The scan time needed to acquire 20 slices by the 2D technique was 1360 RR intervals. 
By comparison, the scan time to acquire 24 slices in 3 slabs by the 3D technique was 
609 RR intervals, which is a 55% reduction in scan time. If 24 slices were to be 
acquired by both techniques, there would have been a 63% reduction in scan time 
with the 3D technique. 
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Figure 9.1 Matched transverse T1-weighted FSE images of the carotid arterial 
wall. The top image was acquired with the 2D technique, the bottom image with 
the 3D technique. The left and right carotid arteries are imaged simultaneously. 
RJV = right jugular vein, RCA = right (common) carotid artery, LCA = left 
(common) carotid artery, LJV = left jugular vein.  
 
 
 
 
 
Chapter 9 Page 166 2D v 3D Sequence Comparison 
 
Table 9.1. Carotid artery parameters as measured by 2D and 3D MR techniques 
for a 20 slice model of the carotid bifurcation, expressed as average of left and 
right arteries (mean and 95% confidence intervals)  
 
 2D 3D R2 p Slope* Intercept  
Total Vessel Volume 
[mm3] 
2325 
(2221, 2428) 
2286 
(2184, 2387) 
0.93 <0.001 0.94 90 
Lumen Volume 
[mm3] 
1581 
(1511, 1652) 
1506 
(1443, 1569) 
0.92 <0.001 0.86 146 
Wall Volume [mm3] 744 
(706, 781) 
780 
(738, 822) 
0.77 <0.001 0.98 54 
W/OW Ratio [%] 32.0 
(31.4, 32.6) 
33.9 
(33.3, 34.5) 
0.30 <0.001 0.57 15.7 
W/OW Ratio = Wall / Outer Wall Ratio 
* 2D = independent variable, 3D = dependent variable 
 
 
Table 9.2. Mean difference, mean absolute value, and mean difference expressed 
as percentage of mean absolute value, for carotid artery variables by 2D and 3D 
MR techniques. 
 
 Mean 
Difference (3D-
2D) 
Mean 
Absolute 
Value 
Mean Difference as Percentage 
of Mean Absolute Value (3D v 
2D) [%] 
Total Vessel 
Volume [mm3] 
-39 2305 -1.7 
Lumen 
Volume [mm3] 
-75 1544 -4.9 
Wall Volume 
[mm3] 
+36 762 +4.7 
W/OW Ratio 
[%] 
+1.9 32.9 +5.8 
W/OW Ratio = Wall / Outer Wall Ratio 
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Figure 9.2 Scattergram showing values as measured by 2D and 3D techniques 
plotted with a line of identity for comparison for: vessel volume (top left), lumen 
volume (top right), wall volume (bottom left) and W/OW (bottom right).  
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Figure 9.3 Bland-Altman plots with lines indicating mean difference, 95% 
confidence intervals of mean difference, and 95% limits of agreement (LoA) for: 
vessel volume (top left), lumen volume (top right), wall volume (bottom left) and 
W/OW (bottom right). 
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9.4 DISCUSSION 
 
9.4.1 Main Findings 
The main finding of this study is that multi-slab volume selective 3D carotid wall FSE 
MR yields similar results to a conventional 2D technique for quantitative carotid wall 
parameters, with small parameter differences ranging from 1.7% to 5.8%, but with a 
significant reduction in scan time and improvement in SNR. The values for total 
vessel volume were very similar, whereas the 3D technique yielded values for lumen 
volume that were 4.9% less, and wall volume that were 4.7% greater than those from 
the 2D technique. These discrepancies may result from a greater degree of slow-
moving blood flow artefact in 3D images being contoured as vessel wall, and were 
probably noticeable only due to the large sample size. The resolution of both 
techniques is identical, so the difference cannot be attributed to different degrees of 
partial volume averaging. The comparison between the techniques is less good for the 
variable W/OW ratio, which is derived by dividing wall volume by total volume, 
thereby magnifying measurement error. This suggests that the carotid wall volume 
might be a more reliable parameter of atherosclerosis burden when comparing across 
MR techniques. However, in a follow-up study using the 2D technique only, Mani et 
al found better reproducibility for W/OW than for wall volume, and W/OW has other 
advantages in clinical studies, such as the ability to meaningfully compare scans with 
differing numbers of slices [Saam 2005a].  
The 3D technique described in this paper was 55% faster than the conventional 2D 
technique but 24 slices of data were acquired as opposed to 20 slices by the 2D 
technique. Therefore, when comparing acquisition time per slice, the potential time 
saving was 63%. As well as reducing scan time, the intrinsically higher SNR of 3D 
imaging can be used to increase resolution. Despite the time saving, the SNR of our 
3D sequence was over twice that of the 2D sequence. Extra resolution in the slice 
select direction would improve the power of the technique to identify small plaque 
components. In general, the benefits of reduced scan time and improved resolution 
need to be weighed against the consequent reduction in SNR, and the final protocol 
will depend on the desired clinical application. 3D carotid wall imaging also has good 
reproducibility, although this has not yet been reproduced in patients with carotid 
atherosclerosis [Varghese 2005b, Chu 2006]. Finally, 3D data have the advantage that 
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Figure 9.4 Matched transverse T1-weighted FSE images of the carotid arterial 
wall. The top image was acquired with the 2D technique, the bottom image with 
the 3D technique. A higher degree of blood pool artefact is clearly visible with 
the 3D technique. RJV = right jugular vein, RICA = right internal carotid artery, 
RECA = right external carotid artery, LICA = left internal carotid artery, LECA 
= left external carotid artery, LJV = left jugular vein. 
any slice orientation can be retrospectively displayed by selecting appropriate 3D 
voxels from it, and this can be most helpful if, for example, the carotid arteries are not 
parallel.  
Offsetting these advantages, however, are some limitations of 3D carotid MR, 
including incomplete blood signal suppression (figure 9.4), and a longer scan time for 
any single acquisition (one slab by 3D vs. one slice by 2D), which introduces some 
potential for increased movement artefact through, for example, swallowing. For all 
our patients, the 3D images were performed second, and we conjecture that they 
might therefore show a greater degree of such artefacts as the subjects were more tired 
by this point. Nevertheless, the 3D sequence performed well. Blood signal is 
suppressed by double inversion recovery (DIR). Using this technique, a theoretical 
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maximum slab thickness of 5cm has been suggested, [Koktzoglou 2007a], although 
slow recirculating blood in the carotid bulb may still be problematic [Steinman 2002]. 
Some additional techniques may prove useful to mitigate these limitations. Flow-
sensitive phase images can be used to identify blood signal, and tongue navigators can 
be used to reduce swallowing artefact. Also, computer-assisted modelling software 
can help in contouring images where there is considerable blood signal [Crowe 2006; 
Crowe 2005b; Koktzoglou 2007b]. 
 
The 2D and 3D imaging techniques lend themselves to different imaging applications. 
The 2D technique is ideal for imaging a single plaque, where only a few slices are 
required which may be repeated with differing contrast weightings. The 3D technique 
is ideal for volumetric assessment of a much larger region of the carotid bifurcation. 
With the reduction in imaging time, larger scale studies are now feasible. Future 
applications may include population-based surveys looking at factors such as ageing, 
as well as therapeutic trials.  
9.4.2 Study Limitations 
The primary limitation of this study is that it was performed only in normal subjects 
and not in patients with carotid atherosclerosis. In general, patients tolerate longer 
total scan times less well than healthy volunteers, and therefore the faster 3D 
technique might be expected to perform better than the 2D technique in a clinical 
setting. However, the 3D technique relies on the subject remaining still during each 
sequence acquisition, and, as the individual acquisition time is typically longer for a 
3D scan and patients are typically less able to remain still than volunteers, this may 
reduce this potential benefit of the 3D technique in a clinical setting, especially as 
scans may need to be repeated. Further work will address this question. An additional 
limitation is that only one viewer was used to analyse all datasets so that no data was 
available on interobserver variability with this technique. However, previous work has 
shown the interstudy variability to be of the order of 4.5% [Varghese 2005a, Varghese 
2005b]. 
 
In conclusion, multi-slab volume selective 3D FSE carotid arterial wall MR 
performed similarly to a conventional 2D FSE technique for measuring carotid wall 
volume, but with substantially reduced scan time. 
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CHAPTER 10 
INTEGRATED CARDIAC AND VASCULAR ASSESSMENT IN  
TAKAYASU’S ARTERITIS BY CARDIOVASCULAR MAGNETIC RESONANCE  
 
10.1 INTRODUCTION 
Takayasu’s arteritis (TA) is an idiopathic chronic inflammatory disease of unknown 
aetiology, resulting in a granulomatous pan-arteritis of the aorta and its major 
branches. It is characterized by adventitial thickening, cellular infiltration of the tunica 
media and intimal hyperplasia leading to marked vessel wall thickening, while 
subsequent fibrosis of the tunica media and intima may lead to arterial stenosis and, 
on occasion, thrombosis or aneurysm formation [Ishikawa 1988, Kerr 1994a, Kerr 
1994b]. 
 
Despite predominantly affecting young women, TA is associated with a significantly 
increased risk and higher prevalence of atherosclerosis [Numano 2000, Seyahi 2006]. 
Chronic inflammation leads to persistent vascular injury, and TA is an independent 
risk factor for atherogenesis. Cardiovascular complications, including cardiac failure, 
cerebrovascular accident, myocardial infarction and ruptured aortic aneurysm, are the 
major causes of morbidity and mortality [Subramanyan 1989, Mwipatayi 2005]. 
 
Vascular imaging is essential for diagnosis and follow-up of patients with TA. 
Historically this has been performed invasively, but, although intra-arterial 
angiography is still considered the ‘gold standard’ for diagnosis, non-invasive 
imaging is now preferred by many centers [Arend 1990, Andrews 2004, Andrews 
2007]. Current clinical practice utilizes serial magnetic resonance angiography (MRA) 
or computed tomography (CT) angiography and 18Fluorodeoxyglucose positron 
emission tomography (PET) for clinical follow-up. PET provides information about 
the degree of vascular inflammation, and may be used to guide immunosuppression 
[Webb 2004]. However, both MRA and CT are predominantly used to image the 
arterial lumen, while low spatial resolution means that PET is unable to provide  
detailed information about vessel wall thickening. In addition, the cumulative 
radiation dose associated with follow-up with PET, CT and invasive angiography can 
be considerable [Kissin 2004]. 
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Cardiovascular MR (CMR) has a number of advantages as a single technique for a 
multifaceted cardiovascular assessment. Arterial wall imaging can be performed 
without the access limitations of ultrasound, and in the carotid artery, quantitative 
vessel wall analysis by CMR has excellent reproducibility, reducing sample sizes in 
clinical trials [Corti 2001, Saam 2005a, Varghese 2005b, Keenan 2008b]. By going 
beyond lumenography, more detailed information is available about the pathological 
process at a tissue level, as narrowing of the lumen is a relatively late phenomenon in 
atherosclerosis [Glagov 1987]. Cardiac morphology and function can be derived more 
accurately and more reproducibly than by other techniques [Grothues 2002, Keenan 
2007]. CMR is the preferred modality for myocardial tissue characterization, 
identifying regions of myocardial infarction and fibrosis using gadolinium-based 
contrast agents [Kim 1999, McCrohon 2003]. Endothelial function can also be 
determined by measuring the response of the brachial artery to ischemia-mediated 
hyperemia (flow-mediated dilatation - FMD) [Sorensen 2002, Tanner 2007]. These 
approaches have not been performed in TA before. We hypothesized that patients 
with TA may have myocardial and endothelial abnormalities, and evaluated this in a 
study of an integrated cardiac and vascular assessment at a single MR sitting. 
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10.2 METHODS 
10.2.1 Patients 
Sixteen subjects with TA were prospectively recruited from our rheumatology clinics. 
All subjects were female and fulfilled American College of Rheumatology diagnostic 
criteria [Arend 1990]. All completed a health questionnaire assessing disease severity, 
length of diagnosis, treatment, comorbidities and cardiovascular risk factors. In 
addition, a database of clinical information was reviewed to assess disease activity. 
TA was considered active if the patient fulfilled criteria as defined by Kerr et al [Kerr 
1994a], with active disease defined as new onset or worsening of two or more of: 1) 
fever or arthralgia, 2) raised ESR (> 20 mm/hr), 3) new claudication, bruit or vascular 
pain, 4) new typical angiographic features. Physical examination and 
electrocardiograph (ECG) were performed. CMR was performed in three parts: 
carotid artery, brachial artery reactivity, and cardiac study with gadolinium. Using 
advertising campaigns, two populations of age-matched normal female volunteers 
were prospectively recruited. Both populations were screened with a questionnaire, 
physical examination, blood tests and ECG, and volunteers with cardiac risk factors, 
or who were found to be hypertensive, diabetic or hypercholesterolemic, or who had 
an abnormal ECG were excluded from the study. Fifty normal volunteers underwent 
CMR carotid artery vessel wall imaging, and 60 normal volunteers with, in addition, a 
normal serum B-type natriuretic peptide (BNP), underwent CMR cardiac study 
(without gadolinium).  
 
10.2.2 CMR Protocol  
Imaging was performed on a 1.5 Tesla scanner (Siemens Sonata, Erlangen, Germany). 
For carotid imaging, a purpose-built bilateral four-channel phased-array carotid 
surface coil (Machnet BV, Eelde, the Netherlands) and a specially-designed head and 
neck cushion were used. Using a standard 2 dimensional (2D) fast spin echo (FSE) 
CMR sequence, a contiguous stack of high-resolution T1-weighted FSE images was 
acquired perpendicular to the carotid artery, centered on the carotid bifurcation 
bilaterally. Slice thickness was 2mm, and 20 contiguous slices were acquired for each 
side, giving 40mm of longitudinal coverage per artery. Typical sequence parameters 
were: field of view (FOV) 110mm read x 65mm phase (up to 30% bigger phase FOV 
depending on patient size), pixel size 0.43mm x 0.43mm (interpolated to 0.21mm x 
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0.21mm during reconstruction), ECG-gated to every cardiac cycle with end-diastolic 
triggering, TE 9.6ms, echo train length 9 with a readout time of 76ms, band width 230 
Hz/pixel, 4 averages. Dark blood preparation was used with the inversion time (TI) 
determined by average R-R interval.  
 
Image analysis was performed using Atheroma Tools (a plug-in of CMRtools, 
Cardiovascular Imaging Solutions, London, UK) [Varghese 2006]. The internal and 
external carotid artery surfaces were contoured for each slice giving the lumenal area 
and the total vessel area. Data from the 20 slices were then used to produce a 3D 
model from which the lumen volume, wall volume and total vessel volume were 
derived for the standardized 40 mm length. The total wall volume was also expressed 
as a percentage of the total vessel volume (wall/outer wall or W/OW ratio) [Saam 
2005a]. For each patient, data were expressed as a mean of left and right carotid 
arteries. In addition, a visual assessment was made of the presence or absence of 
atherosclerotic plaque, and of the diffuse generalized vessel wall thickening 
characteristic of TA [Meini 2006]. 
 
A previously validated CMR protocol for endothelial function was used [Sorensen 
2002, Wiesmann 2004]. In brief, a 2cm small loop surface coil was placed over the 
brachial artery. The right brachial was used unless the artery was known to be 
proximally occluded, in which case the left was used. The artery was occluded distal 
to the coil for 5 minutes by inflating a blood pressure cuff on the forearm to 20 mmHg 
above systolic pressure. On release of the cuff, the artery was scanned immediately 
and at 1-minute intervals up to 5 minutes after cuff deflation. A segmented FLASH 
gradient echo sequence was used with the following imaging parameters: 8 views per 
segment, TE 14 ms, field of view 7x3.5 cm, matrix size 256x128, pixel size 0.27x0.27 
mm, with diastolic trigger delay; acquisition time was 12 cardiac cycles. The cross-
sectional area of the artery was calculated at baseline and at maximal dilatation, and 
the resulting FMD was expressed as the percentage change in area. For assessment of 
endothelium-independent dilatation, the percent change in brachial artery area was 
measured before and after sublingual administration of 400µg glyceryl trinitrate. 
 
A standard CMR protocol was used for the cardiac study, and volumetric 
measurements were made as previously described [Maceira 2006]. Briefly, using front 
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and back surface coils and retrospective ECG triggering, steady-state with free 
precession (SSFP) end-expiratory breath-hold cines were acquired in the vertical and 
horizontal long axis planes, with subsequent contiguous short-axis cines from the 
atrioventricular (AV) ring to the apex. Imaging parameters were: repetition time 
3.2ms, TE 1.6 ms, flip angle 60º, slice thickness 7mm. Acquisition time was 18 
cardiac cycles, in-plane pixel size was 2.1 x 1.3mm and temporal resolution was 21.6 
±1ms. Left ventricular volumes and function were measured using standard 
techniques [Grothues 2002, Keenan 2007], and analyzed using LVtools (a plug-in of 
CMRtools, Cardiovascular Imaging Solutions, London, UK). Volumes and mass were 
indexed to body surface area (BSA) [Maceira 2006]. Cine images were reviewed for 
evidence of valvular heart disease. Late gadolinium enhancement (LGE) images were 
acquired 10 minutes after intravenous gadolinium-DTPA (Schering; 0.1 mmol/kg) in 
identical short-axis planes using an inversion-recovery gradient echo sequence. 
Inversion times were adjusted to null normal myocardium (typically 320 to 440 ms; 
pixel size 1.7 x 1.4mm). Additional LGE images were acquired with phase swapping 
to exclude artefact. Two experienced readers, who were blinded to all clinical data, 
reviewed the LGE studies, assessing studies for the presence or absence of LGE, and, 
if present, for the pattern [Kim 1999]. Where there was disagreement, a third 
independent observer decided. 
 
10.2.3 Statistics and Ethics 
Descriptive statistics were performed on baseline population data, and populations 
were compared. A t-test was performed to compare data between patient groups.  For 
carotid artery parameters, age-adjusted Z scores and 95% reference ranges were 
derived for the normal population (as previously described [Keenan 2008e]), and 
these were used to assess the TA population. Z scores are a standard statistical method 
of characterizing a normally-distributed population, where a Z score of +1 indicates 1 
standard deviation greater than the value predicted for a given age, and a Z score of 0 
indicates the observed value is equal to what would be expected for a patient’s age. A 
multivariate regression analysis was performed to assess the relative contribution of 
vascular risk factors in the TA population. A t test was used to assess data for 
endothelial function, and left ventricular volume, function and mass. For LGE, 
descriptive statistics only were derived. All subjects gave written informed consent, 
and approval was obtained from the hospital research ethics committee. 
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10.3 RESULTS 
 
10.3.1 Patients 
Baseline clinical data for patients with TA (n=16) and both groups of normal subjects 
(n=50 for carotid artery study and n=60 for LV study) are shown in table 10.1. 
Patients with TA were significantly shorter and heavier than normal volunteers, with 
higher systolic and diastolic blood pressure, reflecting at least in part corticosteroid 
use. Six of the 16 TA patients had active disease. Two patients had previously had 
cardiac surgery, in one case coronary artery bypass grafting and in the other an aortic 
valve replacement. In one TA patient with bilateral subclavian artery occlusions, 
endothelial function and LGE were not assessed; the remaining patients completed the 
full protocol. 
 
10.3.2 Carotid Arteries 
The carotid arteries were considerably thickened in patients with TA (figure 10.1, 
table 10.2). Carotid artery wall volume was 63% higher than in normal controls. The 
mean W/OW ratio (index of vascular thickening) was 48%, compared with a normal 
value of 32%. For all patients with TA, the W/OW ratio was outside the normal range 
as determined from the reference population (figure 10.2) 
 
On a univariate regression analysis, a diagnosis of TA was positively associated with 
wall volume, and W/OW ratio, and negatively associated with lumen volume. A 
multivariate regression analysis was performed to assess the confounding effects of 
hypertension, diabetes, smoking, corticosteroid therapy and statins on these results. 
None of the patients included in the study were taking non-steroidal anti-
inflammatory drugs or cyclo-oxygenase 2 antagonists. In the multivariate analysis, 
wall volume and W/OW ratio remained significantly associated with TA status, 
confirming that TA was an independent predictor of vessel wall thickening (table 
10.3). Also in the multivariate analysis, statin therapy was independently positively 
associated with W/OW ratio (coefficient 3.85, p=0.05), and hypertension was 
independently associated with lumen volume and total vessel volume (lumen volume: 
coefficient =1.13, p=0.05; total vessel volume: coefficient =1.08, p=0.05). 
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Table 10.1 Baseline characteristics of subjects studied (mean ± SD, N (%)). 
Parameter TA Normals 
(Carotids) 
Normals  
(LV) 
N 16 50 60 
Age 49 ± 14 44 ± 14 49 ± 16 
Height [m]  1.60 ± 0.07 *† 1.66 ± 0.07 1.65 ± 0.07 
Weight [kg] 70 ± 15 * 63 ± 9 65 ± 12 
BSA [m2] 1.75 ± 0.19 † 1.71 ± 0.14 1.71 ± 0.14 
SBP 134 ± 18 *† 117 ± 11 122 ± 15 
DBP 79 ± 7 *† 73 ± 7 72 ± 8  
    
Years of Diagnosis 7 ± 5 N/A N/A 
Occlusive large vessel disease (%) 7 (44)   
Cerebrovascular disease (%) 1 (6)   
Coronary artery disease (%) 3 (19)   
Hypertension (%) 9 (56)   
Diabetes mellitus (%) 2 (13)   
Hyperlipidaemia (%) 6 (38)   
Current smoking (%) 1 (6)   
    
Active disease (%)‡ 6 (38)   
ESR [mm/h] 34.0 ± 26.2   
CRP [mg/L] 18.2 ± 17.5   
    
Current Therapy    
Corticosteroids (%) 13 (81)   
Azathioprine (%) 2 (13)   
Methotrexate (%) 9 (56)   
Infliximab (%) 1 (6)   
Statin (%) 9 (56)   
Antihypertensive agents (%) 10 (63)   
 
* p <0.05 vs normals (carotids);  † p <0.05 vs normals (LV); ‡ Active disease as 
described by [Kerr 1994a] 
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Figure 10.1 T1-weighted transaxial CMR images of bilateral common carotid 
arteries (arrows) in (A) a normal volunteer, (B and C) two patients with TA. (A) 
The normal subject’s arterial wall is thin and smooth. (B) moderate 
circumferential thickening is present bilaterally. The lumenal surface is of high 
signal, surrounded by a thick rim of low signal (arrows). (C) Severe 
circumferential thickening is present, particularly on the left, causing a tight 
lumenal stenosis. 
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Table 10.2 Carotid artery parameters in TA patients and normal subjects (mean 
left and right) for a 20 slice model of the carotid bifurcation (Mean +/- CI). 
Parameter TA  
(N=16) 
Normals 
(N=50) 
p 
 
Lumen volume [mm3] 1224 
(1055, 1393) 
1398 
(1326, 1469) 
0.04 
Wall volume [mm3] 1045 
(929, 1161) 
640 
(618, 661) 
<0.001 
Total vessel volume [mm3] 2268 
(2061, 2476) 
2037 
(1941, 2134) 
0.03 
W/OW ratio [%] 48 
(42, 54) 
32 
(31, 32) 
<0.001 
 
Figure 10.2 Left: Carotid artery wall volume (top) and wall / outer wall (W/OW) 
ratio (bottom) in TA by age for mean of left and right carotid arteries. The lines 
indicate the mean and upper and lower 95% confidence intervals for the sex-
matched normal population. Right: Box plot of the same data as on left. The y 
axis indicates the age and sex-matched Z score derived from the normal 
population, so that a Z score of +2 indicates 2 standard deviations above the 
value expected for a normal age and sex-matched individual. Note that the 
W/OW values for all TA patients were abnormal. 
Chapter 10 Page 181 Takayasu’s Arteritis 
 
Table 10.3. Multivariate regression analysis of carotid arterial wall parameters 
comparing TA population with normal controls. 
Variable Coefficient p  Adjusted 
Coefficient* 
p  
Lumen Volume -0.74 0.02  -1.34 0.12 
Wall Volume 4.56 <0.01  3.66 <0.01 
Total Volume 0.58 0.06  -0.10 0.9 
W/OW 8.79 <0.01  6.93 0.01 
* after controlling for hypertension, diabetes, smoking, steroid usage and statin usage. 
 
On visual assessment (figure 10.1), 15 (47%) of common carotid arteries (in 10 [67%] 
patients) had gross circumferential thickening typical of Takayasu’s arteritis. In 5 
patients this was bilateral, and in 5 it affected the left side only. No patient had only 
right-sided circumferential thickening. Ten (67%) common carotid arteries (in 7 
[44%] patients) contained atherosclerotic plaque. This was bilateral in 3 patients. Four 
arteries contained both TA-type circumferential thickening, and atherosclerotic 
plaque. 
 
10.3.3 Endothelial Function 
Endothelial function was significantly impaired. Mean flow-mediated dilatation was 
6.3% for patients with TA (95% CI 2.4% to 10.2%), compared with 15.5% (95% CI 
11.6 to 19.4) in historical controls (p=0.004) [Weismann]. Endothelium independent 
vasodilation as assessed by mean percentage increase in brachial artery area after 
sublingual GTN was no different from controls: TA 48% (95% CI 33 to 63) v 57% 
(95% CI 44 to 70%) (p = 0.39). 
 
10.3.4 Left Ventricular Parameters 
BSA-indexed left ventricular (LV) end-systolic volume (ESV) was significantly less 
for the TA patients, resulting in an increased ejection fraction (74% vs 67% in 
normals, p<0.001, table 10.4). Four (25%) patients with TA had left ventricular 
hypertrophy (LVH) by indexed LV mass criteria [Maceira 2006], but there was no 
overall difference between groups for indexed LV mass. Of the 15 patients with a 
native aortic valve, 5 (33%) had aortic regurgitation, which in all cases was mild.  
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Table 10.4 Left ventricular parameters for patients with TA and normal 
controls. Absolute values are given, and values indexed for body surface area 
(BSA). LVEDV = left ventricular end-diastolic volume, LVESV = left ventricular 
end-systolic volume, LVSV = left ventricular stroke volume, LVEF = left 
ventricular ejection fraction. 
 
Parameter TA 
(N=16) 
Normals 
(N=60) 
P 
LVEDV [ml] 120 
(108, 133) 
129 
(124, 134) 
0.16 
LVESV [ml] 32 
(25, 40) 
42 
(39, 45) 
<0.001 
LVSV [ml] 88 
(81, 95) 
86 
(82, 90) 
0.62 
LVEF [%] 74 
(71, 78) 
67 
(66, 68) 
<0.001 
LV Mass [g] 113 
(104, 123) 
108 
(103, 113) 
0.37 
LVEDV/BSA [ml/m2] 69 
(61, 77) 
75 
(73, 77) 
0.06 
LVESV/BSA [ml/m2] 19 
(14, 23) 
25 
(24, 26) 
<0.001 
LV Mass/BSA [g/m2] 65 
(59, 72) 
63 
(61, 65) 
0.67 
 
 
10.3.5 Myocardial Fibrosis 
Late gadolinium enhancement (LGE) was identified in 4 of 15 (27%) patients with 
TA. The patterns of LGE identified were subendocardial in 2, and focal mid-wall in 2. 
None of these 4 patients was known to have coronary artery disease. One had 
previously undergone aortic valve replacement, and in addition to a zone of 
subendocardial LGE also had a focal area of transmural apical fibrosis consistent with 
LV venting at the time of surgery (figure 10.3). 
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 10.4 DISCUSSION 
 
10.4.1 General Observations 
The management of Takayasu’s Arteritis (TA) is complex and clinically challenging. 
The non-specific nature of presenting symptoms typically results in delayed diagnosis 
and failure to initiate adequate treatment early in the disease course [Andrews 2007]. 
Thus the outlook for patients is often poor with substantial morbidity and mortality up 
to 35% [Kerr 1994a, Maksimowicz-McKinnon 2007]. Advances in CMR, such as 
those we describe in our study, address current shortcomings in clinical management, 
offering the prospect of earlier diagnosis, more detailed monitoring, and more 
complete cardiovascular assessment. CMR may also facilitate more accurate tailoring 
of treatment, so minimizing both vascular injury and side-effects of therapy. The 
sensitivity of the technique will allow earlier identification of disease relapse and 
detection of the onset of accelerated atherosclerosis.   
 
CMR clearly identified the circumferential thickening of the carotid arterial wall 
associated with TA. In addition to demonstrating the presence or absence of vessel 
wall thickening and pre-symptomatic atherosclerotic plaque, CMR yielded a robust 
quantification of carotid wall volume and the W/OW ratio. This quantitative approach 
is a strength of CMR. The multivariate analysis indicated that TA was an independent 
predictor of arterial thickening, despite the high prevalence of cardiovascular risk 
factors. In every patient the W/OW ratio was elevated, although the degree of 
thickening varied between patients and between arteries. Given that the diagnosis of 
TA is often significantly delayed, these data suggest that the W/OW ratio may offer a 
sensitive method for early diagnosis in patients presenting with pre-stenotic disease. 
Previous CMR studies in TA have generally only used MRA. Where vessel wall 
CMR has been attempted, only descriptive data have been derived and no quantitative 
studies have been performed [Gotway 2005, Sueyoshi 2006, Steeds 2006]. Tso used 
short tau inversion recovery CMR to look for oedema in the wall of the aorta and 
major branches. They found oedema in 94% of patients with clinically active TA, but 
also in 56% of patients with clinically inactive disease, and the difference was not 
significant [Tso 2002]. Choe used contrast-enhanced vessel wall CMR to identify 
inflammation in the aorta, and CMR and clinical findings were concordant in 88.5% 
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[Choe 2000]. To our knowledge, our study is the first in TA to use quantitative CMR 
assessment of the arterial wall, providing a novel method of longitudinal follow up.  
CMR also revealed impaired endothelial function in TA. We are not aware of any 
previous studies of endothelial function in TA. This is important, as endothelial 
dysfunction is an important early step in atherogenesis [Celermajer 1994, Weismann 
2004]. Endothelial dysfunction has previously been linked with vascular inflammation 
in other inflammatory conditions such as Behcet’s syndrome, SLE and primary 
systemic vasculitis, where it has been shown that therapy can normalize endothelial 
function [Raza 2000, Chambers 2001, Lima 2002, El-Magadmi 2004]. Thus, 
endothelial function assessment provides an additional, novel method for assessing 
cardiovascular risk and monitoring therapy in TA.  BAR by CMR has better 
reproducibility than ultrasound, probably because CMR measures the arterial area 
whereas ultrasound measures diameter which has been identified as a source of  
inaccuracy as the artery is usually oval-shaped [Sorensen 2002, Ong 2002].   
 
 
 
Figure 10.3 Late gadolinium-enhancement CMR images in a patient with TA 
demonstrating subendocardial late enhancement (arrows) in a typical 
myocardial infarction pattern. (A) Four chamber view, (B) Left Ventricular 
Outflow Tract (LVOT) view, (C) Short axis view. (LV = left ventricle, RV = right 
ventricle, LA = left atrium, AO = aorta).  
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CMR also identified dynamic LV systolic function in TA. In addition, 33% of patients 
had mild aortic regurgitation and 25% of patients had LV hypertrophy (LVH). 
Although LVH may be related to hypertension, which was common in this cohort, it 
has also been associated with increased vascular stiffness in the inflammatory 
arthritides and SLE [Pieretti 2007]. There is limited previous work in TA assessing 
the LV by echocardiography: one study identified LVH in half of all TA patients 
studied. Two further echocardiography studies in TA found LV systolic dysfunction 
in 18%, and aortic regurgitation of at least moderate severity in 50% [Soto 2006, 
Pfizenmaier 2004, Hashimoto 1992]. LVH has been found in other systemic 
inflammatory conditions such as SLE, where it has been attributed to increased 
vascular stiffness [Pieretti 2007]. Arterial stiffness is known to be increased in TA, 
and both this and LVH are associated with an increased risk of cardiovascular disease 
[Roman 2005, Ng 2006, Levy 1990]. Our findings would support the presence of a 
response to increased vascular stiffness in patients with TA, and suggest that accurate 
assessment may allow identification of patients most at risk of accelerated 
atherosclerosis.  
 
Myocardial scarring has not previously been imaged in TA, and was identified in 27% 
of our patients. Enhancement was found either in the subendocardium or the mid-
wall, the former probably indicating myocardial infarction. This emphasizes the need 
for excluding coronary artery involvement in TA. The presence of myocardial 
infarction has important prognostic and therapeutic implications, and identifying this 
by CMR may be of considerable importance for individual patients. The significance 
of the regions of mid-wall fibrosis is likely to represent inflammatory cardiac 
involvement in TA [Dumarey 2007], and this has been shown to predict cardiac 
events in other conditions, such as dilated cardiomyopathy [Assomull 2006]. Overall, 
cardiac imaging is not routinely performed in TA, yet in this study significant cardiac 
pathology in the form of LVH or LGE has been identified by CMR in 6 out of 15 
patients (40%). This suggests that there may be significant unidentified cardiac 
disease in this patient group, which is of particular importance in the light of cardiac 
disease being the major cause of morbidity and mortality in TA [Subramanyan 1989, 
Mwipatayi 2005, Maksimowicz-McKinnon 2007].  
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An additional major challenge for imaging in TA is the identification of active disease 
in patients who appear to be quiescent clinically. One series of surgical biopsy 
specimens from patients with clinically inactive disease demonstrated histological 
evidence of arterial wall inflammation in 44% [Kerr 1994a]. PET has good sensitivity 
and specificity for the diagnosis of TA, but is of relatively limited use in serial follow-
up, as are ultrasound and oedema-weighted vessel MR [Webb 2004]. One of the 
strengths of CMR is the use of different approaches within a single imaging session. 
CMR vessel wall imaging is complementary to MRA, and cardiac volumes, 
endothelial function and myocardial scarring can also be assessed. This multifaceted 
approach within a single modality has the potential to simplify patient management, 
and to help identify the true level of persistent disease and tissue damage in TA 
patients. However, the ability of CMR to accurately quantify disease activity in the 
arterial wall remains to be demonstrated. 
 
10.4.2 Study Limitations 
This study is limited in size because of the rarity of TA, however in the TA literature 
16 patients is considered a cohort of significant size. Similarly, because of the rarity 
of TA, the cohort is necessarily heterogenous, with a high incidence of comorbidities. 
However, this is typical of cohorts seen in clinical practice. The cross-sectional design 
does not allow the estimation of the potential for the long-term monitoring of disease 
activity. 
 
10.4.3 Conclusion 
Using state-of-the-art CMR technology, this study has assessed TA patients in several 
novel ways. It has accurately quantified the extent of vessel wall thickening, identified 
impaired endothelial function, and described a high prevalence of myocardial 
scarring. In addition to early diagnosis, this integrated approach could be used for 
disease monitoring and tailoring of therapy for both the vasculitis and associated 
accelerated atherosclerosis. Such approaches should now be examined in prospective 
trials. 
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CHAPTER 11 
INTEGRATED CARDIAC AND VASCULAR ASSESSMENT IN  
SYSTEMIC LUPUS ERYTHEMATOSUS BY CARDIOVASCULAR MAGNETIC 
RESONANCE  
 
11.1 INTRODUCTION 
Systemic lupus erythematosus (SLE) is an autoimmune multisystem inflammatory 
disease, in which there is a high prevalence of cardiovascular disease, even though the 
majority of patients are women[Roman 2003, Asanuma 2003, D’Cruz 2007]. 
Compared to non-affected peers, SLE cohorts have been found to have up to fifty 
times greater incidence of myocardial infarction, and even after controlling for 
vascular risk factors, SLE patients had a relative risk of death of 17 for myocardial 
infarction and 7.9 for stroke [Manzi 1997, Esdaile 2001]. SLE is an independent risk 
factor for atherosclerosis, and is associated with endothelial dysfunction, a sensitive 
early indicator of vascular disease [Bruce 2003, El-Magdami 2004, Karp 2008]. The 
exact reasons for accelerated atherosclerosis in SLE are not known, and are likely to 
be multifactorial [Haskard 2004].  
 
Investigation for cardiovascular disease (CVD) is not routine in SLE in the absence of 
symptoms, although an increased awareness of the magnitude of the excess risk has 
led to a lower threshold for non-invasive and invasive vascular imaging for screening, 
and to investigate clinical syndromes such as angina. In SLE research, non-invasive 
vascular imaging (chiefly ultrasound assessment of the carotid arteries) is a common 
tool for assessing arterial thickening, and CT coronary artery calcification (CAC) 
scoring has also been performed in a research context [Asanuma 2003, Wolak 2004]. 
 
Cardiovascular magnetic resonance (CMR) has a number of potential advantages as a 
single technique for a multifaceted cardiovascular assessment. These include imaging 
of the vessel wall without the limitations of ultrasound; and proven reproducibility of 
quantitative carotid artery vessel wall analysis by CMR, which reduces sample sizes 
in clinical trials [Corti 2005, Saam 2005a, Varghese 2005, Keenan 2008b]. 
Furthermore, cardiac morphology and function can be derived more accurately and 
more reproducibly than by other techniques [Grothues 2002, Keenan 2007]. CMR is 
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the preferred modality for myocardial tissue characterization, identifying regions of 
myocardial inflammation, infarction and fibrosis using gadolinium-based contrast 
agents [Kim 1999, McCrohon 2003]. Endothelial dysfunction can be identified by 
measuring brachial flow-mediated dilatation (FMD) in response to reactive hyperemia 
[Sorensen 2002, Tanner 2007]. This combined assessment of endothelium, arterial 
wall and heart gives a broad assessment of vascular health and risk, with the 
convenience of a single scan. The purpose of this cross-sectional study was to assess 
the utility of this approach in a cohort of SLE patients. To our knowledge, no previous 
study has done this. 
  
 
 
11.2 METHODS 
 
11.2.1 Patients 
Eleven patients with SLE were prospectively recruited from our rheumatology clinics. 
All subjects were female and fulfilled the American College of Rheumatology 
diagnostic criteria [Tan 1982, Hochberg 1997]. All completed a health questionnaire 
assessing disease severity, length of diagnosis, treatment, comorbidities and 
cardiovascular risk factors. In addition, a database of clinical information was 
reviewed. Physical examination and electrocardiograph (ECG) were performed. A 
CMR study was performed in three parts: 1. carotid artery, 2. brachial artery 
reactivity, 3. cardiac study with gadolinium. Using advertising campaigns, two 
populations of normal female volunteers were prospectively recruited. Both 
populations were screened with a questionnaire, physical examination, blood tests and 
ECG, and volunteers with cardiac risk factors, or who were found to be hypertensive, 
diabetic or hypercholesterolemic, or who had an abnormal ECG were excluded from 
the study. Fifty normal volunteers underwent CMR carotid artery vessel wall imaging, 
and 60 normal volunteers, with, in addition, a normal serum B-type natriuretic peptide 
(BNP), underwent a CMR (without gadolinium). 
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11.2.2 CMR Protocol  
Imaging was performed on a 1.5 Tesla scanner (Siemens Sonata, Erlangen, Germany). 
For carotid imaging, a purpose-built bilateral four-channel phased-array carotid 
surface coil (Machnet BV, Eelde, the Netherlands) and a specially-designed head and 
neck cushion were used. Using a standard 2 dimensional (2D) fast spin echo (FSE) 
CMR sequence, a contiguous stack of high-resolution T1-weighted FSE images was 
acquired perpendicular to the carotid artery, centered on the carotid bifurcation 
bilaterally, as previously described [Keenan 2008e]. Briefly, slice thickness was 2mm, 
and 20 contiguous slices were acquired for each side, giving 40mm of longitudinal 
coverage per artery. Typical sequence parameters were: field of view (FOV) 110mm 
read x 65mm phase (up to 30% bigger phase FOV depending on patient size), pixel 
size 0.43mm x 0.43mm (interpolated to 0.21mm x 0.21mm during reconstruction), 
ECG-gated to every cardiac cycle with end-diastolic triggering, TE 9.6ms, echo train 
length 9 with a readout time of 76ms, band width 230 Hz/pixel, 4 averages. Dark 
blood preparation was used with the inversion time (TI) determined by average R-R 
interval.  
 
Image analysis was performed using Atheroma Tools (a plug-in of CMRtools, 
Cardiovascular Imaging Solutions, London, UK) [Varghese 2006]. The internal and 
external carotid artery surfaces were contoured for each slice giving the lumenal area 
and the total vessel area. Data from the 20 slices were then used to produce a 3D 
model from which the lumen volume, wall volume and total vessel volume were 
derived for the standardized 40 mm length. The total wall volume was also expressed 
as a percentage of the total vessel volume (wall/outer wall or W/OW ratio) [Saam 
2005a]. For each patient, data were expressed as a mean of left and right carotid 
arteries. In addition, a visual assessment was made of the presence or absence of 
atherosclerotic plaque [Meini 2006]. 
 
A previously validated CMR protocol for endothelial function was used [Sorensen 
2002, Wiesmann 2004]. In essence, a 2cm small loop surface coil was placed over the 
right brachial artery. The artery was occluded distal to the coil for 5 minutes by 
inflating a blood pressure cuff on the forearm to 20 mmHg above systolic pressure. On 
release of the cuff, the artery was scanned immediately and at 1-minute intervals up to 
5 minutes after cuff deflation. A segmented FLASH gradient echo sequence was used 
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with the following imaging parameters: 8 views per segment, TE 14 ms, field of view 
7x3.5 cm, matrix size 256x128, pixel size 0.27x0.27 mm, with diastolic trigger delay; 
acquisition time was 12 cardiac cycles. The cross-sectional area of the artery was 
calculated at baseline and at maximal dilatation, and the resulting FMD was expressed 
as the percentage change in area. For assessment of endothelium-independent 
dilatation, the percent change in brachial artery area was measured before and after 
sublingual administration of 400µg glyceryl trinitrate. 
 
A standard CMR protocol was used for the cardiac study, and volumetric 
measurements were made as previously described [Maceira 2006]. Briefly, using front 
and back surface coils and retrospective ECG triggering, steady-state with free 
precession (SSFP) end-expiratory breath-hold cines were acquired in the vertical and 
horizontal long axis planes, with subsequent contiguous short-axis cines from the 
atrioventricular (AV) ring to the apex. Imaging parameters were: repetition time 
3.2ms, TE 1.6 ms, flip angle 60º, slice thickness 7mm. Acquisition time was 18 
cardiac cycles, in-plane pixel size was 2.1 x 1.3mm and temporal resolution was 21.6 
±1ms. Left ventricular volumes and function were measured with standard techniques 
using LVtools (a plug-in of CMRtools, Cardiovascular Imaging Solutions, London, 
UK) [Grothues 2002, Keenan 2007]. Volumes and mass were indexed to body surface 
area (BSA) [Maceira 2006]. Cine images were reviewed for evidence of valvular heart 
disease. Late gadolinium enhancement (LGE) images were acquired 10 minutes after 
intravenous gadolinium-DTPA (Magnevist, Schering; 0.1 mmol/kg) in identical short-
axis planes using an inversion-recovery gradient echo sequence. Inversion times were 
adjusted to null normal myocardium (typically 320 to 440 ms; pixel size 1.7 x 
1.4mm). Additional LGE images were acquired with phase swapping to exclude 
artefact. Two experienced readers, who were blinded to all clinical data, reviewed the 
LGE studies, assessing studies for the presence or absence of LGE, and, if present, for 
the pattern [Kim 1999]. Where there was disagreement, a third independent observer 
decided. 
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11.2.3 Statistics and Ethics 
Descriptive statistics were performed on baseline population data, and populations 
were compared. An unpaired t-test was performed to compare data between patient 
groups.  For carotid artery parameters, age-adjusted Z scores and 95% reference 
ranges were derived for the normal population (as previously described [Keenan 
2008e]), and these were used to assess the TA population. Z scores are a standard 
statistical method of characterizing a normally-distributed population, where a Z score 
of +1 indicates 1 standard deviation greater than the value predicted for a given age, 
and a Z score of 0 indicates the observed value is equal to what would be expected for 
a patient’s age. A multivariate regression analysis was performed to assess the relative 
contribution of vascular risk factors in the SLE population. A t-test was used to assess 
data for endothelial function, and left ventricular volume, function and mass. For 
LGE, descriptive statistics only were derived. All subjects gave written informed 
consent, and approval was obtained from the hospital research ethics committee. 
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11.3 RESULTS 
 
11.3.1 Patients 
Baseline clinical data for patients with SLE (n=11) and both groups of normal 
subjects (n=50 for carotid artery study and n=60 for LV study) are shown in table 
10.1. The patients studied had established SLE with a mean duration of 16 years. Four 
patients (36%) had documented cardio- or cerebrovascular disease, 9 (82%) had 
previous or current hypertension, and 6 (55%) hyperlipidaemia. Patients with SLE 
were significantly shorter and heavier than normal volunteers, with higher systolic 
and diastolic blood pressure, reflecting at least in part steroid use, with 10/11 (91%) 
patients taking prednisolone. Five (45%) patients were taking a second 
immunosuppressive in addition to steroids, 3 (27%) were taking hydroxychloroquine 
and 5 (45%) statins. All patients completed the full protocol except one in whom LGE 
images were not acquired. 
 
11.3.2 Carotid Arteries 
The carotid arteries were significantly thickened in patients with SLE. Carotid artery 
wall volume was 19% greater than in normals (p<0.001), while in 6 patients (55%) 
the W/OW ratio (index of vascular thickening) was outside the normal range. (table 
10.2, figures 10.1 and 10.2) The detected abnormality was confined to the arterial 
wall, as lumen volume and total vessel volume were no different from normal 
subjects. In 7 patients (64%) atherosclerotic plaque was identified, although in 4 of 
these patients there was no clinical evidence of atherosclerosis. A multivariate 
regression analysis was performed to assess the relationship between individual 
vascular risk factors and vessel wall thickening, expressed as W/OW (table 10.3). 
Hypertension, diabetes, corticosteroid and statin use were all significantly associated 
with elevated W/OW. However, after controlling for these factors, only diabetes and 
steroid use remained independently associated with W/OW, while statin use was 
significantly negatively associated with W/OW.   
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11.3.3 Endothelial Function 
Mean flow-mediated dilatation in SLE was 4.0% (CI -3.4% to 11.4%), indicating 
significant endothelial dysfunction when compared with historical controls (mean 
FMD 15.5% (CI 11.6 to 19.4%), p = 0.011) [Weismann 2004]. In response to GTN, 
the mean increase in brachial artery area was 60% (CI 41-79%), and this was no 
different from historical normals, indicating that endothelium-independent 
vasodilatation was not impaired. 
 
 
11.3.4 Left Ventricular Parameters 
Left ventricular parameters are presented in table 10.4. Body surface area (BSA) 
indexed left ventricular end-systolic volume (LVESV) was significantly reduced in 
the SLE patients, and this was reflected in a trend to higher ejection fraction in SLE 
(71% v 67%, p=0.09). One patient with SLE had left ventricular hypertrophy (LVH) 
by BSA-indexed LV mass criteria [Varghese 2006].  
 
 
11.3.5 Myocardial Fibrosis 
Myocardial scarring by LGE was identified in 6 of 10 (60%) patients studied. Two 
patients had previously unrecognized myocardial infarctions (one transmural with 
associated mural thrombus, figure 10.3), 3 had midwall scarring and 1 had 
subepicardial scarring.  
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Table 11.1. Baseline characteristics of subjects studied (mean ± SD, N (%)). 
 
Parameter SLE Normals (Carotids) Normals (LV) 
N 11 50 60 
Age 47 ± 12 44 ± 14 49 ± 16 
Height [m]  1.61 ± 0.04 * 1.66 ± 0.07 1.65 ± 0.07 
Weight [kg] 71 ± 18 * 63 ± 9 65 ± 12 
BSA [m2] 1.77 ± 0.23 1.71 ± 0.14 1.71 ± 0.14 
SBP 131 ± 16 * 117 ± 11 122 ± 15 
DBP 83 ± 13 *# 73 ± 7 72 ± 8  
    
Years of Diagnosis 16 ± 9 N/A N/A 
Cerebrovascular disease (%) 3 (27)   
Coronary artery disease (%) 1 (9)   
Hypertension (%) 9 (82)   
Diabetes mellitus (%) 1 (9)   
Hyperlipidaemia (%) 6 (55)   
Current smoking (%) 2 (18)   
    
Current Therapy    
Corticosteroids (%) 10 (91)   
Azathioprine (%) 2 (18)   
Methotrexate (%) 2 (18)   
Hydroxycholoquine (%) 3 (27)   
Mycophenolate mofetil (%) 2 (18)   
Statin (%) 7 (64)   
Antihypertensive agents (%) 6 (55)   
* = p <0.05 v normals (carotids).   # = p <0.05 v normals (LV). 
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Table 11.2. Carotid artery parameters for a 20 slice model of the carotid 
bifurcation. 
 
Parameter SLE 
(N=11) 
Normals 
(N=50) 
p 
SLE v Normals 
Plaque identified N (%) 
 
7 (64) 0 (0) <0.01 
Lumen volume [mm3] 1388 
(1234, 1544) 
1398 
(1342, 1454) 
0.92 
Wall volume [mm3] 761 
(656, 867) 
640 
(618, 661) 
<0.01 
Total vessel volume [mm3] 2150 
(1922, 2379) 
2037 
(1963, 2112) 
0.34 
W/OW ratio [%] 35 
(33, 38) 
32 
(31, 32) 
<0.01 
 
 
 
Table 11.3. Multivariate regression analysis of wall / outer wall (W/OW) ratio, 
indicating the strength of association with vascular risk factors and therapies. 
 
Variable Coefficient * p  Adjusted 
Coefficient $ 
p  
Hypertension 1.70 <0.01  3.2 0.08 
Diabetes  5.03 <0.01  4.99 <0.01 
Smoker 1.27 0.27  -0.64 0.54 
Corticosteroid use 2.37 <0.01  5.04 <0.01 
Statin use 1.9 <0.01  -1.29 <0.01 
 
* Coefficient indicates average number of standard deviations difference from the Z 
score of the normal population  
$ after controlling for hypertension, diabetes, smoking, steroid usage and statin usage. 
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Figure 11.1 T1-weighted transaxial CMR images of bilateral common carotid 
arteries (white arrows) in (a) a normal volunteer, and (b) a patient with SLE. 
The normal subject’s arterial wall is thin and smooth (long arrows), but in the 
SLE patient, the arterial wall is thickened, the lumenal surface is of high signal, 
and is surrounded by a thick rim of low signal (short arrows). (c and d) 
Transaxial CMR images of the left internal (ICA) and external carotid arteries 
(ECA) in a 58 year old female with SLE (c = T1-weighted, d = T2-weighted). An 
atherosclerotic plaque is seen with fibrous cap (arrow) and underlying 
calcification (*). 
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Table 11.4. Left ventricular (LV) parameters for patients with SLE and normal 
controls. Absolute values are given, and values indexed for body surface area (BSA). 
EDV = end diastolic volume, ESV = end systolic volume, SV = stroke volume, EF = 
ejection fraction. 
 
Parameter SLE 
(N=11) 
Normals 
(N=60) 
p 
SLE v Normals 
LVEDV [ml] 118 
(104, 131) 
129 
(124, 134) 
0.27 
LVESV [ml] 34 
(28, 40) 
42 
(39, 45) 
0.03 
LVSV [ml] 83 
(71, 96) 
86 
(82, 90) 
0.81 
LVEF [%] 71 
(65, 76) 
67 
(66, 68) 
0.09 
LV Mass [g] 107 
(93, 122) 
108 
(103, 113) 
0.60 
LVEDV/BSA [ml/m2] 67 
(59, 74) 
75 
(73, 77) 
0.05 
LVESV/BSA [ml/m2] 20 
(16, 24) 
25 
(24, 26) 
0.02 
LV Mass/BSA [g/m2] 60 
(54, 66) 
63 
(61, 65) 
0.15 
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Figure 11.2: Left column. Carotid artery wall volume (top) and wall / outer wall 
(W/OW) ratio (bottom) in SLE by age for mean of left and right carotid arteries. 
The regression lines indicate the mean and upper and lower 95% confidence 
intervals for the sex-matched normal population. Right column. Box plot of the 
same data as on left.  The y axis indicates the age and sex-matched Z score 
derived from the normal population, so that a Z score of +2 indicates 2 standard 
deviations above the value expected for a normal age and sex-matched 
individual. 
 
Chapter 11 Page 199 Systemic Lupus Erythematosus 
 
11.4 DISCUSSION 
 
11.4.1 General Observations 
This CMR cardiovascular assessment has identified carotid arterial thickening, 
endothelial dysfunction, and a high degree of previously unrecognised cardiac 
pathology in a cohort of patients with established SLE. This comprehensive analysis 
of the cardiovascular status of each patient was obtained following a single attendance 
at the CMR Unit. Thus we propose that CMR offers an important new approach for 
risk stratification of patients with SLE, allowing early identification of those most at 
risk and sensitive non-invasive monitoring of the efficacy of therapeutic intervention. 
 
Carotid arterial wall volume was increased in SLE with no reduction in lumen volume 
because in early atherosclerosis the artery remodels outwards, as described by Glagov, 
who noted that lumenal volume does not begin to be lost until over 40% of the vessel 
cross-sectional area is represented by the arterial wall [Glagov 1987]. Arterial wall 
imaging is essential to detect these early changes; they would not be identifiable by 
lumenographic techniques such as angiography. To our knowledge, CMR has not 
previously been used for quantitative arterial wall assessment in SLE. It is an ideal 
end point in clinical trials of therapies for atherosclerosis, as its high degree of 
interscan reproducibility allows small sample sizes [Asanuma 2003, Corti 2005, 
Varghese 2005].  
 
Previous ultrasound-based studies are divided on whether diffuse vessel wall 
thickening is a feature of SLE. A case-control study comparing SLE patients with and 
without clinical atherosclerosis found a higher C-IMT in the atherosclerosis group 
[Svenungsson 2001]. However, in two registries, C-IMT was between 5 and 10% less 
in patients with SLE than in healthy controls [Manzi 1999, Roman 2003]. CMR wall 
volume is a different measurement than C-IMT (3 dimensional versus 1 dimensional), 
and these two techniques cannot be directly compared, but in our cohort the carotid 
arterial wall is clearly thickened in SLE.  
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Figure 11.3. (a-d) Images from a 36 year old female with SLE: in the early phase 
after gadolinium injection, two chamber (a) and four chamber views (b). The 
black filling defect (white arrow) indicates a mural thrombus at the apex of the 
left ventricle. Four chamber (c) and short axis (d) views in the late phase after 
gadolinium. Transmural late gadolinium enhancement (LGE) is visible in the 
mid-septum and at the apex of the LV.  The filling defect caused by the mural 
thrombus is still visible (arrowhead). The appearances indicate two regions of 
transmural myocardial infarction.  
(e and f) Images from a 41 year old female with SLE. Two chamber (e) and short 
axis (f) views in the late phase after gadolinium injection. Subendocardial LGE is 
present in the anteroseptal LV extending from the base of the heart to the mid-
ventricle, consistent with a previous subendocardial myocardial infarction. (LV= 
left ventricle, RV = right ventricle).  
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Steroid use was independently associated with W/OW ratio in a multivariate 
regression analysis (as was diabetes, but there was only 1 diabetic patient in the 
cohort). This finding is in keeping with other studies. The nature of the relationship 
between steroid use and atherosclerosis has been difficult to determine as steroids are 
directly atherogenic, as well as increasing cardiovascular risk by elevating body mass, 
increasing diabetes prevalence and adversely affecting lipid composition. Finally, 
steroid use is a surrogate marker for disease severity of SLE. Previous studies 
generally agree that steroid use is associated with CAD in SLE. In one large cohort, 
SLE patients with CAD had a longer mean duration of steroid use, and, in a second 
study, a higher cumulative steroid dosage [Petri 1992, Svenungsson 2001]. Also, a 
recent cohort study of 4094 person-years of follow up found that steroid dosing 
independently correlated with the incidence of CAD, even when other relevant factors 
including SLE activity had been controlled for [Karp 2008]. However, this is not a 
uniform consensus. In a fourth cohort, steroid use and cumulative dosage was less in 
patients with carotid plaque, suggesting that better immunosuppression may prevent 
atherogenesis [Roman 2003].  
 
As well as increased arterial wall volume, CMR identified a high prevalence of 
atherosclerotic plaque (64%). Four of these seven patients had no clinical evidence of 
atherosclerotic disease. Thus CMR offers a means for early detection of premature 
atherosclerosis which would allow aggressive secondary prevention to be initiated. In 
patients who do not have SLE, the presence of carotid plaque is associated with a 3 
times greater incidence of myocardial infarction,  but this has not been demonstrated 
in SLE, presumably because of the small patient numbers in each cohort [Salonen 
1993, Belcaro 1996]. In SLE, the presence of plaque correlates with markers of 
disease severity, and a recent longitudinal study has demonstrated accelerated plaque 
progression [Roman 2003, Thompson 2008].  
 
In patients presenting with SLE early in the disease course, a significant increase in 
carotid wall volume or evidence of atherosclerotic plaque is less likely. Hence, the 
capacity of CMR to identify impaired endothelial function by FMD is another means 
to stratify cardiovascular risk of these patients, and allow longitudinal assessment of 
treatment efficacy. Endothelial dysfunction is associated with all major risk factors for 
atherosclerosis, and is an important early step in atherogenesis [Celermajer 1994]. 
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Previous work using ultrasound has demonstrated endothelial dysfunction in SLE, 
where it has been correlated with vascular thickening [Lima 2002, El-Magadmi 2004]. 
It has also been correlated with vascular inflammation in conditions such as Behcet’s 
syndrome and primary systemic vasculitis (PSV). In Behcet’s, endothelial dysfunction 
was normalized by antioxidants, while in PSV, remission induction was associated 
with normalization of endothelial function [Raza 2000, Chambers 2001]. As noted for 
TA in chapter 10, BAR by CMR has better reproducibility than ultrasound, probably 
because CMR measures the arterial area whereas ultrasound measures diameter which 
has been identified as a source of  inaccuracy as the artery is usually oval-shaped 
[Sorensen 2002, Ong 2002].   
  
It is striking that myocardial scarring was identified in 60% of SLE patients. No 
previous study has reported the use of gadolinium-enhanced CMR to examine for 
myocardial scarring in SLE. In particular, two patients had previously unrecognized 
myocardial infarctions, one with adherent mural thrombus. The identification of 
myocardial infarction has major prognostic and therapeutic implications for the care 
of individual patients. Although routine cardiac imaging is not currently performed in 
SLE, early identification of cardiac disease (and particularly coronary artery disease) 
can lead to the timely initiation of secondary prevention. A single photon emission 
computed tomography (SPECT) study showed myocardial perfusion abnormalities in 
35% of a female population of SLE patients with no previous history of CAD, while 
an electron beam CT study found mean coronary artery calcification scores were 8 
times higher in SLE patients than controls [Bruce 2000, Wolak 2004]. Taken together, 
these findings suggest that there is a significant undetected burden of cardiac disease 
in SLE. The positive LGE studies in 4 additional SLE patients suggest myocardial 
fibrosis related to previous myocarditis, or primary myocardial scarring. Myocarditis 
is a recognized feature of SLE, and its recognition is important as aggressive 
immunosuppression is frequently required [Law 2005]. One previous study has used 
CMR to look for myocarditis in patients with SLE. However, only T2 (oedema-
weighted) imaging was performed without gadolinium, limiting the information 
available from the scan. Nevertheless, an increase in tissue edema was noted in 
patients with active SLE [Singh 2005]. 
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11.4.2 Study Limitations 
This is a small study, and the cross-sectional design does not allow the potential for 
the long term monitoring of cardiovascular disease activity using CMR to be 
demonstrated. 
 
 
11.4.3 Conclusion 
CMR offers an integrated assessment of cardiovascular health, assessing the 
endothelium, arterial wall and myocardium. Using this in a cohort of patients with 
established SLE has identified carotid arterial wall thickening, atherosclerotic plaque, 
endothelial dysfunction, and a high incidence of myocardial scarring. This approach 
may be used for cardiovascular risk stratification, for targeting earlier secondary 
prevention, or to provide a variety of reproducible end-points for clinical trials. Early 
initiation of secondary prevention is important given the aggressive nature of 
atherosclerosis in SLE, and reproducible end-points are needed to allow small sample 
sizes in clinical trials given the low prevalence of SLE. We propose that this approach 
should now be evaluated in a larger prospective multicenter study. 
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CHAPTER 12 
GENERAL DISCUSSION AND CONCLUSIONS 
 
12.1 VALIDATION OF ARTERIAL WALL MAGNETIC RESONANCE USING 
HUMAN POST MORTEM CAROTID ARTERIES 
Quantitative carotid arterial wall imaging has been used as a surrogate marker of 
atherosclerosis, and as an end-point in clinical trials, but so far the only validation that 
has been performed is inter-scan reproducibility. An ex vivo validation was important 
therefore to show the accuracy of the technique. In the study described in Chapter 7, 
we demonstrated that measurements of arterial wall volume and lumenal volume 
using a routine 2D clinical CMR sequence were accurate when compared to a high 
resolution 3D validation sequence. Validation was also performed with microscope 
measurements of histological sections. Once again, correlation was good, but there 
were some inaccuracies, presumably related to changes in the arterial tissue with 
histological processing. Overall, these data indicate that the measurements obtained 
by carotid arterial wall CMR are accurate. 
 
12.2 DETERMINATION OF THE NORMAL RANGE OF CAROTID ARTERY 
WALL VOLUME AND DISTENSIBILITY BY AGE AND SEX BY A 2-
DIMENSIONAL CMR METHOD 
Although volumetric CMR arterial wall measurements have been performed in 
clinical studies, they have not been studied in a normal population, and changes 
associated with ageing have never been assessed. This data, from 100 subjects without 
modifiable cardiac risk factors, aged between 20 and 69, is presented in Chapter 8. 
We demonstrated that there was a significant increase in arterial wall volume with 
age, especially in men, and that this change did not impinge upon the arterial lumen, 
confirming Glagov’s hypothesis of outward arterial remodelling. We also 
demonstrated how this approach and these normal data can be used to discriminate 
between patient groups by studying a small group of patients with coronary disease. 
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These data will be useful for further studies of other at risk groups as we showed in 
chapters 10 and 11. 
 
12.3 COMPARISON OF 2D AND MULTI-SLAB 3D MAGNETIC RESONANCE 
TECHNIQUES FOR MEASURING CAROTID WALL VOLUMES 
The 2-dimensional (2D) technique is the conventional technique for vessel wall 
imaging, however newer 3-dimensional (3D) techniques offer reduced scan times and 
increased signal-to-noise ratio (SNR). However, these techniques have not been 
directly compared in a large study. In Chapter 10 we present the results of this 
comparison in 100 subjects. We showed that measurements from the 3D technique 
correlate well with the 2D technique, with a 63% reduction in scan time and a 
doubling of SNR. This suggests that the 3D technique should be used for future 
quantitative vessel wall imaging studies. 
 
12.4 INTEGRATED CARDIAC AND VASCULAR ASSESSMENT IN 
TAKAYASU’S ARTERITIS AND SYSTEMIC LUPUS ERYTHEMATOSUS BY 
CARDIOVASCULAR MAGNETIC RESONANCE 
In Chapters 11 and 12 we used the quantitative arterial wall imaging approach and the 
normal data from Chapter 9 to study patients in two populations at risk of accelerated 
atherosclerosis. We combined the arterial wall assessment with an assessment of 
endothelial function and of myocardial function and fibrosis in order to perform a 
comprehensive CMR assessment of vascular health. We studied patients with two of 
the inflammatory arthritidies: Takayasu’s arteritis (TA) and systemic lupus 
erythematosus. Patients with TA have gross arterial wall thickening which we were 
able to quantify accurately by CMR, revealing abnormalities in all patients. In 
addition we demonstrated impaired endothelial function for the first time in TA. In 
SLE, we demonstrated carotid arterial wall thickening, as well as a high incidence of 
atherosclerotic plaque. Endothelial function was impaired, and, in addition, we found 
myocardial scarring in 60% of patients including patients with previously 
unrecognised myocardial infarctions. These studies show that important information 
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about vascular health can be obtained in TA and SLE patients by CMR, with 
implications for clinical practice, and they suggest how randomised controlled trials 
of new therapies could be monitored by CMR. 
 
12.5 CONCLUSIONS 
Cardiovascular magnetic resonance arterial wall imaging is an accurate way of 
measuring thickening of the carotid arterial wall. The work in this thesis has 
contributed to the validation of this approach, and has provided valuable normal data, 
while indicating how the arterial wall changes with age. New techniques have been 
established and compared with existing methods, and the techniques have been 
applied in two at-risk populations, characterising these populations in novel ways. 
These approaches may now be applied in larger clinical trials. 
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CHAPTER 13 
FUTURE DIRECTIONS 
 
Several areas for future work have been identified. These include overcoming artefact, 
sequence development and sequence comparison, and new clinical applications for 
CMR arterial wall imaging. 
 
13.1 OVERCOMING MOVEMENT ARTEFACT 
As mentioned in chapter 9, one of the limitations of the 3 dimensional (3D) volume 
selective CMR sequence for vessel wall imaging is its susceptibility to movement 
artefact. During the course of a 10 minute scan, patient movement (in particular 
swallowing) can lead to severe artefact that may make images difficult or impossible 
to interpret. Dr Lindsey Crowe made some initial efforts to address this issue by using 
a modified sequence gated with a swallowing navigator. The navigator’s sample 
volume was placed at the back of the tongue; thus swallowing could be identified, and 
any lines of k-space that had been acquired during the swallow could be rejected 
[Crowe 2005b]. However this sequence was difficult to use, so instead, for the work 
described in chapter 9, the slab thickness was reduced from 56mm to 16mm, thereby 
reducing the scan time to about 3 minutes, significantly reducing artefact.  However, 
the problem of movement artefact needs further systematic investigation. 
 
13.1.1 A New Induction Device to Detect Swallowing 
Engineers at the CMR Unit at Royal Brompton Hospital have recently developed a 
new device to detect patient swallowing. This is a carbon fibre coil that is lightly 
secured to the subject’s laryngeal prominence. When the subject swallows, the coil is 
tilted in the static B0 field and a current is induced. This current is then detected and 
used to gate the scanner, rejecting lines of k-space acquired during a swallow. This 
technique can be combined with the 3D FSE sequence described in chapter 9. Blinded 
assessment of this approach to determine whether it can reduce imaging artefact will 
be needed.  
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13.1.2 Characterisation of Motion Artefact 
Motion artefact during carotid arterial wall imaging has been ascribed mainly to 
swallowing, although breathing, arterial pulsation, and patient postural movement 
may all have a role. The exact nature of the problem has not been studied in detail, 
and this is essential to design future methods to address it. A small study by Boussel 
has attempted to characterise motion using a real time gradient echo sequence. 
However data was only acquired in the xy plane, thereby ignoring the potential 
contribution of diaphragmatic motion [Boussel 2006]. 
 
It would be possible to study carotid artery motion using real time images acquired 
simultaneously in two perpendicular planes centred on the carotid bifurcation, thereby 
allowing motion to be tracked in 3 dimensions. An interleaved steady state with free 
precession (SSFP) real time CMR sequence could be written to acquire this data, and 
post processing software would be needed that can analyse the datasets. This approach 
could characterise carotid artery movement in more detail, and lead to the design of 
further gating methodologies to improve image quality. 
 
 
 
 
13.2 COMPARISON OF THREE 3D SEQUENCES 
Two new 3D sequences have recently been developed. They are SPACE (Sampling 
Perfection with Application of Optimized Contrasts using different flip angle 
Evolutions) and diffusion prepared SSFP. SPACE is a 3D sequence that uses a 
variable flip angle; it was originally developed to reduce tissue heating (specific 
absorption rate (SAR)) for imaging at 3T. However it has a high sampling efficiency, 
providing rapid imaging at high resolution which is truly 3 dimensional with isotropic 
voxel size [Lichy 2005]. This sequence has not yet been used for vessel wall imaging. 
Diffusion prepared SSFP was mentioned in section 9.1 as a modification of the 3D 
balanced SSFP sequence [Koktzoglou 2007b]. Diffusion weighting has been 
evaluated as a method to reduce the artefact from incomplete flow suppression in the 
arterial lumen. It has previously been evaluated for arterial wall imaging in the carotid 
artery, and reported time savings over 2D were similar to those reported with the 
multislab 3D sequence reported in chapter 9. In general, 3D sequences have been 
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shown to have benefit over 2D in terms of scan time, resolution and signal to noise 
ratio (SNR). However these sequences have never been compared head-to-head, and 
in particular spin echo has not been compared with gradient echo. It is now important 
to compare these 3D sequences directly to decide on the optimum sequence for further 
work. 
 
 
 
 
13.3 ULTRASHORT ECHO TIME (UTE) SEQUENCE 
Ultrashort echo time (UTE) sequences were developed to target tissue components 
with very short T2, such as cartilage, tendons and bone (which has a T2 of 0.4-0.5ms). 
The sequences are designed to minimise the time delay between tissue excitation and 
data acquisition so that data is acquired before the signal from connective tissue has 
undergone T2 decay. To do this, significant modifications are needed to the sequence, 
and a radial method of acquiring k-space is used [Young 2003, Gatehouse 2004]. As 
the UTE sequence can obtain signal from bone, it has been postulated that it may be 
used to detect calcification and other fibrous or semi-hard components in 
atherosclerotic plaque (which have low or zero signal on conventional sequences). 
Work using a UTE sequence to image carotid arteries ex vivo and in vivo would be of 
interest.  
 
 
 
 
13.4 A CMR-DRIVEN RANDOMISED CONTROLLED TRIAL OF STATIN THERAPY IN 
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 
As described in chapter 3, patients with SLE are at substantially increased risk of 
cardiovascular disease (CVD), and a diagnosis of SLE is one of the strongest known 
risk factors for CVD [Johnson 1989, Roman 2003]. Therapeutic efforts have focussed 
on primary and secondary prevention by targeting risk factors and improving disease 
control. In the non- SLE population, several large trials have studied the primary 
prevention of CVD with HMG-CoA reductase inhibitors (statins) in 
hypercholesterolaemic patients. These are the West of Scotland Coronary Prevention 
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Study (WOSCOPS), the Air Force / Texas Coronary Atherosclerosis Prevention 
Study (AFCAPS TexCaPS), and the Anglo-Scandinavian Cardiac Outcomes Trial- 
Lipid Lowering Arm (ASCOT-LLA) [Shepherd 1995, Downs 1998, Sever 2003]. All 
showed a reduction in cardiovascular events with statin therapy. 
 
Extrapolating from this data, we have postulated that there may be a role for statins in 
the primary prevention of CVD in patients with SLE, given that a diagnosis of SLE is 
a stronger risk factor for CVD than hypercholesteroaemia. However, the mechanism 
of atherogenesis in SLE may be different: the pathogenesis of accelerated 
atherosclerosis in SLE is still a matter of debate with a greater role for immunological 
activation, and disease activity itself is correlated with CVD [Karp 2008]. As SLE is a 
relatively uncommon condition, it would be difficult to design a clinical trial with 
adequate power using only clinical end-points. Quantitative CMR-based vessel wall 
assessment has previously been used as the primary end-point in clinical trials [Corti 
2005]. As reproducibility is high, small differences between populations can be 
detected with small sample sizes (as described in section 5.4). The proposed trial 
medication is rosuvastatin. Since its launch in 2003, it has been shown to have a 
higher potency than other statins with an acceptable safety profile. In the ASTEROID 
trial, IVUS-derived end points were use to demonstrate that rosuvastatin induced 
plaque regression [Nissen 2006]. This was the first time that plaque regression had 
been demonstrated in a large scale trial, although it had previously been described in 
smaller trial by CMR (51 patients versus 507) [Corti 2005]. A randomised trial of 
statin treatment in SLE patients would be of great interest.  
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CHAPTER 15 
APPENDIX A: SUPPLEMENTARY THESIS DETAILS 
 
15.1 PERSONAL CONTRIBUTION TO THE RESEARCH 
I was appointed in October 2004 as the second research fellow in arterial wall 
imaging under the supervision of Professor Dudley Pennell with funding from 
CORDA (a charity whose main interest is atherosclerosis prevention). My predecessor 
Dr Anitha Varghese had previously validated a 3-dimensional (3D) CMR sequence 
for arterial wall imaging and, together with colleagues in the visual information 
processing group in the department of computing at Imperial College, developed 
software for image analysis. 
 
My project had four main elements. The first was to validate the CMR vessel wall 
imaging methodology ex vivo with tissue specimens. The second was to perform 
carotid artery imaging on a large number of normal subjects to derive age-specific 
normal data, and to assess changes in arterial wall parameters with ageing. The third 
was to perform a sequence comparison between the new 3D sequence and the 
conventional 2D sequence. Finally, I was to assess the utility of this technique, and of 
the normal data I had derived, by scanning populations with a high incidence of 
vascular disease – I studied two populations of patients with the inflammatory 
arthritides Takayasu’s Arteritis and Systemic Lupus Erythematosus. 
 
In a preliminary year of research, I developed the 2D and 3D sequences to the point 
where they were performing reliably. In this I was assisted by physicist colleagues 
Professor David Firmin and Dr Peter Gatehouse. I personally undertook all study 
planning, ethical committee submissions, case record form design, and other study 
logistics under the supervision of Prof. Pennell.  
 
For the post mortem carotid artery project (chapter 7), I obtained the permission of all 
relatives. Artery removal and initial preparation were performed by Dr Mary 
Sheppard, Consultant Histopathologist, assisted by Mr Anthony Phillips and Mr Chris 
Archer in the pathology department at the Brompton Hospital. The scanning box was 
designed and made by me, with the help of Mr Ray Hughes and Mr Steve Collins. I 
Chapter 15 Page 249 Appendices 
 
performed all CMR scans. Slide preparation was performed by Dr Joseph Boyle, Miss 
Lorraine Lawrence of Imperial College, and me. I acquired all photomicrographs of 
the slides. I analysed all the 3D CMR images, and I was assisted in analysing the 2D 
CMR images by Dr Agata Grasso, CMR Fellow, Brompton Hospital. I analysed all 
the photomicrographs. 
 
For the normal subjects project, and the 2D versus 3D sequence comparison (chapters 
8 and 9), I recruited all 122 volunteers, I performed all the scans and I analysed all the 
data. I was assisted in analysing the distensibility data by Dr Didier Locca, CMR 
Fellow, Brompton Hospital. 
 
For the TA and SLE projects (chapters 10 and 11), the subjects were identified by Dr 
Justin Mason and Professor Dorian Haskard at the Hammersmith Hospital. I 
performed all the scans and analysed all the data, with the exception of the left 
ventricular data in the normal subjects which was acquired by Dr Alicia Maceira, 
former CMR Fellow, Brompton Hospital. I was assisted in the analysis of late 
gadolinium enhanced images by Drs Ravi Assomull and Rory O’Hanlon, CMR 
Research Fellows at the Brompton Hospital. 
 
For all projects, statistical analysis was performed by me with the assistance of Mr 
Michael Roughton, former Medical Statistician at the Brompton Hospital. All papers 
and chapters were written by me under the supervision of Professor Dudley Pennell. 
Dr Mark Tanner supplied several physics diagrams which I adapted to produce some 
figures in chapter 4. 
 
 
 
15.2 SUPERVISION 
This thesis was supervised by Dudley Pennell, Professor of Cardiology, Imperial 
College London, UK, and Director of Cardiovascular Magnetic Resonance, Royal 
Brompton Hospital, London, UK. 
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15.3 PRESENTATIONS AND AWARDS ARISING FROM THIS WORK  
Oral Presentation, European Society of Biomechanics Conference (ESB), Lucerne, 
2008. MRI Based Reconstruction of Plaque Structure and its Relations to Shear Stress 
in a Patient-Specific in Vivo Study (collaborative work, presentation given by Dr G. 
Soloperto, Imperial College). 
 
Oral presentation, Society of Cardiovascular Magnetic Resonance Conference 
(SCMR), Rome, 2007. Age-related changes in carotid artery lumen and wall volume 
in a population free of cardiac risk factors. 
  
Oral presentation, Society of Cardiovascular Magnetic Resonance Conference 
(SCMR), Rome, 2007. The Role of Cardiovascular Magnetic Resonance in Patients 
Presenting with Chest Pain, Raised Troponin and Unobstructed Coronary Arteries. 
 
Oral presentation, British Cardiovascular Society Conference (BCS) 2007, Glasgow, 
UK. Age-related changes in carotid artery lumen and wall volume in a population free 
of cardiac risk factors. 
 
Poster presentation, Shear Stress Symposium 2007, Rotterdam, Netherlands. MRI 
Based Reconstruction of Plaque Structure and its Relations to Wall Shear Stress in 
Stenosed Human Carotid Artery Bifurcation (collaborative work presented by Dr G. 
Soloperto, Imperial College, who received the young investigator award). 
 
Invited lecture, Nation Heart and Lung Institute (NHLI), Imperial College, London, 
CMR Course, October 2006. Read with the Experts: Cases in Atherosclerosis. 
 
Invited lecture, Nation Heart and Lung Institute (NHLI), Imperial College, London, 
CMR Course, October 2005. Endothelial Function. 
 
Invited lecture, Nation Heart and Lung Institute (NHLI), Imperial College, London, 
CMR Course, October 2005. Read with the Experts: Interactive Case Presentations. 
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Invited lecture, Academic Medical Centre, Amsterdam, Holland, September 2005.  
CMR of the Arterial Wall. 
 
 
 
 
 
15.4 FUNDING 
Personal support for this research was from CORDA- a cardiovascular research 
charity. 
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CHAPTER 16 
APPENDIX B: DETERMINATION OF VENTRICULAR VOLUMES AND MASS 
  
In the patients with TA and SLE described in chapters 10 and 11, a routine CMR 
cardiac study with gadolinium contrast was performed in addition to the arterial 
imaging discussed above. As this was not directly relevant to CMR of the arterial 
wall, the methodology is given here. 
  
 
16.1 INTRODUCTION 
CMR has many advantages for the assessment of ventricular mass and function 
[Keenan 2007]. Since its inception in the early 1980s it has rapidly become the 
reference standard against which other techniques are measured [Koch 2004, 
Heuschmid 2005]. Any plane can be acquired, so the entirety of both ventricles can be 
imaged to produce a full 3-dimensional dataset of ventricular volume, mass and 
function. No geometrical assumptions need to be made about the heart, rendering 
CMR superior to echocardiography where 3-dimensional measurements are 
extrapolated from M-mode or 2D data, which can lead to inaccuracies, especially in 
disease states [Bellenger 2000]. 
 
 
16.2 ACCURACY OF CMR VENTRICULAR MEASUREMENTS 
CMR has the best accuracy of any imaging technique for the measurement of left and 
right ventricular volumes and mass. This was established ex vivo by comparing CMR 
measurement of left and right ventricular volumes with the water displacement 
volume of casts of the ventricular cavity [Longmore 1985, Rehr 1985, Jauhainen 
1998]. In vivo the accuracy of volume measurement has been demonstrated by 
comparing the left and right ventricular stroke volumes in normal subjects (where 
they must be equal) [Sechtem 1987]. Volumetric measurements have also been 
validated by comparing them with stroke volumes derived from aortic and pulmonary 
arterial flow mapping [Firmin 1987, Kondo 1991]. Measurement of LV mass by CMR 
has been validated in human autopsy hearts and in animals [Katz 1998, Myerson 
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2002]. RV mass measurements have been validated against ex vivo animal hearts 
[Katz 1993, Bloomgarden 1997]. Accuracy has been confirmed in disease states, 
where the abnormal shape of the heart may lead to inaccuracies in the geometrical 
assumptions inherent in M mode and 2D echocardiography-derived measurements. 
Disease states studied include myocardial infarction, dilated cardiomyopathy, left 
ventricular hypertrophy, and congenital heart disease [Shapiro 1989, Semelka 1990, 
Helbeing 1995]. 
 
 
16.3 REPRODUCIBILITY OF CMR VENTRICULAR MEASUREMENTS 
A high degree of reproducibility is important for the clinical follow up of patients, but 
is essential in research, as the better the inter-study reproducibility, the smaller the 
sample size needed to detect a true clinical difference between patient populations. 
CMR has the best interstudy reproducibility of any imaging technique for both mass 
and volume in the left and right ventricles [Grothues 2002, Grothues 2004]. 
Reproducibility is superior to 2-dimensional echocardiography [Semelka 1990]. It has 
been estimated that a drug trial designed to demonstrate a 10g decrease in LV mass 
for a treatment compared to placebo, with a power of 80% and a p value of 0.05, 
would require a sample size of 505 patients using 2D echocardiography, but only 14 
patients using CMR [Bottini 1995]. 
 
 
16.4 IMAGE ACQUISITION 
Left ventricular volumetric and mass data was acquired in the studies described in 
Chapters 10 and 11. A standardised methodology was used [Maceira 2006, Keenan 
2007]. Initially, a series of transverse pilot views were obtained. From these the mitral 
valve and left ventricular apex were identified, and so vertical long axis (VLA) cine 
image was obtained. The VLA was then used to plan the horizontal long axis (HLA), 
which shows all four chambers and the mitral and tricuspid valves. The HLA and 
VLA views were then used to plan the short axis. The first short axis plane was placed 
using the end-diastolic image at the base of the heart covering the most basal portion 
of the left and right ventricles just forward of the atrioventricular ring. Further short 
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axis images were acquired sequentially every 1cm along the long axis of the heart to 
the cardiac apex. This resulted in two long axis cine images and a stack of about 10 
short axis cines (figure 16.1). Each cine image was acquired in a breathhold of about 
10 seconds, so the ventricular dataset was acquired in under 5 minutes. All cines were 
acquired at end-expiration to improve reproducibility [Taylor 1997]. 
 
Cine images were acquired using a steady state in free precession (SSFP) sequence 
(True-FISP (fast imaging with steady-state precession)), with an in-plane resolution of 
1.4 x 1.8mm, a slice thickness of 8mm, and a temporal resolution of 50ms, which is 
optimum for assessing ventricular function at resting heart rates [Moon 2002]. 
Retrospective ECG-gating was used.  
 
 
Figure 16.1 Acquiring a ventricular dataset. 1. Transaxial dark blood scout 
image with imaging plane of vertical long axis (VLA) cine through mitral valve 
annulus and left ventricular apex indicated (line). 2. VLA cine at end diastole 
with imaging plane of horizontal long axis (HLA) cine indicated (line). 3. HLA 
cine at end diastole with imaging planes of short axis cines indicated (lines).4-12. 
Short axis cines at end diastole at 1cm intervals from left ventricular base to 
apex. 
 
Chapter 16 Page 255 Appendix B 
 
16.5 IMAGE ANALYSIS 
Background 
Quantitative analysis of CMR ventricular datasets has been regarded as time-
intensive, however, using PC software with intensity-based thresholding for semi-
automated myocardium-blood border definition, a complete dataset for LV volumes 
and mass can be analysed in less than 5 minutes. Standard ranges for ventricular 
volumes, function and mass have been determined, and these ranges have been 
normalised for body surface area [Lorenz 1999, Maceira 2006].  
 
 
Figure 16.2 Semi-automated analysis of left and right ventricular mass, volume 
and systolic function (CMRtools, Cardiovascular Imaging Solutions, London). 
Intensity-based thresholding and long-axis valve plane tracking greatly reduce 
the time required to analyse images. 
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Practical Method 
Each short axis slice has a thickness, and so is a volume. By contouring the 
endocardial surface at end-diastole and end-systole, and then summating the slices, 
the total volume of blood at end-diastole and end-systole can be determined and hence 
ventricular function. Likewise, by contouring the epicardial surface, the total volume 
of the heart is determined and, by subtracting the blood volume, the volume of 
myocardial tissue is determined. By convention this is done at end-diastole. The mass 
is determined using the density of myocardium (1.05 g/cm3). 
 
In this study, a computer-assisted semi-automated methodology was used (LVtools, a 
plug-in of CMRtools, Cardiovascular Imaging Solutions, London UK). This has two 
main advantages over the manual approach. Firstly, in the manual approach, the 
operator must trace the epicardial and endocardial borders by hand. The automated 
approach uses intensity-based thresholding: the signal intensity within a defined zone 
is used to delineate individual voxels as blood or myocardium and the observer can 
alter the threshold until the appearances correlate with visual assessment. This 
improves accuracy and speed when dealing with myocardial trabeculations. Secondly, 
using the long axis views, the software is able to track the mitral valve plane, and so 
takes account of the long axis motion of the heart in its assessment of ventricular 
function (typically 1-2 cm). This generates a three-dimensional model of the 
myocardium and blood pool from which volumetric data is derived (figure 16.2). 
  
 
16.6 LATE GADOLINIUM ENHANCEMENT IMAGES 
Late gadolinium enhancement (LGE) images were acquired 10 minutes after 
intravenous gadolinium-DTPA (Bayer Schering Pharma AG, Berlin, Germany; 0.1 
mmol/kg) in identical short-axis planes using an inversion-recovery gradient echo 
sequence. Inversion times were adjusted to null normal myocardium (typically 320 to 
440 ms; pixel size 1.7 x 1.4mm). Additional LGE images were acquired with phase 
swapping to exclude artefact. Two experienced readers, who were blinded to all 
clinical data, reviewed the LGE studies, assessing studies for the presence or absence 
of LGE, and, if present, for the pattern [Kim 1999]. Where there was disagreement, a 
third independent observer decided. 
